Trial Oversight Register

Aggregated regulatory and safety notifications across 965 EU clinical trials

965 trials affected 2,071 events total 354 in active trials

As of 5 June 2026 · CTIS public registry snapshot

204 Serious breach notifications
168 trials
1,367 Temporary halts
475 trials
124 Urgent safety measures
112 trials
135 Unexpected events
109 trials
241 Corrective measures
205 trials
How we calculate these numbers (oversight register methodology)

Population

  • Trials shown = any trial in CTIS whose trials record has at least one non-empty JSON array in any of the five oversight fields: seriousBreaches, temporaryHalts, urgentSafetyMeasures, unexpectedEvents, correctiveMeasures.
  • Trial status is not filtered — the register includes recruiting, ended, halted, suspended, expired and revoked trials. Status is shown per row.
  • "Active trials affected" counts trials whose ctPublicStatusCode is 3 or 4 (both map to "Recruiting" in CTIS public API).

Event types

  • Serious breaches (seriousBreaches) — Article 52 CTR notifications of breaches that affect the safety/rights of subjects or the reliability and robustness of the data.
  • Temporary halts (temporaryHalts) — Article 38 CTR sponsor-initiated halts (not a permanent end). Each halt event has a submit date and reason; lifting the halt is a separate restart record (not counted here).
  • Urgent safety measures (urgentSafetyMeasures) — Article 54 CTR measures taken to protect subjects from immediate hazard.
  • Unexpected events (unexpectedEvents) — Article 53 CTR notifications of any event significantly affecting benefit-risk balance (not a SUSAR — those are reported via EudraVigilance, not CTIS).
  • Corrective measures (correctiveMeasures) — measures imposed by a Member State concerned under Article 77 CTR (regulatory enforcement actions).

Bucket arithmetic

  • Per-card large number = total event count across all trials (each individual breach, halt, USM etc. counted once, summed across trials).
  • Per-card small "X trials" line = distinct trials with ≥ 1 event of that type. A trial with 4 breaches counts as 1 trial in the breach bucket.
  • Filter button counts at top of the table use the same "distinct trials" semantic.
  • Sum of "trials" lines across cards (1,069) is larger than the total trials affected (965) because 104 trials carry more than one type of event (e.g. both a breach and a halt).

Dates and sorting

  • "Most recent event date" per trial = the maximum across all event dates: submissionDate for breaches/USM/UE, submitDate for halts (different JSON field name in CTIS), sponsorSubmitDate for corrective measures.
  • Default sort: trial status ascending (recruiting first) then decision date descending. User can re-sort by event date or event count.

Caveats

  • Multiple primary sponsors: the sponsor column shows only one canonical name (first is_primary=1 record). Co-sponsored trials are not multi-attributed here (unlike the Transparency scoreboard).
  • SUSARs (Suspected Unexpected Serious Adverse Reactions) are not in CTIS oversight fields — they flow through EudraVigilance and the EMA Annual Safety Report. This register only covers CTIS-public regulatory notifications.
  • Event records reflect what sponsors and competent authorities have submitted; under-reporting and reporting lag are both real and not measurable from this view.
965 trials shown
Phase 3 Study of ALXN1850 in Pediatric Participants with HPP Previously Treated with Asfotase Alfa
2023-505674-15-00 Revoked Latest: 2024-05-10 Hypophosphatasia
1 corrective measure
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
2025-522475-28-00 Pending Latest: 2026-04-16 Pulmonary Hypertension (PH) with Heart Failure wit
1 corrective measure
A Long-Term Extension Study to Evaluate the Safety and Efficacy of Ritlecitinib in Participants With Severe AA Who Have Completed Studies B7…
2024-515439-31-00 Pending Latest: 2026-01-28 Alopecia areata
1 corrective measure
ADfind
2025-521833-97-00 Pending Latest: 2025-11-27 Moderate-to-severe atopic dermatitis
1 breach
Phase 2A–Evaluation of AUP1602-C with foam dressing as a new treatment for diabetic foot ulcers
2024-519317-66-00 Pending Latest: 2025-09-10 Diabetic Foot Ulcer
1 corrective measure
A Study to Learn About the Study Medicine Called Aztreonam-Avibactam in Neonates and Infants Less Than 9 Months of Age With Suspected or Con…
2023-507757-15-01 Pending Latest: 2025-05-05 Sepsis
1 corrective measure
Study of Oral Weekly GS-1720 and GS-4182 Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed
2024-511054-50-00 Pending Latest: 2025-07-29 HIV-1 Infection
1 urgent safety 1 unexpected event
Effect of Minocycline on Inflammation in Depressed Patients
2024-520076-10-01 Pending Latest: 2026-03-10 Depression
1 corrective measure
Open label safety study of tasimelteon indicated in the treatment of blind individuals with no light perception having problems synchronizin…
2024-516721-31-00 Pending Latest: 2025-03-03 Non-24 Hour Sleep-Wake Disorder
1 urgent safety
Effect of Sildenafil in association to Hypothermia on survival without brain lesions In term Neonates with hypoxic-ischemic Encephalopathy: …
2023-508928-35-00 Pending Latest: 2024-11-29 Hypoxic ischemic encephalopathy
1 corrective measure
Phase 1/2 Study of BLU-451 in certain advanced cancers
2022-502527-21-00 Pending Latest: 2023-10-24 Advanced cancers with EGFR Exon20 insertions mutat
1 urgent safety
Long-term safety and efficacy evaluation of lunsekimig (SAR443765) in adult participants with moderate-to-severe asthma.
2025-522896-27-00 Recruiting Latest: 2026-05-21 Asthma
1 halt
An Open-label Study to evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in children with gMG
2025-520993-20-00 Recruiting Latest: 2026-03-10 Generalized Myasthenia Gravis
2 corrective measures
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRES…
2025-522170-36-00 Recruiting Latest: 2026-05-27 Diabetes Mellitus, Type 1
1 corrective measure
A Phase 2, randomized, multicenter, open-label neoadjuvant study evaluating zanidatamab in combination with chemotherapy in participants wit…
2025-523204-68-00 Recruiting Latest: 2026-05-09 HER2-positive breast cancer
2 halts
KHENERFIN
2025-522361-30-00 Recruiting Latest: 2026-01-14 Primary Mitochondrial Disease, Mitochondrial DNA 3
1 corrective measure
Study Evaluating Zipalertinib with Chemotherapy for Lung Cancer Patients with Uncommon EGFR Mutations After Surgery
2025-521775-31-00 Recruiting Latest: 2026-05-04 Stage IB-IIIA NSCLC Patients with uncommon EGFR Mu
7 halts
LuMIERE: A Phase 1/2, Multicenter, Open label, Non randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and…
2023-508995-12-01 Recruiting Latest: 2026-02-10 Recurrent or metastatic non-small cell lung cancer
1 unexpected event
Study to assess the pharmacokinetics, safety, and tolerability of iptacopan in pediatric PNH patients
2024-515926-10-00 Recruiting Latest: 2025-08-11 Paroxysmal Nocturnal Hemoglobinuria (PNH)
1 corrective measure
A 2-Part, Randomized, Double-Blind, Placebo-Controlled Study in Participants with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping t…
2024-517499-39-00 Recruiting Latest: 2025-07-24 Duchenne Muscular Dystrophy
1 corrective measure
Testosterone Replacement Therapy in Women with Turner Syndrome
2024-517755-12-00 Recruiting Latest: 2026-02-26 Turner Syndrome
1 halt
Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants from Approximately 2 Months of Age
2023-507600-32-00 Recruiting Latest: 2025-07-11 Pneumococcal Immunization
1 corrective measure
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients with FLT3-ITD Negative AML
2023-507936-20-00 Recruiting Latest: 2025-07-11 Acute myeloid leukemia
1 breach
COLCOT-T2D
2024-516646-19-00 Recruiting Latest: 2025-06-04 Type 2 diabetic patients with no prior cardiovascu
1 corrective measure
A dose ranging study to investigate efficacy and safety of subcutaneous TOUR006 compared with placebo in participants 18 to 80 years of age …
2024-514801-69-00 Recruiting Latest: 2026-05-11 Thyroid Eye Disease
1 unexpected event
A Phase 2 Study of AMG 193 in Subjects With MTAP-deleted Advanced NSCLC
2024-514459-14-00 Recruiting Latest: 2025-03-25 Non-Small Cell Lung Cancer
2 corrective measures
A Randomized, Double-Blind, Placebo-Controlled, MultiRegional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemal…
2023-507097-41-01 Recruiting Latest: 2025-08-21 Patients with limited-stage small cell lung cancer
6 halts 1 corrective measure
An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients w…
2023-507853-13-00 Recruiting Latest: 2026-01-22 Ulcerative Colitis
6 halts
A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants…
2024-514239-21-00 Recruiting Latest: 2025-05-14 Spinal Muscular Atrophy
1 corrective measure
A Phase 1 Study to Determine the Safety, Tolerability and Pharmacokinetics of 177Lu-EVG321 in Patients with Small Cell Lung Cancer
2024-518039-12-00 Recruiting Latest: 2026-02-02 Small Cell Lung Cancer
1 halt
A study to learn about how safe BAY 3389934 is, its suitable dose, and how it affects the participants with sepsis and coagulopathy
2024-515635-30-00 Recruiting Latest: 2025-05-28 Coagulopathy
4 halts
A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK10…
2024-512659-19-00 Recruiting Latest: 2025-02-17 Advanced Melanoma
1 corrective measure
AMUNDSEN - Acute Myocardial infarction Upbound to percutaneous coronary intervention, immediately (STEMI) or in the Next three Days (NSTEMI)…
2024-518195-31-00 Recruiting Latest: 2025-05-28 acute myocardial infarction
1 corrective measure
A study evaluating the effects of filgotinib in children and teenagers with ulcerative colitis
2024-511458-32-00 Recruiting Latest: 2025-05-28 Ulcerative colitis
6 halts
A study to determine how safe MB-CART2019.1 is and how well it works in children and adolescents with B cell neoplasms
2023-506348-17-00 Recruiting Latest: 2025-07-28 Relapsed/refractory (r/r) mature B cell neoplasms
1 corrective measure
Phase I/II clinical trial of autologous hematopoietic stem cell gene therapy in rag1-deficient severe combined immunodeficiency
2023-510204-50-00 Recruiting Latest: 2026-04-24 Severe combined immunodeficiency based on genetic
1 breach
Bemarituzumab in patients with FGFR2b-positive advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed…
2024-512484-31-00 Recruiting Latest: 2025-11-20 FGFR2b-positive, advanced or metastatic adenocarci
1 halt
Dose dense re-challenge of high dose methotrexate (hd-mtx) with glucarpidase (cpg2) for relapsed primary cns lymphoma (pcnsl): A phase 1 tri…
2024-511900-17-00 Recruiting Latest: 2024-12-23 Oncology: RELAPSED PRIMARY CNS LYMPHOMA
1 halt
A Multicenter, Two-arm, Double-blind, Double dummy, Parallel-group Study for efficacy and safety evaluation of prolonged release formulation…
2024-518347-38-00 Recruiting Latest: 2025-05-17 Menière's disease
1 halt
Efficacy and Safety of a New Formulation of Oral Cladribine Compared with Placebo in Participants with Generalized Myasthenia Gravis (MyCla…
2023-507746-83-00 Recruiting Latest: 2026-01-16 Generalized Myasthenia Gravis
1 halt
A study to investigate efficacy and safety of INT230-6 compared with US standard of care in participants aged ≥ 18 years old with metastatic…
2024-512423-36-00 Recruiting Latest: 2025-05-06 Undifferentiated pleomorphic sarcoma
3 halts
A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients with NMDAR or LGI1 mediated autoimm…
2023-504226-18-00 Recruiting Latest: 2025-08-18 NMDAR or LGI1 mediated autoimmune Encephalitis
3 corrective measures
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab.
2024-513185-19-00 Recruiting Latest: 2026-01-12 Extensive stage small cell lung cancer (ES-SCLC)
1 unexpected event
A Ph2 Superiority Study with InO Monotherapy vs ALLR3 for Induction Treatment of Childhood HR ALL
2023-509810-13-00 Recruiting Latest: 2025-10-13 Acute Lymphoblastic Leukemia (ALL)
1 corrective measure
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects with Moderately to Severely Active Crohn's Dis…
2023-509618-12-00 Recruiting Latest: 2025-07-11 Crohn's Disease (CD)
1 corrective measure
CeRebrUm and CardIac protection with ALlopurinol in Neonates with Critical Congenital Heart Disease requiring Cardiac Surgery with Cardiopul…
2024-513041-37-00 Recruiting Latest: 2026-01-13 Brain injury in neonates with critical congenital
1 breach
Study of GS-1427 in Participants With Moderately to Severely Active UC
2023-508304-38-00 Recruiting Latest: 2024-09-05 Ulcerative Colitis (UC)
1 corrective measure
Study of efficacy and safety of iptacopan in complement 3 glomerulopathy patients
2023-509331-83-00 Recruiting Latest: 2025-07-11 complement 3 glomerulopathy
1 corrective measure
A Phase Ib Safety, Pharmacokinetics and Pharmacodynamics Study of TU7710 in Patients with Haemophilia A or B
2024-511814-20-00 Recruiting Latest: 2025-03-12 Hemophilia
1 corrective measure
Disitamab Vedotin with Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
2022-501105-12-00 Recruiting Latest: 2025-01-02 Urothelial Carcinoma
2 halts 1 corrective measure
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis
2023-503699-25-00 Recruiting Latest: 2025-03-06 Progressive Pulmonary Fibrosis
2 halts
A study to investigate the safety and efficacy of mRNA-3927 in participants with genetically confirmed propionic acidemia
2022-502910-10-00 Recruiting Latest: 2025-08-22 Propionic Acidemia
6 halts 1 unexpected event
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis
2023-503697-21-01 Recruiting Latest: 2025-03-07 Idiopathic pulmonary fibrosis
2 halts
A Phase 2/3 Safety, Pharmacokinetics, and Efficacy Study ofNirmatrelvir/Ritonavir in Pediatric, Nonhospitalized Symptomatic Participants Wit…
2023-509773-23-00 Recruiting Latest: 2024-05-27 SARS-CoV-2 Infection
4 halts
Clinical trial that compares MK-2870 with or without pembrolizumab to chemotherapy in people with breast cancer that cannot be surgically re…
2023-504918-29-00 Recruiting Latest: 2024-11-04 Hormone receptor positive breast cancer
1 unexpected event
A phase 3 study to look at the effects of 2 treatments used together (ficlatuzumab and cetuximab) on the overall survival of adults with a c…
2023-505606-42-00 Recruiting Latest: 2024-11-12 Head and Neck Squamous Cell Carcinoma (HNSCC)
1 urgent safety
A proof of concept study to evaluate treatments´efficacy by monitoring Minimal Residual Disease using ctDNA in HR-positive/HER2-negative ear…
2023-505661-89-00 Recruiting Latest: 2024-08-09 Early-stage, Hormone Receptor (HR)-positive / Huma
1 halt
MATRIX-IPC 2022-029 A phase I/II study evaluating Tuvusertib (M1774), an ATR Inhibitor, in combination with fulvestrant in hormone receptors…
2023-507485-10-00 Recruiting Latest: 2026-06-01 advanced breast cancer
5 halts
A clinical study to investigate if the investigational product, called LN -145 (also known as Tumor Infiltrating Lymphocytes) is safe and be…
2024-510778-26-00 Recruiting Latest: 2025-11-28 Metastatic Non-Small-Cell Lung Cancer
5 halts 1 unexpected event
Efficacy, safety, tolerability, and pharmacokinetics of risankizumab in pediatric subjects with active juvenile psoriatic arthritis
2023-506026-36-00 Recruiting Latest: 2025-07-11 Juvenile Psoriatic Arthritis
1 corrective measure
A research study to evaluate the safety and effectiveness of Zilovertamab Vedotin with or without Nemtabrutinib in adults with B-cell Malign…
2022-501374-19-00 Recruiting Latest: 2025-08-06 Aggressive and Indolent B-cell Malignancies (mantl
6 halts
A clinical study of different treatments for kidney cancer (MK-3475-03A)
2023-506838-68-00 Recruiting Latest: 2024-12-19 Renal cell carcinoma
1 urgent safety
[18F]PSMA-1007 PET CT in patients with newly-diagnosed prostate cancer
2023-504026-19-01 Recruiting Latest: 2025-12-16 Prostate Cancer
2 breaches
Pragmatic trial on the safety and tolerability of an optimized dose of rifampicin in tuberculosis patients
2023-509885-39-00 Recruiting Latest: 2026-01-20 Tuberculosis
2 halts
A Study of Repotrectinib versus Crizotinib in Participants with Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-po…
2023-505604-32-00 Recruiting Latest: 2025-10-14 Non small cell lung cancer (NSCLC)
1 corrective measure
CHIP-AML22/Quizartinib sub-study: study of the safety and efficacy of quizartinib in children and adolescents with FLT3-ITD positive AML wit…
2023-505000-27-01 Recruiting Latest: 2026-03-09 newly diagnosed pediatric FLT3-ITD positive and NP
2 breaches
Trial of Two Adagrasib Dosing Regimens in NSCLC with KRAS G12C Mutation
2023-503523-25-00 Recruiting Latest: 2024-03-06 Non-small cell lung cancer
1 corrective measure
Study to investigate lifileucel regimen plus pembrolizumab compared with pembrolizumab alone in participants with untreated, advanced melano…
2022-503140-41-00 Recruiting Latest: 2026-01-26 Melanoma
8 halts 1 unexpected event 1 corrective measure
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participan…
2023-505749-14-00 Recruiting Latest: 2024-11-26 c-Met overexpressing EGFR wildtype non-squamous no
1 breach
An extension phase 2/3 study to test the safety of long term administration of oral PHA-022121 for acute treatment of angioedema attacks in …
2023-505766-28-00 Recruiting Latest: 2025-06-05 Hereditary angioedema
1 corrective measure
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and how Drug Move…
2022-501599-25-00 Recruiting Latest: 2025-10-08 juvenile idiopathic arthritis
1 corrective measure
A Phase 3, Open-Label, Uncontrolled Study to Evaluate the Activity, Safety, Pharmacokinetics and Pharmacodynamics of Roxadustat for the Trea…
2022-501980-42-00 Recruiting Latest: 2025-08-12 Anemia associated with Chronic Kidney Disease
1 corrective measure
A study of anifrolumab in children and adolescents (5 to < 18 years old) with moderate to severe lupus to find the appropriate anifrolumab d…
2022-502289-25-00 Recruiting Latest: 2025-08-13 Moderate to Severe Active Systemic Lupus Erythemat
1 corrective measure
Randomised, double-blind, placebo-controlled study to assess safety and efficacy of PRI-002 in patients with MCI or mild dementia due to Alz…
2022-503148-41-00 Recruiting Latest: 2025-09-11 Alzheimer's disease
1 urgent safety
Ulcerative Colitis: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects with Moderately to Severely Active Ulcerati…
2022-501788-41-00 Recruiting Latest: 2025-07-22 Ulcerative Colitis
1 corrective measure
A phase 2, multicenter, double-blind, two-arm study of subcutaneous RO7790121 for the treatment of subjects with moderate to severe active c…
2023-504265-23-00 Recruiting Latest: 2024-01-17 Crohn's disease
2 halts
A study to learn how safe fenfluramine is, how well it works, and how it moves through the bloodstream in infants with Dravet syndrome
2022-502359-75-00 Recruiting Latest: 2025-07-22 Dravet syndrome
1 corrective measure
A study to test the effect of chemotherapy before surgery compared to surgery alone in patients with high risk retroperitoneal sarcoma.
2023-505261-84-00 Recruiting Latest: 2026-04-03 Primary high risk leiomyosarcoma or liposarcoma of
2 unexpected events
Long-term Extension Study to Assess Adverse Events and Tolerability of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Ag…
2022-501099-24-00 Recruiting Latest: 2024-07-05 Migraine
1 corrective measure
Setrusumab vs Bisphosphonates in Pediatric Subjects with Osteogenesis Imperfecta (Cosmic)
2023-504196-24-00 Recruiting Latest: 2025-07-10 osteogenesis imperfecta
1 breach
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) …
2022-501100-94-00 Recruiting Latest: 2025-07-09 Episodic Migraine
1 halt 2 corrective measures
Stem cell transplantation in diffuse cutaneous systemic sclerosis: upfront therapy or rescue therapy after failure of immunosuppressants
2023-505877-34-00 Recruiting Latest: 2025-02-14 Diffuse cutaneous systemic sclerosis according to
1 breach
Kidney cancer
2023-505605-16-00 Recruiting Latest: 2024-04-02 Metastatic Clear Cell Renal Cell Carcinoma (ccRCC)
1 halt
A basket study to investigate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with solid tumors
2022-502654-14-00 Recruiting Latest: 2024-11-06 Endometrial cancer
1 unexpected event
A Phase 1/2/3 Study of UX701 Gene Therapy in Adults with Wilson Disease”.
2022-502873-40-00 Recruiting Latest: 2025-09-05 Wilson disease
1 corrective measure
Phase 3, Open-label Study of ARV-471 (PF-07850327) vs Fulvestrant in Participants With ER(+)/ HER2(-) Advanced Breast Cancer (VERITAC-2)
2022-500544-38-00 Recruiting Latest: 2023-10-12 Advanced Breast Cancer
3 halts
Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Patie…
2022-501876-24-00 Recruiting Latest: 2024-04-25 Relapsed or Refractory (R/R) Chronic Lymphocytic L
4 halts
A Phase 1/2a Study of UCART20x22 in B-Cell Non-Hodgkin Lymphoma [NatHaLi-01]
2022-501607-27-00 Recruiting Latest: 2024-12-04 Relapsed or refractory B-cell Non-Hodgkin lymphoma
4 halts
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants with Early Breast Cancer (EMBER-4)
2022-501007-28-00 Recruiting Latest: 2025-08-07 Breast Neoplasms
1 unexpected event
Treatment of infants under one year with acute lymphoblastic leukemia according to the Interfant-21 protocol
2022-502503-30-00 Recruiting Latest: 2026-04-07 Acute lymphoblastic leukemia
17 halts 2 urgent safety 2 corrective measures
Phase III clinical trial of ABCB5+ MSCs for the treatment of EB
2022-500266-10-00 Recruiting Latest: 2023-12-07 Recessive Dystrophic Epidermolysis Bullosa(RDEB) a
4 halts
A Phase 3 Study to Investigate the Efficacy and Safety of Brepocitinib in Adults with Dermatomyositis
2022-500367-12-00 Recruiting Latest: 2025-11-20 Dermatomyositis
1 urgent safety
AMAZE 1: A research study investigating how well the medicine NNC0487-0111 helps people with excess body weight lose weight
2024-520440-42-00 Recruiting Latest: 2026-05-07 Obesity
1 corrective measure
A Phase 1/2 clinical trial of DT-7012 as monotherapy and in combination with an immune checkpoint inhibitor in participants with selected ad…
2025-523758-15-00 Recruiting Latest: 2026-02-10 Cancer
1 urgent safety
To compare the Safety and activity of GDC-4198 Alone and in Combination with Giredestrant against Abemaciclib and Giredestrant in Participan…
2025-521128-31-00 Recruiting Latest: 2026-02-11 Locally Advanced or Metastatic Estrogen Receptor-P
1 urgent safety
Pasritamig vs Placebo in late line Metastatic Castration-resistant Prostate Cancer (mCRPC)
2025-520927-26-00 Recruiting Latest: 2026-02-04 Metastatic Castration-resistant Prostate Cancer (m
1 corrective measure
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic …
2025-522860-34-00 Recruiting Latest: 2026-05-20 Chronic lymphocytic leukemia (CLL)
1 halt
A Study to Assess the Long-Term Efficacy and Safety of Afimkibart (RO7790121) in Patients with Atopic Dermatitis who participated in previou…
2025-520771-59-00 Recruiting Latest: 2026-02-11 Atopic Dermatitis
1 corrective measure
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
2025-521242-26-00 Recruiting Latest: 2025-12-08 Moderately to Severely Active Ulcerative Colitis
1 corrective measure
A Phase 3 Study of JNT-517 in Participants with Phenylketonuria
2024-519554-37-00 Recruiting Latest: 2026-03-17 Phenylketonuria
1 corrective measure
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin i…
2024-518365-10-00 Recruiting Latest: 2026-04-20 Previously Untreated Advanced or Metastatic Non-Sq
1 breach
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and …
2024-516652-18-00 Recruiting Latest: 2026-01-12 Atherosclerotic cardiovascular disease (ASCVD) and
1 corrective measure
A Study to Test How Safe, Effective and How Body’s Responds to the Combination of Mosunetuzumab and Pirtobrutinib Together to Treat Patients…
2024-514152-32-00 Recruiting Latest: 2025-12-03 Relapsed or Refractory Chronic Lymphocytic Leukemi
1 corrective measure
A study to investigate the effect of AZD6793 in participants with moderate to very severe chronic obstructive pulmonary disease
2025-520473-40-00 Recruiting Latest: 2026-04-03 Moderate to Very Severe Chronic Obstructive Pulmon
1 urgent safety
AIDA-DEP - Accelerated Intermittent theta-burst stimulation with D-cycloserine Augmentation for DEPression - a multicenter, randomized, plac…
2025-521686-27-01 Recruiting Latest: 2026-04-09 Major Depression
1 breach
A Phase 3, randomized, parallel-group, double-blind, multicenter study investigating the safety and efficacy of NT 201 compared with placebo…
2025-520499-24-00 Recruiting Latest: 2026-02-11 Moderate to Severe Platysma Prominence
1 corrective measure
A clinical trial to evaluate efficacy and safety of Xeomin® injections for preventing chronic migraine
2024-515682-34-00 Recruiting Latest: 2025-10-03 Chronic migraine
1 corrective measure
A clinical trial to evaluate efficacy and safety of Xeomin® injections for preventing episodic migraine
2024-515715-22-00 Recruiting Latest: 2025-10-14 Episodic migraine
1 corrective measure
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
2024-513613-12-00 Recruiting Latest: 2025-11-26 Part A: Healthy volunteers (Part A is not applicab
1 corrective measure
A clinical study of MK-5684 in people with certain solid tumors (MK-5684-015)
2024-519563-18-00 Recruiting Latest: 2026-03-27 Breast cancer, Ovarian cancer, Endometrial cancer
1 urgent safety
Darolutamide and bipolar androgen therapy for mCRPC patients (DaroBAT)
2025-521051-23-00 Recruiting Latest: 2026-04-29 metastatic castration-resistant prostate cancer
1 urgent safety
A Phase 3 study of NBTXR3 with or without cetuximab in LA-HNSCC
2024-520386-31-00 Recruiting Latest: 2026-03-24 Locally Advanced Head & Neck Squamous Cell Carcino
1 urgent safety
A phase II randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of an oral solution of 9-Δ …
2024-520287-34-01 Recruiting Latest: 2025-10-15 Chronic neuropathic pain due to multiple sclerosis
1 corrective measure
CAPRI-3 Phase 3 clinical study to evaluate the use of continuing cetuximab treatment beyond first line progression in molecular selected met…
2024-519322-20-00 Recruiting Latest: 2026-01-26 metastatic colorectal cancer
1 corrective measure
(MOTOR Study) Neuromuscular MOniTOring in pediatric anesthesia. Randomized clinical study
2024-517057-27-00 Recruiting Latest: 2025-07-22 patients scheduled to undergo elective surgical pr
1 corrective measure
Randomized, controlled, multi-center clinical trial for the treatment of osteoarthritis behind the kneecap with tissue engineered nasal cart…
2024-513683-25-00 Recruiting Latest: 2025-09-10 Patellofemoral osteoarthritis
1 corrective measure
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
2024-517529-26-00 Recruiting Latest: 2026-03-27 Chronic Inflammatory Demyelinating Polyneuropathy
1 urgent safety
A Phase 3, Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Ravulizumab in Pediatri…
2024-520167-13-00 Recruiting Latest: 2025-06-19 Immunoglobulin A Nephropathy
1 corrective measure
A Study to Determine Safety and Long-Term Effectiveness of Faricimab in Participants with Age-Related Macular Degeneration
2024-517545-13-00 Recruiting Latest: 2025-07-09 Neovascular Age-Related Macular Degeneration
1 corrective measure
A Study to Assess the Adverse Events and Change in Disease Activity of Atogepant Oral Tablets in Pediatric Participants with Chronic Migrain…
2024-513836-28-00 Recruiting Latest: 2025-07-24 Chronic Migraine
1 corrective measure
A Phase 1/2a, First-in-human Study to Evaluate BMS-986470 in Healthy Volunteers and Participants with Sickle Cell Disease
2023-510283-12-00 Recruiting Latest: 2026-03-24 Sickle Cell Disease
2 unexpected events
Detection of tumour DNA in the blood of patients receiving standard therapy for hormone receptor-positive (HR+) HER2 low expression (HER2 lo…
2024-515349-41-00 Recruiting Latest: 2025-07-08 Metastatic Breast Cancer HR+, HER2-
1 corrective measure
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmona…
2024-517458-90-00 Recruiting Latest: 2026-02-27 Chronic obstructive pulmonary disease (COPD)
2 breaches
Dapagliflozine for cardio-renal protection at ICU discharge
2024-510941-32-00 Recruiting Latest: 2025-05-26 Adult patients discharged alive from ICU with a de
1 corrective measure
A study to see how a single increasing dose of the oral drug AD-700 affects the ability of a CT scan to detect activated brown fat in health…
2025-520584-41-00 Recruiting Latest: 2025-09-04 Metabolism dysfunction
1 halt
A 2-Part, Randomized, Double-Blind, Placebo-Controlled Study in Participants with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping t…
2024-517584-23-00 Recruiting Latest: 2025-07-24 Duchenne Muscular Dystrophy
1 corrective measure
A clinical study of ifinatamab deruxtecan and pembrolizumab with or without chemotherapy in people with esophageal cancer (MK-3475-06E)
2024-514273-22-00 Recruiting Latest: 2025-04-16 Esophageal squamous cell carcinoma
1 corrective measure
Randomized, double-blind, placebo-controlled Phase I study in healthy individuals on autotaxin-inhibition with MJK2134025 in single-ascendin…
2024-513116-10-00 Recruiting Latest: 2025-10-22 Stroke
1 corrective measure
Lu177-Dotatate every 16 weeks to reduce adverse events in patients with midgut neuroendocrine tumors
2024-517921-14-00 Recruiting Latest: 2026-04-30 Neuroendocrine tumors of midgut origin
2 breaches
The use of dupilumab in treatment of indolent systemic mastocytosis with skin involvement
2023-509111-89-00 Recruiting Latest: 2026-03-10 Systemic mastocytosis with a slow course and invol
1 urgent safety
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATI…
2023-508874-27-00 Recruiting Latest: 2025-12-19 Heart condition
1 halt
A study Investigating Subcutaneously Administered Pozelimab in Combination with Cemdisiran or Cemdisiran Alone in Adult Participants with Ge…
2023-509547-27-00 Recruiting Latest: 2025-06-25 Geographic Atrophy Secondary to Age-Related Macula
1 corrective measure
Lung Microbiota’s evolution after use of Nitrous Oxide on pediatric patient needing airway samples - MicroNO
2024-518197-14-00 Recruiting Latest: 2025-04-30 Pediatric respiratory disorder
1 corrective measure
RECLAIM: an Adaptive Platform Trial for the Evaluation of Treatments for Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)
2024-511580-28-02 Recruiting Latest: 2025-10-27 PASC: post-acute sequelae of SARS-CoV-2 infection
1 breach
A clinical study of tulisokibart in people with Crohn’s disease or ulcerative colitis (MK-7240-011)
2024-513533-20-00 Recruiting Latest: 2025-05-06 Crohn’s Disease or Ulcerative Colitis
1 corrective measure
Prophylactic Anti-aRrhythmic therapy with Amiodarone in critically ill patients admitted for an out-of-hospital Cardiac Arrest with initial …
2023-510099-30-00 Recruiting Latest: 2025-01-28 Out-of-hospital cardiac arrest with initial shocka
1 corrective measure
A phase II randomized clinical study of the combination of avelumab plus cetuximab as rechallenge strategy in pre-treated RAS/BRAF wild type…
2024-519481-44-00 Recruiting Latest: 2026-01-27 colorectal metastatic cancer
1 corrective measure
Phase 1/2 multicenter, open-label, dose-escalation study of IDP-121 in patients with relapsed/refractory hematologic malignancies (CASSANDRA…
2024-519194-19-00 Recruiting Latest: 2025-12-22 Chronic lymphocytic leukemia (CLL)
1 urgent safety
Inmmunotherapy with peripheral blood, autologous, a dult T cells, expanded and transduced (gene modified) with a lentiviral vector expressin…
2024-515624-36-00 Recruiting Latest: 2026-01-26 Refractary or relapse non-Hodgkin T CD30+ lymphoma
1 unexpected event
Oxytocin and attachment development: Looking beyond the expected?
2024-518004-49-00 Recruiting Latest: 2025-01-24 Healthy children
2 halts
Phase II, multicentre, randomised, open-label trial with MAP +/- denosumab regimen for the treatment of patients with metastatic osteosarcom…
2024-518167-35-01 Recruiting Latest: 2025-03-13 Patients with Metastatic Osteosarcoma
1 halt
A study to assess the efficacy and safety of ITI-1284 as adjunctive treatment in patients with Generalized Anxiety Disorder
2024-513302-56-00 Recruiting Latest: 2025-10-23 Generalized Anxiety Disorder
3 halts
Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma
2024-511188-26-00 Recruiting Latest: 2025-09-25 Relapsed/refractory multiple myeloma in patients w
2 corrective measures
A Phase 1/2 Dose-Exploration and Dose-Expansion Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients with Alpha-1 Antitry…
2023-509256-34-00 Recruiting Latest: 2026-03-12 Alpha-1 Antitrypsin Deficiency (AATD)-Associated L
1 urgent safety
A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Transfusion-Dependent β-Thalassemi…
2024-513349-35-00 Recruiting Latest: 2025-07-09 Transfusion-Dependent-Thalassemia
1 corrective measure
A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Severe Sickle Cell Disease
2024-513978-22-00 Recruiting Latest: 2025-07-09 Severe sickle cell disease (SCD)
1 corrective measure
Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 …
2022-500747-21-00 Recruiting Latest: 2025-09-12 Geographic Atrophy
1 corrective measure
A study to investigate the safety and efficacy of MEDI0618 compared to placebo in adult participants with episodic migraine
2024-512904-21-00 Recruiting Latest: 2025-03-27 Migraine
6 halts
A clinical study of V940 and pembrolizumab to treat lung cancer (V940-009)
2023-506327-29-00 Recruiting Latest: 2025-07-28 Non-Small Cell Lung Cancer
1 corrective measure
Neoadjuvant immune checkpoint inhibition and novel IO combinations in early-stage colon cancer - the NICHE trial
2024-513314-35-00 Recruiting Latest: 2025-06-11 Adenocarcinoma of the Colon or rectosigmoid (consi
2 breaches
A phase III, randomised, open-label, Multicenter International Trial comparing ruxolitinib with either HydRoxycarbamIDe or interferon Alpha …
2024-516109-21-00 Recruiting Latest: 2024-12-09 Polycythaemia Vera (PV)
1 urgent safety
Trial to Better Characterize the Status of HRD leading to a Benefit from Olaparib in Combination with Bevacizumab in Patients with Advanced …
2024-517363-24-00 Recruiting Latest: 2026-03-17 Advanced FIGO Stage III‐IV High Grade Serous or En
1 breach
A trial to learn how safe Dato-DXd is and how well it works in people with NSCLC that has advanced after receiving osimertinib
2024-511362-37-00 Recruiting Latest: 2025-09-29 Non squamous non-small cell lung cancer (NSCLC)
7 halts
Sclerotherapy of hydro and spermatoceles with 2ml Aetoxysclerol 30mg/ml vs. a combination of 2ml Aetoxysclerol 30mg/ml and 25ml of ethanol 9…
2022-502284-38-00 Recruiting Latest: 2025-04-07 Spermatocele
2 halts
ANACOMP. A RANDOMIZED PHASE III MULTICENTER TRIAL COMPARING THE EFFICACY AND SAFETY OF ANAKINRA VERSUS INTRAVENOUS IMMUNOGLOBULIN (IVIG) RET…
2024-516244-25-00 Recruiting Latest: 2025-10-27 Kawasaki disease
1 halt
Randomized, double-blind, placebo-controlled trial evaluating efficacy and safety of dimethyl fumarate in brain atrophy reduction, synaptic …
2024-517214-16-00 Recruiting Latest: 2026-01-21 Alzheimer’s disease
1 urgent safety
COMparison of B-cell dePletion by rituximAb and anti-CD 19 CAR-T therapy in patients with rhEumatoid arthritis- The COMPARE TRIAL
2024-514955-13-00 Recruiting Latest: 2026-01-28 Rheumatoid Arthritis
1 breach
Brigatinib in pediatric and young adult patients with ALK+ ALCL, IMT or other solid tumors (Briga-PED)
2024-513412-10-00 Recruiting Latest: 2026-01-06 Anaplastic Large Cell Lymphoma (ALCL)
1 breach
Evaluating oral peri-operative acetylsalicylic acid in subjects undergoing endovascular coiling-only of unruptured brain aneurysms
2024-517674-23-00 Recruiting Latest: 2026-02-05 Subjects undergoing elective endovascular coiling-
1 halt
Prevention of opioid-induced constipation in patients with advanced cancer.
2023-509462-38-00 Recruiting Latest: 2024-12-02 Patients with advanced cancer.
1 breach
Single and multiple ascending dose of ZP9830 in healthy participants
2023-509929-51-00 Recruiting Latest: 2026-01-26 Autoimmune diseases
1 halt
A clinical study to assess the safety and efficacy of oral ART0380 as a single agent or in combination in solid tumors
2024-511534-12-00 Recruiting Latest: 2025-02-04 Advanced or Metastatic Solid Tumours
2 halts
Anakinra in Cerebral haemorrhage to Target secondary Injury resulting from Neuroinflammation - a phase II clinical trial
2024-517230-17-00 Recruiting Latest: 2025-01-21 Intracerebral haemorrhage
2 breaches
GRAALL 2024 - A 3-cohort Randomized Study evaluating the role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Tran…
2024-511437-35-00 Recruiting Latest: 2025-11-17 Patients aged 18-65 years old with newly diagnosed
2 halts
Cell therapy for Inclusion Body Myositis (IBM) by muscle injection of autologous uncultured Adipose-Derived Stromal Vascular Fraction (ADSVF…
2024-511858-44-00 Recruiting Latest: 2026-02-25 Inclusion Body Myositis
2 corrective measures
Clinical study on the treatment of scabies disease
2024-513288-14-00 Recruiting Latest: 2025-03-20 Scabies
1 halt
Evaluation of Local Co-administration of Autologous ADIpose Derived Stromal Vascular Fraction With Microfat for Refractory Perianal CROHN’s …
2024-517794-24-00 Recruiting Latest: 2026-02-19 crohn disease
1 corrective measure
Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (petosemtamab) as single agent or in combination in advanced solid …
2024-513627-16-01 Recruiting Latest: 2025-05-23 Colorectal cancer metastatic
1 breach
ASIC Channels and Migraine Disease - Proof-of-Concept Study on the Efficacy of Amiloride in Migraine Aura Prophylaxis
2024-516044-25-00 Recruiting Latest: 2024-10-28 Migraines with aura
1 halt
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
2022-501050-11-01 Recruiting Latest: 2025-12-18 Acute Lymphoblastic Leukaemia
3 breaches
First -in-Human Study of DS-3939a in Subjects with Advanced Solid Tumors
2023-507937-14-00 Recruiting Latest: 2026-01-29 Metastatic Solid Tumor
2 urgent safety
A study evaluating the safety and efficacy of an experimental drug for chronic lung disease against normally prescribed care in extremely pr…
2024-515914-41-00 Recruiting Latest: 2024-12-19 Chronic Lung Disease
1 urgent safety
Treatment of Established Status Epilepticus in the Elderly - a prospective, randomized, double-blind comparative effectiveness trial
2024-516634-35-00 Recruiting Latest: 2024-10-14 Convulsive or nonconvulsive benzodiazepine-resista
1 halt
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication: BIOMEDE 2.0
2023-506027-29-00 Recruiting Latest: 2025-02-19 Children, adolescents and adults with newly diagno
1 breach
Intracochlear application of (Extracellular Vesicle-enriched Secretome Fraction; VSF1.01) for the Reduction of Cochlear Implant Surgery Rela…
2024-512498-29-00 Recruiting Latest: 2025-04-15 hearing loss
1 halt
MEPENDAX: Phase I/II study of axitinib (Inlyta®) and oral metronomic etoposide for pediatric children and AYA with refractory/relapsing medu…
2023-509585-38-00 Recruiting Latest: 2026-03-04 Ependymoma
1 urgent safety
A Phase I, open-label, multi-center study of radiation dosimetry, safety, and tolerability of extended lutetium (177Lu) vipivotide tetraxeta…
2024-512338-13-00 Recruiting Latest: 2026-01-07 Metastatic Castration-Resistant Prostate Cancer
1 unexpected event
ARGO Colchicine versus Placebo in Acute Myocarditis Patients to Reduce Late Gadolinium Enhancement Mass on Cardiac Magnetic Resonance and th…
2024-514610-13-00 Recruiting Latest: 2025-11-03 patients suffering from acute myocarditis confirme
1 urgent safety
An open single-center, phase I proof of concept trial to assess the safety and feasibility of adoptive cell therapy with autologous EBV-spec…
2024-515563-55-00 Recruiting Latest: 2025-01-24 Multiple sclerosis
1 halt
A clinical trial to learn about the effects of YTB323 in people with difficult to treat severe diffuse cutaneous systemic sclerosis (dcSSc)
2023-510380-34-00 Recruiting Latest: 2025-09-10 Diffuse cutaneous systemic sclerosis (dcSSc)
1 corrective measure
A modular multi-Basket trial to improve personalized medicine in cancer patients
2024-514238-19-00 Recruiting Latest: 2026-01-21 Subjects with advanced solid tumour
1 urgent safety
Ketamine sedation as neuroprotective agent following out-of-hospital cardiac arrest
2024-515987-29-00 Recruiting Latest: 2026-02-13 Out-of-hospital cardiac arrest
1 breach
A trial to learn how well saruparib with camizestrant works and how safe it is in adults with advanced breast cancer that is hormone recepto…
2023-504180-16-00 Recruiting Latest: 2025-03-20 Advanced Breast Cancer
1 corrective measure
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia
2023-505232-36-00 Recruiting Latest: 2026-01-19 Essential thrombocythemia
4 halts
A clinical trial to learn about the effects of YTB in people with difficult to treat active systemic lupus erythematosus (SLE), or active k…
2023-510150-17-00 Recruiting Latest: 2025-09-10 Active, refractory systemic lupus erythematosus (S
1 corrective measure
ZELA trial: Phase 2b/3 Multicenter Study to Evaluate the Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developi…
2024-513420-41-00 Recruiting Latest: 2025-12-19 prematurity in neonates
2 corrective measures
INNOVATIVE TREATMENT OF SCARRED VOCAL FOLDS BY LOCAL INJECTION OF AUTOLOGOUS ADIPOSE-DERIVED STROMAL VASCULAR FRACTION: EFFICACY VERSUS PLAC…
2024-517384-24-00 Recruiting Latest: 2026-02-19 SCARRED VOCAL FOLDS
1 corrective measure
Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients with Parkinson's Disease (ROCK-PD)
2024-517413-33-00 Recruiting Latest: 2025-02-12 Idiopathic Parkinson's Disease
1 halt
Is local injection of mesenchymal stem cells after endoscopic dilation safe and does it improve the outcome of intestinal stricture in patie…
2024-511034-12-00 Recruiting Latest: 2025-06-18 Crohn's disease
1 halt
RIISC
2024-513669-38-00 Recruiting Latest: 2025-08-05 Stroke, Ischemic, TIA, Cardiac Disease, Atheroscle
1 urgent safety 1 unexpected event
68-Ga-FAPI-46 positron emission tomography (PET) to better visualise pancreatic and bile duct cancer.
2024-516486-36-00 Recruiting Latest: 2025-03-17 cholangiocarcinoma (bile duct cancer)
1 halt
Tezepelumab (Anti-TSLP-mab) in progressive pulmonary fibrosis interstitial lung disease with evidence of eosinophilia - A prospective two-ar…
2024-510884-51-00 Recruiting Latest: 2025-05-26 Progressive pulmonary fibrosis interstitial lung d
1 halt
Tolerance of intra-articular injection of autologous stromal vascular fraction for the treatment of rhizarthrosis_FVS-RHIZA
2024-515317-18-00 Recruiting Latest: 2025-12-22 Adults with a rhizarthrosis stage DELL 1 to 3
1 unexpected event
Recombinant coagulation Factor VIIa administered at the earliest time for the treatment of stroke caused by bleeding in the brain - FASTEST…
2024-517383-28-00 Recruiting Latest: 2025-01-25 Acute haemorrhagic stroke
2 halts
EORTC 2022-MG: Treatment with tebentafusp or observation for patients with melanoma of the eye after surgery or radiation (ATOM Trial)
2023-510333-28-00 Recruiting Latest: 2025-08-06 Uveal Melanoma
7 halts 1 urgent safety 1 unexpected event
NOVEL TREATMENT OF DIABETIC FOOT ULCER BY AUTOLOGOUS STROMAL VASCULAR FRACTION OF ADIPOSE TISSUE
2024-516342-19-00 Recruiting Latest: 2026-02-17 Diabetic Foot ulcERs
4 corrective measures
A study to evaluate long-term Infigratinib in children with Achondroplasia
2024-513857-55-00 Recruiting Latest: 2025-09-05 Achondroplasia
1 corrective measure
Interest of Oxytocin as an Adjuvant Treatment of Psycho-educational Measures in Challenging Behaviors in Children With Autism Spectrum Disor…
2024-516306-28-00 Recruiting Latest: 2025-06-02 Autism with Spectrum Disorders and Moderate to Sev
1 breach
Single arm phase 2 trial of neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positiv…
2024-516582-36-00 Recruiting Latest: 2025-07-08 Early stage HER2-positive breast cancer
1 breach 2 halts
Phase 1 study of a Propranolol (HEMANGIOL®) and oral metronomic Vinorelbine (NAVELBINE®) combination on children and teenagers With Refracto…
2024-517185-42-00 Recruiting Latest: 2026-04-16 Children and teenagers with refractory/relapsing s
1 breach 1 urgent safety
Clinical trial testing an investigational drug RVU120 for myelofibrosis (myeloproliferative neoplasm, MPN)
2024-511688-27-00 Recruiting Latest: 2025-04-04 Myelofibrosis
1 urgent safety
A phase 3 study to evaluate petosemtamab vs. investigator's choice in previously treated metastatic / recurrent head and neck cancer.
2023-510322-32-00 Recruiting Latest: 2025-03-21 patients with incurable, metastatic/recurrent head
1 corrective measure
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination…
2023-503442-30-00 Recruiting Latest: 2024-12-17 Multiple Myeloma
1 urgent safety
Improving public cancer care by implementing precision medicine in Norway
2023-507894-16-00 Recruiting Latest: 2025-09-04 Cancer
2 urgent safety
Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children with Sickle Cell Dis…
2024-513750-30-00 Recruiting Latest: 2026-02-25 Sickle Cell Disease
1 halt
A Phase 3 Study of I-DXd in Subjects with Relapsed SCLC
2023-509628-16-00 Recruiting Latest: 2026-05-22 Small Cell Lung Cancer (SCLC)
10 halts 1 urgent safety
A Phase 1b/2, Study of I-DXd in Combination with Atezolizumab with or without Carboplatin in First-line ES‑SCLC
2023-509629-36-00 Recruiting Latest: 2024-12-09 Extensive-stage Small Cell Lung Cancer (ES-SCLC)
1 corrective measure
HARMONi-3
2024-513087-26-00 Recruiting Latest: 2024-10-29 Metastatic Non-small Cell Lung Cancer
1 corrective measure
Substudy 06D: Combination Therapies in 2L Advanced Gastroesophageal Adenocarcinoma
2023-509306-29-00 Recruiting Latest: 2026-03-30 Gastroesophageal cancer
1 breach 1 unexpected event
Substudy 06C: Combination Therapies in Gastroesophageal Adenocarcinoma
2023-509307-33-00 Recruiting Latest: 2026-03-30 Gastroesophageal cancer
1 breach 1 unexpected event
Study of ARO-DUX4 in Adult Patients With Facioscapulohumeral Muscular Dystrophy Type 1
2023-509748-89-00 Recruiting Latest: 2026-02-05 Facioscapulohumeral muscular dystrophy (FSHD)
1 breach
Foetal neural stem cells transplantation in progressive multiple sclerosis
2024-511028-15-00 Recruiting Latest: 2025-09-17 Progressive Multiple Sclerosis
1 halt
Phase 1 Single Ascending Doses (SAD) of M5542 in Healthy Participants
2024-513069-37-00 Recruiting Latest: 2025-01-10 Healthy
1 halt
A phase III placebo-controlled efficacy and safety study of mocravimod as an adjunctive and maintenance treatment in AML patients undergoing…
2024-512752-38-00 Recruiting Latest: 2025-09-29 Adjunctive and maintenance treatment to HCT
6 halts
The CORTAD study
2024-512888-31-00 Recruiting Latest: 2026-05-28 Primary adrenal insufficiency (PAI)
1 breach
Combining anti-PD-L1 immune checkpoint inhibitor durvalumab with TLR-3 agonist rintatolimod in patients with metastatic pancreatic ductal ad…
2024-514597-42-00 Recruiting Latest: 2026-03-26 Metastatic pancreatic cancer
1 breach
Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-resistant Patients Scheduled to Undergo …
2023-507560-39-00 Recruiting Latest: 2025-08-20 Acquired Antithrombin Deficiency (Heparin Resistan
6 halts
MagnetisMM-6: A Phase 3 Study of Elranatamab (PF-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Bortezomib + Lenalidomide + Dex…
2024-514139-50-00 Recruiting Latest: 2025-11-27 Multiple myeloma
7 halts
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-fibrosis)
2023-509912-27-00 Recruiting Latest: 2024-11-27 Metabolic Dysfunction-Associated Steatotic Liver D
1 corrective measure
A Phase 2 Study to Test Effects of Using DAY101 in Children with Brain Cancer
2024-510691-20-00 Recruiting Latest: 2025-05-27 RAF-Altered, Recurrent or Progressive Low-Grade Gl
1 halt
A Phase 1/2, Multicenter Study Evaluating the Safety, Tolerability, and Biodistribution of RCT2100 with Single-Ascending Doses in Healthy Pa…
2024-512169-15-00 Recruiting Latest: 2025-10-15 Cystic Fibrosis
1 corrective measure
Study of MK-5684-based Therapies in Advanced Prostate Cancer
2023-506288-33-00 Recruiting Latest: 2025-01-22 Metastatic castration resistant prostate cancer (m
8 halts
ORIAMI
2023-508249-42-00 Recruiting Latest: 2026-02-12 Acute mesenteric ischemia
1 halt 1 urgent safety
A phase II, multicenter, open-label study evaluating Glofitamab in combination with Venetoclax plus Zanubrutinib or Venetoclax alone in subj…
2023-506706-40-00 Recruiting Latest: 2025-12-03 Mantle-Cell Lymphoma
2 urgent safety
A Phase 2 Study of Teclistamab in Combination with Daratumumab or Lenalidomide in Elderly Patients with Newly Diagnosed Multiple Myeloma - I…
2024-514101-65-00 Recruiting Latest: 2025-10-07 Multiple Myeloma
1 corrective measure
A Phase 1/2, Multicenter, Open Label, Dose Escalation and Dose Expansion Study of JK06, a 5T4 Antibody Drug Conjugate, in Patients with Unre…
2024-512421-92-00 Recruiting Latest: 2025-09-25 Unresectable, Locally Advanced or Metastatic Cance
4 halts 1 urgent safety
Randomised, controlled phase II proof-of-concept trial to assess the efficacy of abaCavIr/lamivudine treatment on the interferon signature i…
2023-508611-22-00 Recruiting Latest: 2024-09-06 systemic lupus
1 corrective measure
Whole body HER3 quantification with radiolabelled Patritumab deruxtecan (HER3-DXd) PET/CT
2023-508233-14-00 Recruiting Latest: 2026-02-11 EGFR mutation positive advanced stage NSCLC
2 breaches
STROKE-POC
2024-510866-18-00 Recruiting Latest: 2025-02-05 Spasticity after Stroke
1 halt
A Phase 3b Study to Evaluate Efficacy and Safety of a Single Dose of Autologous CRISPR Cas9 Modified CD34+ Human Hematopoietic Stem and Prog…
2024-514641-12-00 Recruiting Latest: 2025-07-09 Transfusion-dependent β-thalassemia (TDT)
1 corrective measure
A study in men with advanced prostate cancer to determine the safety and effects of a test drug (Lutetium (177Lu) rhPSMA 10.1 injection)
2024-511537-35-00 Recruiting Latest: 2026-03-16 Metastatic castration-resistant prostate cancer (m
1 urgent safety
TOLEDDO: Effect of weekly GLP1 agonist treatment in "double diabetes": a randomized, open-label study
2024-514906-30-00 Recruiting Latest: 2024-10-14 "double diabetes"
1 halt
A study to test how different doses of BI 1703880 in combination with ezabenlimab are tolerated in people with different types of advanced c…
2024-511501-37-00 Recruiting Latest: 2025-10-01 Advanced solid tumours
1 halt
IMpact of Phenylephrine vs. norAdrenaline on systemic hemodynamics and Cerebral Tissue circulation and oxygenation in anesthetized brain tum…
2024-515400-40-00 Recruiting Latest: 2024-11-14 low blood pressure during anesthesia
1 breach
A Study to Evaluate the Efficacy and Safety of XyloCore, a Glucose Sparing Experimental Solution, for Peritoneal Dialysis (ELIXIR)
2024-513562-19-00 Recruiting Latest: 2025-08-06 End-Stage Kidney Disease
5 halts
A first-in-human study to determine the safety and tolerability of different doses of GEH200520 Injection and GEH200521 (18F) Injection and …
2024-515218-42-00 Recruiting Latest: 2024-12-03 Irresectable or metastatic solid tumour or a local
1 halt
Treatment of chemo-refractory viral infections after allogeneic stem cell transplantation with multispecific T cells against CMV, EBV and Ad…
2024-512321-84-00 Recruiting Latest: 2025-04-14 Patients after HSCT suffering from new or reactiva
1 corrective measure
A Phase 2b Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects with Moderately to Severely Active Crohn’s Disease
2023-506704-14-00 Recruiting Latest: 2025-10-27 Moderately to Severely Active Crohn's Disease
1 breach
A clinical study of the safety and effectiveness of an investigational cell therapy given with and without an investigational RNA-based vacc…
2024-514962-38-00 Recruiting Latest: 2025-05-26 Solid Tumors
1 breach 2 unexpected events
Exploratory clinical trial to assess safety, tolerability efficacy and pharmacokinetics of CEB-01 PLGA membrane in participants with pancrea…
2024-512742-42-00 Recruiting Latest: 2025-11-20 Pancreatic carcinoma
2 breaches
VANCALLO - Prevention of C. difficile infections by oral vancomycin in patients treated for allogeneic hematopoietic stem cell transplantati…
2024-513490-45-00 Recruiting Latest: 2024-11-08 Patients hospitalized for allogeneic hematopoietic
1 unexpected event
A clinical study of MK-2870 and chemotherapy to treat lung cancer (MK-2870-009)
2023-504910-31-00 Recruiting Latest: 2025-05-19 Non-small Cell Lung Cancer (NSCLC)
2 halts
Study of Combination Therapies in Esophageal Cancer
2023-505189-26-00 Recruiting Latest: 2024-11-04 Advanced esophageal squamous cell carcinoma
1 unexpected event
Treatment of advanced or metastatic triple negative breast cancer with tumor infiltrating lymphocytes (TILs).
2024-511915-21-01 Recruiting Latest: 2025-03-07 advanced or metastasic triple-negative breast canc
1 halt
Treatment with acetylcholine esterase inhibitors in anorexia nervosa : a multicenter double-blind randomised controlled trial versus placebo
2024-511681-37-00 Recruiting Latest: 2025-08-07 Anorexia nervosa
1 breach
Addition of sulfalasazine to chemotherapy for the treatment of AML in the elderly
2024-513084-38-00 Recruiting Latest: 2024-06-26 Recently diagnosed non favorable Acute Myeloid Leu
1 halt 1 urgent safety
An open-label, dose-escalation, dose-finding, and proof-of-concept trial of SP-420 in subjects with transfusion-dependent α- or β-thalassemi…
2023-507396-21-00 Recruiting Latest: 2026-01-26 transfusion-dependent α- or β-thalassemia or low-r
1 corrective measure
Long-term clinical trial of PQ Grass in paediatric subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass poll…
2023-508520-36-00 Recruiting Latest: 2026-04-27 Seasonal allergic rhinitis/rhinoconjunctivitis ind
2 breaches
Clinical trial of MK-2870 in combination with pembrolizumab in people who have had surgery to treat triple negative breast cancer
2023-504962-52-00 Recruiting Latest: 2024-11-01 Triple negative breast cancer.
1 unexpected event
An open-label Phase 2 trial to investigate efficacy and safety of intraamniotic administrations of ER004 to male subjects with X-linked hypo…
2024-512632-30-00 Recruiting Latest: 2024-06-19 X-linked hypohidrotic ectodermal dysplasia (XLHED)
1 urgent safety
A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Other Therapeutic Agents in Participants with Head …
2023-508418-40-00 Recruiting Latest: 2024-08-21 Head and Neck Squamous Cell Carcinoma
1 corrective measure
method VALIDation and evaluation of non-radioactive methods to measure Glomerular Filtration Rate
2023-509156-34-02 Recruiting Latest: 2026-02-05 Chronic Kidney Disease Kidney Failure
1 halt
A Long-term Follow-up Study of Subjects with β-Thalassemia or Sickle Cell Disease Treated with Autologous CRISPR-Cas9 Modified Hematopoietic…
2024-512654-19-00 Recruiting Latest: 2025-07-09 Sickle Cell Disease
1 corrective measure
A prospective randomized single blind multicenter phase II study of organ perfusion with Custodiol-N compared with Custodiol in heart transp…
2023-510492-57-00 Recruiting Latest: 2025-01-03 heart transplantation in children
1 halt 1 corrective measure
Chemotherapy for the treatment of standard risk adult medulloblastomas
2024-513243-85-00 Recruiting Latest: 2024-05-29 Adult medulloblastoma
1 halt
A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects with Metastatic or Unresectable Non-Small Cell Lun…
2023-506539-14-00 Recruiting Latest: 2025-01-28 Oncology
1 halt
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients with Advanced Liver Cancers (M…
2023-506611-17-00 Recruiting Latest: 2024-10-15 Advanced liver cancers
1 unexpected event
VEX-AZA: Treating VEXAS Syndrome with Azacitidine. A Single-Arm, Multicenter Phase II Study on the Efficacy and Safety of Azacitidine in Pat…
2024-510715-30-00 Recruiting Latest: 2026-02-10 VEXAS
1 breach
PHASE Ib STUDY WITH THE COMBINATION OF LB–100 (PP2A INHIBITOR) AND ATEZOLIZUMAB (PD–L1 INHIBI-TOR) IN METASTATIC COLORECTAL CANCER PATIENTS …
2023-505534-98-00 Recruiting Latest: 2025-11-17 Microsatellite stable colorectal cancer patients
1 corrective measure
Combination of baricitinib and anti-TNF in rheumatoid arthritis
2024-511442-39-00 Recruiting Latest: 2024-09-11 Rheumatoid arthritis (RA)
1 halt
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezom…
2023-507632-20-00 Recruiting Latest: 2025-08-04 Multiple Myeloma
1 unexpected event
EORTC 1820-CLTF: Open-Label, phase II, Multi-Center, study of Anti-CCR4 Monoclonal Antibody (mogamulizumab) Plus Total Skin Electron Beam th…
2022-502434-10-00 Recruiting Latest: 2024-11-07 Cutaneous T-cell lymphoma, a category of cancers o
1 halt
MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a…
2023-505436-35-00 Recruiting Latest: 2024-10-07 Untreated FLIPI 2-5 Follicular Lymphoma
1 urgent safety
A Trial to Learn if REGV131-LNP1265 is Safe and Works to Help the Body Make Clotting Factor in Adult Patients with Hemophilia B
2023-507260-40-00 Recruiting Latest: 2025-07-28 Hemophilia B
1 corrective measure
High-Intensity Inpatient MDMA-Assisted Psychotherapy for Treatment-Refractory Posttraumatic Stress Disorder: An Open-Label Pilot Study
2023-508229-28-00 Recruiting Latest: 2025-02-12 posttraumatic stress disorder
1 unexpected event
COLCHICINE IN SECONDARY PREVENTION OF VASCULAR EVENTS AND RENAL PROGRESSION IN PATIENTS WITH MODERATE CHRONIC RENAL DISEASE
2023-505868-11-00 Recruiting Latest: 2026-03-16 CHRONIC RENAL DISEASE
1 breach
Efficacy of endothelin receptor antagonism in treatment of coronary artery spasm: a randomized controlled clinical trial. (EDIT-CAS)
2023-507782-25-00 Recruiting Latest: 2026-02-18 Coronary vasomotor dysfunction (spasm)
1 breach
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
2023-506987-15-00 Recruiting Latest: 2025-04-10 Metastatic Castration-Resistant Prostate Cancer
1 breach
Study of two doses of crizanlizumab versus placebo in adolescent and adult sickle cell disease patients
2023-508689-14-00 Recruiting Latest: 2025-09-29 Sickle cell disease
1 breach
StAtins for Venous Event Reduction in Patients with Venous Thromboembolism : The SAVER Trial
2023-504486-23-00 Recruiting Latest: 2024-08-05 Venous thromboembolism
1 corrective measure
NeoAdjuvant study comparing sacituzumab govitecan versus sacituzumab govitecan+pembrolizumab treatment in low-risk, triple-negative early br…
2023-508787-29-00 Recruiting Latest: 2025-05-26 Triple-negative early breast cancer with low risk
1 breach
Bomedemstat vs Best Available Therapy (BAT) for Essential Thrombocythemia
2023-504865-21-00 Recruiting Latest: 2024-10-11 Essential Thrombocythemia patients who have an ina
1 urgent safety
DRUP trial
2023-509152-33-00 Recruiting Latest: 2026-02-04 Advanced solid tumor
1 breach
A phase I/IIa, dose-finding study to assess the safety and immunogenicity of an Orf virus-based COVID-19 vaccine booster (Prime-2-CoV_Beta) …
2024-511266-36-00 Recruiting Latest: 2024-03-26 The clinical trial itself does not investigate a m
1 halt
Maternal oxygen therapy during pregnancy for unborn babies with underdeveloped structures on the left side of the heart
2024-512679-11-00 Recruiting Latest: 2025-02-11 unborn baby with developmental disorder of the lef
1 halt
Phase 3 study of adjuvant V940 and Pembrolizumab in resected Stage II, IIIA, IIIB NSCLC
2023-504923-20-00 Recruiting Latest: 2025-07-28 Stage II, IIIA, IIIB (N2) Non-small Cell Lung Canc
1 corrective measure
A phase I safety, dose finding and feasibility trial of GD2IL18CART in patients with relapsed or refractory GD2 positive solid cancers
2022-501725-21-00 Recruiting Latest: 2025-01-13 Neuroblastoma
1 corrective measure
A clinical study of opevesostat and standard hormone therapy in people with prostate cancer (MK-5684-004)
2023-504957-11-00 Recruiting Latest: 2025-08-06 Metastatic castration resistant prostate cancer
15 halts
A global study to assess the efficacy and safety of durvalumab in combination with bevacizumab or durvalumab alone in patients with hepatoce…
2023-507689-26-00 Recruiting Latest: 2024-06-07 Histologically or cytologically confirmed Locoregi
1 breach
A clinical trial comparing a new treatment (MK-5684) to approved medication for advanced prostate cancer after prior hormonal therapy and ch…
2023-504899-25-00 Recruiting Latest: 2025-06-05 Metastatic castration resistant prostate cancer
12 halts
VyClo ITCC-092
2023-508050-26-00 Recruiting Latest: 2024-08-22 AML
6 halts
A clinical study to compare MK-2870 with pembrolizumab to pembrolizumab alone in people with lung cancer (MK-2870-007)
2023-503376-24-00 Recruiting Latest: 2024-11-04 Metastatic non-small cell lung cancer (NSCLC)
1 unexpected event
Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects wi…
2023-509334-19-00 Recruiting Latest: 2024-04-11 gastro-enteropancreatic neuroendocrine tumors (GEP
3 halts
A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pe…
2023-503412-33-00 Recruiting Latest: 2026-04-01 Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-s
3 halts 1 corrective measure
A study to assess the efficacy and safety of lumateperone in patients with major depressive disorder
2023-503836-41-00 Recruiting Latest: 2024-07-31 Major Depressive Disorder
3 halts
A phase 1B of crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies
2023-504880-18-00 Recruiting Latest: 2024-08-21 Neuroblastoma (NBL)
1 halt
​​Lomustine with or without a second round of brain radiation for the reappearance of glioblastoma
2023-505267-36-00 Recruiting Latest: 2025-07-29 Glioblastoma
1 unexpected event
A Placebo-Controlled, Randomized Double-Blind Parallel Group 12-Month Trial of Fasudil for the Treatment of Early Alzheimer’s Disease
2023-506514-44-00 Recruiting Latest: 2025-09-12 Alzheimer's disease
1 breach
A clinical study to test the effect of niraparib and immunotherapy, for patients with small cell lung cancer (SCLC) that is positive for SLF…
2022-502092-33-00 Recruiting Latest: 2024-05-28 Extensive-disease small cell lung cancer and high
1 corrective measure
A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF)…
2023-504323-25-01 Recruiting Latest: 2026-02-23 breast cancer
1 breach
Renal Lifecycle Trial: A Randomized Controlled Clinical Trial to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in …
2023-508389-13-00 Recruiting Latest: 2024-03-12 Combined endpoint of all-cause mortality, kidney f
1 corrective measure
DOUBLE PRO-TECT Alport: A confirmatory, multicenter, randomized, double-blind, placebo-controlled clinical trial to assess the effect of Dap…
2023-508502-18-00 Recruiting Latest: 2025-07-17 Alport syndrome
1 urgent safety
A study to see how well KarXT is tolerated and how well tolerated it is when taken for long time in participants with psychosis associated w…
2023-504151-27-00 Recruiting Latest: 2025-08-15 Psychosis associated with Alzheimer’s Disease
2 unexpected events
Phase 2 Study of ZN‑c3 in High-Grade Serous Ovarian Cancer
2022-502983-19-00 Recruiting Latest: 2024-06-28 High-Grade Serous Ovarian, Fallopian Tube, or Prim
2 halts 3 urgent safety
Fecal Microbiota Transplantation Trial in Axial Spondyloarthritis
2023-504852-89-00 Recruiting Latest: 2025-05-02 AXIAL SPONDYLOARTHRITIS
1 breach 1 halt 1 urgent safety
Anticoagulation for Stroke Prevention In patients with Recent Episodes of Atrial Fibrillation occurring transiently with stress
2023-509142-35-00 Recruiting Latest: 2026-04-21 Atrial fibrillation after stress (e.g., noncardiac
5 corrective measures
Multi-Center, Open Label Gene Therapy Study of RP-A501 in Male Patients with Danon Disease
2023-506480-34-00 Recruiting Latest: 2025-06-02 Danon Disease
2 halts
HOVON 165 CLL: A prospective randomized phase I/II trial of venetoclax treatment (26 cycles) with 6 cycles or 12 cycles of epcoritamab in pa…
2022-500305-40-00 Recruiting Latest: 2024-06-26 Small Lymphocytic Lymphoma
1 urgent safety
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
2023-508302-24-00 Recruiting Latest: 2024-06-07 Locally Advanced/Metastatic Urothelial Cancer
1 unexpected event
Phase 1 Study of PYX-201 in Solid Tumors
2023-509687-14-00 Recruiting Latest: 2024-08-16 Advanced solid tumors
2 halts
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX versus mFOLFIRINOX Alone in Patients wit…
2022-502404-73-00 Recruiting Latest: 2025-11-28 Pancreatic ductal adenocarcinoma
1 breach
Platform study of JDQ443 in combinations in patients with advanced solid tumors harboring the KRAS G12C mutation
2023-506716-41-00 Recruiting Latest: 2024-07-17 Adult patients with advanced (metastatic or unrese
4 halts
ATLANTIS Protamine - Antagonization of heparin with protamine sulfate to reduce all neurologic ischemic and hemorrhagic events after transca…
2023-504511-32-00 Recruiting Latest: 2023-12-15 Any patients ≥18 years old, eligible for transfemo
1 corrective measure
A 52-week, Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of Siplizumab in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (A…
2023-506174-12-00 Recruiting Latest: 2024-08-09 Amyotrophic Lateral Sclerosis
1 halt
Naldemedine OIBD
2023-507744-36-00 Recruiting Latest: 2024-05-29 Opioid induced bowel dysfunction
1 halt
A Multicenter, Open-Label, Dose-Finding Clinical Trial to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of RV…
2023-505911-19-00 Recruiting Latest: 2025-03-17 Acute Myeloid Leukemia
1 urgent safety
Randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy, safety and tolerability of givinostat in non-ambul…
2023-503521-19-00 Recruiting Latest: 2024-05-28 Duchenne muscular dystrophy (DMD)
1 breach
Low INR to Minimize bleeding with mechanical valves Trial (LIMIT)
2023-508532-56-00 Recruiting Latest: 2025-09-04 Treatment with a Vitamin K Antagonist due to havin
1 halt
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
2023-507041-28-00 Recruiting Latest: 2025-07-28 Solid and Hematological Malignancies
1 corrective measure
Trans-arterial treatment of patients with intra-hepatic cholangiocarcinoma not amenable to resection (TOMCAT)
2023-504433-50-00 Recruiting Latest: 2025-03-05 Intra-hepatic cholangiocarcinoma
1 urgent safety
A Phase 1, Open-Label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preli…
2023-506199-28-00 Recruiting Latest: 2024-04-18 Dose escalation: Advanced Solid Tumors Dose Expans
1 halt
eHealth Based treatment of AdolescenT obesiTy with Low energy diet and sEmaglutide (eBATTLE Obesity)
2023-506289-29-00 Recruiting Latest: 2026-03-20 Obesity
2 breaches
Efficacy of the Doravirine/Tenofovir Disoproxil Fumarate/Lamivudine combination in people living with HIV with a history of M184V/I mutation…
2023-505845-17-00 Recruiting Latest: 2024-12-19 Patients living with HIV-1 who are virologically c
1 urgent safety
An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617…
2022-502956-29-00 Recruiting Latest: 2026-01-06 Oligometastatic prostate cancer (OMPC)
2 unexpected events
Pancreatitis and early omega-3-fatty acid infusion for reduction of organ failure and mortality.
2023-505220-57-03 Recruiting Latest: 2025-01-29 Predicted severe acute pancreatitis
1 breach
SAFETY AND POTENTIAL EFFECT OF INNOVATIVE CELL-BASED THERAPY USING ADIPOSE-DERIVED STROMAL VASCULAR FRACTION IN PATIENTS WITH AUTOIMMUNE XER…
2023-505149-20-00 Recruiting Latest: 2026-02-19 AUTOIMMUNE XEROSTOMIA
1 corrective measure
A study with new methods to monitor newly diagnosed multiple myeloma in participants being treated with a new treatment combination - TAURUS
2023-505221-14-00 Recruiting Latest: 2026-02-17 Multiple Myeloma
3 halts
An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients with Locally Advanced…
2023-503865-48-00 Recruiting Latest: 2024-09-12 Locally Advanced or Metastatic Non-Small Cell Lung
1 breach
A Phase I/II Study of AZD5863 in Adult Participants with Advanced or Metastatic Solid Tumors
2023-504139-42-00 Recruiting Latest: 2024-01-08 Advanced or metastatic solid tumors
1 corrective measure
FARE Trial
2023-506594-35-00 Recruiting Latest: 2025-03-14 Rectal cancer
1 halt
Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN).
2023-507233-19-00 Recruiting Latest: 2026-01-20 Treatment of IgAN
1 corrective measure
CHIP-AML22 Master protocol: Protocol for the treatment of children and adolescents with Acute Myeloid Leukemia (AML)
2023-504999-25-00 Recruiting Latest: 2025-08-19 Acute Myeloid Leukemia
1 breach 1 urgent safety
Clinical Surveillance vs. Anticoagulation for Low-risk Patients with Isolated Subsegmental Pulmonary Embolism: A Multicenter Randomized Plac…
2023-507801-32-00 Recruiting Latest: 2026-03-31 Isolated Subsegmental Pulmonary Embolism
3 halts
A study to investigate the effect of adding cobicistat to venetoclax and azacitidine in patients with acute myeloid leukemia (AML) who are i…
2023-505379-61-00 Recruiting Latest: 2026-03-17 Acute Myeloid Leukaemia
4 breaches
A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic B…
2022-503114-23-00 Recruiting Latest: 2024-02-23 Breast Cancer
1 corrective measure
JAKAHDI - JAK inhibitors in acquired hemophagocytic syndrome in the ICU
2023-504513-77-00 Recruiting Latest: 2025-12-23 Adult patients older than 18 years. Patients admit
1 urgent safety
Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
2023-506604-18-00 Recruiting Latest: 2024-02-13 Triple negative breast cancer
6 halts
A Study to Compare the Efficacy and Safety of Glofitamab as a Single Agent Versus Investigator’s Choice in Patients with Relapsed/Refractory…
2023-503206-37-00 Recruiting Latest: 2025-12-02 Mantle Cell Lymphoma (MCL)
1 unexpected event
An Open-label Study of XEN1101 in Epilepsy
2022-502282-24-00 Recruiting Latest: 2025-11-14 Primary generalized tonic-clonic seizures
1 breach
Phase 1, open-label, multicenter, dose escalation study of SRG-1505 as monotherapy in subjects with mature b-cell malignancies
2023-505204-34-00 Recruiting Latest: 2024-01-08 Mature B-Cell Neoplasm, Non-Hodgkin Lymphoma, Diff
1 corrective measure
A Phase 3, prospective, randomized, double-blind, placebo-controlled, parallel group, international, multi-center study of rotigotine in com…
2023-504602-11-00 Recruiting Latest: 2025-12-16 Mild to moderate Alzheimer's disease
1 breach
Predicting the effect of blood pressure lowering medication using Multi-Omics, a biomarker profile based on blood and urine analyses
2023-505239-10-00 Recruiting Latest: 2026-03-11 Primary (essential) hypertension
1 breach
PRODIGE 88-CIRCULATE PAC: Phase III multicentric, open-label, randomized study to investigate the efficacy of chemotherapy in patients with …
2023-505046-26-00 Recruiting Latest: 2026-06-02 Colon carcinoma
1 corrective measure
FORE-PAIN trial
2022-500176-63-00 Recruiting Latest: 2025-02-10 Acute traumatic pain
3 breaches 1 halt
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell L…
2022-501489-24-00 Recruiting Latest: 2025-09-10 First-line treatment of adult subjects with high-r
7 halts 1 corrective measure
Iberdomide Manteinance Versus Lenalidomide Manteinance Therapy Following Autologous Stem Cell Transplant in Participants with NDMM
2022-501515-14-00 Recruiting Latest: 2025-06-03 Newly Diagnosed Multiple Myeloma (NDMM)
1 unexpected event
APEDOC: The role of peripheral afferents in modulating post-stroke central pain
2023-504676-17-00 Recruiting Latest: 2024-12-20 Patients with central neuropathic pain POST stroke
1 halt
An Open-Label, Multicenter, Multi-Arm Phase 1 Study Evaluating the Safety and Pharmacokinetics of ADU-1805 in Adults with Advanced Solid Tum…
2022-502757-34-00 Recruiting Latest: 2023-10-18 Advanced solid tumors
1 corrective measure
For patients with active multiple sclerosis, impact of annual versus semi-annual infusions of ocrelizumab after 2 years of initial treatment…
2023-505420-62-00 Recruiting Latest: 2024-12-12 Multiple sclerosis
1 breach
177Lu-edotreotide compared to everolimus in neuroendocrine tumors of the lung and thymus
2022-502154-13-00 Recruiting Latest: 2025-08-08 Patients with well to moderately differentiated ne
1 breach
MARSUN: Evaluation of the benefits of the combination of Mosunetuzumab-Lenalidomide versus a treatment chosen by the investigator in Patient…
2022-501810-77-00 Recruiting Latest: 2024-12-23 Relapsed or Refractory Marginal Zone Lymphoma
3 urgent safety 1 unexpected event
REscue of Nephrons with ALe.F02 (RENAL F02)
2022-502184-38-00 Recruiting Latest: 2024-12-10 Rapidly progressive glomerulonephritis
7 halts
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given with Either Cemiplimab, or Cemiplimab + Fianlimab, …
2022-501904-83-00 Recruiting Latest: 2026-03-10 Ovarian Cancer
1 breach
A clinical study in 3 parts with a microdystrophin (called GNT0004), a new gene therapy in boys with Duchenne disease who can still walk. Th…
2023-505187-11-00 Recruiting Latest: 2025-09-23 Duchenne Muscular Dystrophy
1 urgent safety 1 unexpected event
Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
2022-502281-25-00 Recruiting Latest: 2025-11-14 Focal Onset Seizures
1 breach
A phase 1/2 multicenter open-label study to investigate treatment of hydroxyurea (HU) in combination with valproic acid (VPA) or 6- mercapto…
2022-501992-15-00 Recruiting Latest: 2025-09-25 Acute Myeloid Leukemia (AML)
1 urgent safety
Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-1)
2022-500699-76-00 Recruiting Latest: 2025-01-31 Active Systemic Lupus Erythematosus (SLE)
2 halts 1 corrective measure
Tranexamic acid for hyperacute spontaneous IntraCerebral Haemorrhage (TICH-3)
2022-500587-35-01 Recruiting Latest: 2026-04-01 Stroke
4 halts 1 unexpected event
Prophylaxis Study of Marstacimab in Pediatric Hemophilia Participants With or Without Inhibitors
2022-500495-65-00 Recruiting Latest: 2025-12-22 Haemophilia
1 halt
A Phase I/II trial of MK-3475 (pembrolizumab) in children's solid tumors and lymphoma
2022-501257-36-00 Recruiting Latest: 2023-04-21 Treatment of advanced melanoma, or advanced, relap
1 halt
A Study of Subcutaneous Nivolumab + Relatlimab FDC in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-127)
2022-500967-11-00 Recruiting Latest: 2024-02-07 Previously Untreated Metastatic or Unresectable Me
1 corrective measure
A phase 3 trial of brexpiprazole once-weekly (QW) formulation in patients with acute schizophrenia
2022-500583-36-00 Recruiting Latest: 2023-10-31 Acute Schizophrenia
1 halt
A multi-center randomized, double blinded phase IIb trial evaluating oral pooled fecal microbiotherapy MaaT033 to prevent allogeneic hematop…
2022-501831-18-00 Recruiting Latest: 2025-03-26 Patients with hematologic malignancies and undergo
1 unexpected event
A Phase 2/3 Randomized, Placebo-Controlled, Double-blind, Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vericigua…
2022-501238-52-00 Recruiting Latest: 2025-05-27 Heart failure due to systemic left ventricular sys
2 halts
A Study of Aztreonam-Avibactam (ATM-AVI) Compared to Best Available Therapy in Pediatric Participants with Serious Gram-Negative Bacterial C…
2022-501575-12-00 Recruiting Latest: 2023-06-27 Hospital-Acquired Pneumonia
1 halt
Phase 1/2a study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of SQY51 in Paediatric and Adult Patients with a Genetically…
2022-500703-49-01 Recruiting Latest: 2025-03-26 Duchenne muscular dystrophy
2 halts 2 urgent safety
OPtimisation of antiviral Therapy in Immunocompromised COVID-19 patients: a randomized factorial controlled strategy trial: the OPTICOV Stud…
2022-501408-81-01 Recruiting Latest: 2024-02-22 Covid-19
2 halts
WOEST-3
2022-502140-13-00 Recruiting Latest: 2024-04-19 Atrial fibrillation Acute coronary syndrome Chroni
1 corrective measure
Expression-linked and R-ISS-adapted stratification for first line therapy in multiple myeloma patients (ELIAS)
2022-500453-16-00 Recruiting Latest: 2023-09-08 Multiple Myeloma
1 halt
An adaptive, Phase 2, double-blind, randomized, placebo-controlled, multicenter study to evaluate the safety, tolerability, immunogenicity, …
2022-500292-31-00 Recruiting Latest: 2022-12-06 Early stages of idiopathic Parkinson's Disease
1 halt
Effect and safety of flecainide and metoprolol alene to suppress ventricular arrhythmias in arrhythmic mitral valve prolapse.
2022-500814-24-00 Recruiting Latest: 2024-01-16 Arrhythmic mitral valve prolapse
2 breaches
INVITED trial
2022-500906-17-01 Recruiting Latest: 2023-11-27 Type 1 diabetes
1 breach
Nivolumab in combination with cisplatin and 5-fluorouracil as induction therapy in children and adults with EBV-positive nasopharyngeal carc…
2022-500676-59-00 Recruiting Latest: 2025-05-28 EBV-positive nasopharyngeal carcinoma
1 halt
OPTIMISE: Optimized Immunosuppression for Corneal Transplantation: a multi-centre randomized controlled clinical trial
2022-500109-41-00 Recruiting Latest: 2024-03-18 Corneal transplantation, Descemet's Membrane Endot
1 corrective measure
VASODILATATION OR LOOP-DIURETICS FOR INITIAL TREATMENT OF PULMONARY CONGESTION DUE TO ACUTE HEART FAILURE – A RANDOMIZED PLACEBO-CONTROLLED …
2022-500035-36-01 Recruiting Latest: 2024-06-27 Acute heart failure with pulmonary congestion
1 breach
A single dose, randomized, double-blind 2-arm parallel-group study to compare the pharmacokinetics, immunogenicity, and safety for PB016 ver…
2025-522534-31-00 Ended Latest: 2026-01-20 Not applicable, healthy volunteers
1 halt
PEHRICCA : PErioperative CISGEM plus RILVEGOSTOMIG in High-Risk resectable Intrahepatic CholangioCarcinoma
2025-521302-17-00 Ended Latest: 2026-03-26 Hihg risk of cholangiocarcinoma intra hépatic rese
1 halt
A Phase 3 Study to Evaluate the Efficacy and Safety of Ritlecitinib in Children 6 to <12 Years of Age With Severe Alopecia Areata
2024-515438-33-00 Ended Latest: 2026-01-28 Alopecia areata
1 corrective measure
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) ( MOVE-Lp(a) )
2025-521067-13-00 Ended Latest: 2026-04-10 Atherosclerotic Cardiovascular Disease (ASCVD)
14 halts
A Phase II, randomized, open-label, multi-center study of JSB462 (luxdegalutamide) in combination with lutetium (177Lu) vipivotide tetraxeta…
2024-520155-24-00 Ended Latest: 2026-05-08 Metastatic castration resistant prostate cancer (m
2 unexpected events
A Study of Subcutaneous Nivolumab plus Intravenous Ipilimumab and Chemotherapy in Participants with Previously Untreated Metastatic or Recur…
2024-520108-25-00 Ended Latest: 2025-11-19 Non-small cell lung cancer (NSCLC)
5 halts
FTIH study to investigate the safety and preliminary efficacy of the DNA-repair inhibitor GSK4418959 alone or in combination with other anti…
2024-519721-37-00 Ended Latest: 2025-09-25 Neoplasms, Colorectal
1 urgent safety
Autologous tolerogenic dendritic cells (ATDC) for highly sensitized kidney transplant recipients
2024-519978-39-00 Ended Latest: 2026-01-15 Kidney trasplants
1 halt
An open-label safety and tolerability clinical trial of PST-611 in dry age-related macular degeneration.
2024-519025-37-00 Ended Latest: 2025-12-15 Dry age-related macular degeneration.
1 corrective measure
Parenteral Retinol Level and Tolerability Trial
2024-516994-59-00 Ended Latest: 2026-01-26 Bronchopulmonary Dysplasia
2 halts
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole in People Over 18 Years of Age With HR-Positive, …
2024-512925-95-00 Ended Latest: 2025-07-31 Advanced/Metastatic Breast Cancer
14 halts
A Phase I/IIa Study of Roginolisib in combination with dostarlimab with or without docetaxel in Advanced NSCLC (PULMO-01)
2024-517741-14-00 Ended Latest: 2026-03-06 advanced non-squamous non-small cell lung cancer (
1 breach
A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692…
2024-512914-16-00 Ended Latest: 2026-03-25 Relapsing-remitting Multiple Sclerosis
11 halts
Phase I Study of Plitidepsin Administered Intravenously as a Single Dose in Healthy Volunteers
2024-513664-25-00 Ended Latest: 2025-10-30 Virus diseases
1 halt
BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) with Chemotherapy vs Atezolizumab with Chemotherapy as First-line Therapy in Part…
2024-515740-23-00 Ended Latest: 2025-05-29 Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
1 halt
A trial of Lu AF82422 in Participants with Multiple System Atrophy (MSA)
2024-517169-18-00 Ended Latest: 2026-04-06 Multiple System Atrophy
1 urgent safety
Study to test new drug eftilagimod alfa (also known as efti) combined with standard marketed treatments (pembrolizumab and chemotherapy) in …
2024-513621-23-00 Ended Latest: 2026-03-23 Advanced/metastatic non-small cell lung cancer (NS
1 urgent safety
Evaluation of the safety and efficacy of the drug Veonetinib (AL8326) in the post-first treatment of small cell lung cancer, non small cell …
2023-509067-24-01 Ended Latest: 2025-09-15 - Small Cell Lung Cancer (SCLC) patients who need
1 halt
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer
2024-512998-27-00 Ended Latest: 2026-01-13 Non-Small Cell Lung Cancer
1 unexpected event
A clinical trial to learn about the effects of YTB323 in people with difficult-to-treat severe inflammatory myopathies (IIM)
2024-514137-38-00 Ended Latest: 2026-05-22 Severe refractory idiopathic inflammatory myopathi
1 breach 4 halts 1 corrective measure
The Pragmatic EE-PRS Trial assessing Polygenic Risk Driven Statin Therapy for Cardiovascular Disease Prevention
2024-513424-42-01 Ended Latest: 2025-07-09 High polygenic risk for coronary artery disease
1 breach
CLINICAL STUDY TO TEST STEM CELLS FOR THE TREATMENT OF LONG-TERM, NON-HEALING VENOUS LEG ULCERS
2024-512720-11-00 Ended Latest: 2025-07-21 chronic venous ulcers (CVU)
1 breach
A trial to learn how safe AZD8630 is and how well it works in adults with uncontrolled asthma.
2024-514228-18-00 Ended Latest: 2025-04-29 Asthma in adults who remain uncontrolled despite m
1 halt
Phase 3 study of RMC-6236 in patients with previously treated metastatic PDAC
2024-516063-89-00 Ended Latest: 2025-04-15 Metastatic Pancreatic Ductal Adenocarcinoma
3 halts
A clinical trial evaluating the efficacy and safety of the drugs - cyclosporine and methotrexate in children and adolescents with moderate t…
2023-509759-15-00 Ended Latest: 2025-05-15 atopic dermatitis
1 urgent safety 1 unexpected event
Efficacy and safety of Silycus® in Cushing’s disease: a multicenter, single arm, open label, dose titration, proof of concept study (Silycus…
2024-518869-99-00 Ended Latest: 2025-06-19 Cushing's disease
1 halt
A study to investigate the safety and tolerability of SDL-M1 nanoparticles in healthy volunteers
2024-518889-27-00 Ended Latest: 2025-12-18 Septic cholestasis
2 halts
Treatment for previously untreated patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with an IDH1 or IDH2 mutatio…
2022-502832-37-00 Ended Latest: 2026-03-17 Acute myeloid leukemia
1 breach
Melatonin for prevention of agitation after surgery in children (MELA-PAED).
2024-517592-20-00 Ended Latest: 2025-07-09 Emergence delirium
1 halt
A clinical study to evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Comb…
2023-505792-71-00 Ended Latest: 2024-12-18 Multiple Myeloma
1 halt
Hidradenitis Suppurativa: Evaluation of lutikizumab in Adult and Adolescent Subjects
2024-510730-40-00 Ended Latest: 2025-07-11 Hidradenitis Suppurativa
2 corrective measures
Wilms’ tumor (WT1) antigen-targeted dendritic cell vaccination to prevent relapse in adult patients with acute myeloid leukemia: a multicent…
2024-515292-35-00 Ended Latest: 2024-11-07 Acute Myeloid Leukemia
1 halt
LOGGIC/FIREFLY-2: DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients with Low-Grade Glioma Requiring First-Line Systemic Therapy
2024-510742-13-00 Ended Latest: 2026-02-25 Pediatric low-grade glioma harboring an activating
2 breaches
Once-daily inhaled molgramostim nebulizer solution in aPAP
2024-511052-41-00 Ended Latest: 2025-05-15 Autoimmune Pulmonary Alveolar Proteinosis
1 corrective measure
TherVacB_Phase1a: Open phase 1a trial to assess the safety and immunogenicity of a heterologous protein prime/MVA boost therapeutic hepatiti…
2024-514231-26-00 Ended Latest: 2025-04-07 Chronic Hepatitis B
2 halts
AIEOP-BFM 2017 POLAND - Collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia - A randomized phas…
2024-517253-27-00 Ended Latest: 2025-04-11 Acute lymphoblastic leukemia
1 breach
HOVON 172 MF: Study on tasquinimod treatment in patients with myelofibrosis
2024-511565-11-00 Ended Latest: 2025-04-14 Myelofibrosis
1 halt
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)
2023-508636-61-00 Ended Latest: 2025-09-05 Crohn’s Disease
1 breach
A randomized, double-blind, parallel group, placebo-controlled multicenter study to evaluate efficacy, safety and tolerability of ianalumab …
2024-511933-36-00 Ended Latest: 2025-01-17 Diffuse cutaneous systemic sclerosis (dcSSc)
1 corrective measure
A randomised, double-blind, placebo-controlled, two-part study to evaluate the pharmacokinetics, safety and tolerability, and preliminary ef…
2024-515907-20-00 Ended Latest: 2025-05-28 Primary biliary cholangitis (PBC)
6 halts
Opioid-Free Analgesia In Intensive Care Unit (OFICU)
2024-517770-14-00 Ended Latest: 2025-02-14 Intubation
1 halt
Study Title: Single cell characterization of persistent cells upon treatment with durvalumab (MEDI4736) with or without Tremelimumab in MSS …
2023-509619-10-00 Ended Latest: 2024-11-13 MSS and MSI colorectal and endometrial tumors
1 halt
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis
2024-510753-10-00 Ended Latest: 2026-03-03 Prurigo Nodularis
1 breach 1 urgent safety
A phase 1/2 multiple-indication biomarker, safety, and efficacy study in advanced or metastatic Gastrointestinal cancers exploring treatment…
2024-515936-62-00 Ended Latest: 2025-08-14 Patients with advanced or metastatic gastrointesti
1 breach
A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of midostaurin to 10-day decitabine in unfit…
2023-503829-18-00 Ended Latest: 2026-03-17 Acute myeloid leukemia
1 breach
A Phase Ib-II Study of tazemetostat (EPZ-6438) in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or high risk Follicular Lymphoma (FL…
2024-515846-18-00 Ended Latest: 2026-03-19 Newly diagnosed Diffuse Large B Cell Lymphoma
1 unexpected event
Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk…
2024-515769-32-00 Ended Latest: 2026-05-05 HR+/HER2- early breast cancer
1 urgent safety
An open, randomised, controlled phase II trial of CellProtect in combination with Isatuximab antibody versus Isatuximab antibody alone as ma…
2024-514527-42-00 Ended Latest: 2024-09-27 Multiple myeloma
1 halt
A study of safety and tolerability (acceptability of potential side effects) of exidavnemab, at 2 different doses, in patients with Parkinso…
2024-511222-30-00 Ended Latest: 2025-04-02 Multiple System Atrophy
1 breach
An exploratory, multicenter, randomized, open-label with blind evaluation, active controlled study to evaluate the safety and efficacy of Ke…
2024-515667-60-00 Ended Latest: 2024-09-25 Actinic keratosis
1 halt
A PHASE 1/2 STUDY EXPLORING THE SAFETY AND ACTIVITY OF TRIFLURIDINE/TIPIRACIL IN COMBINATION WITH CAPECITABINE AND BEVACIZUMAB IN METASTATIC…
2024-513271-41-00 Ended Latest: 2025-06-24 colorectal metastatic cancer
1 corrective measure
An open-label study to investigate ECUR-506 in male children less than 9 months of age with neonatal onset OTC deficiency
2023-506180-34-01 Ended Latest: 2026-04-09 Ornithine Transcarbamylase Deficiency (OTC)
3 halts
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II…
2024-516530-36-00 Ended Latest: 2024-11-13 low-grade serous carcinoma of the ovary or periton
1 halt
Prospective multicenter randomized controlled double-blind label study of the prophylaxis of recurrent pouchitis after fecal microbiota tran…
2024-517078-52-00 Ended Latest: 2025-09-25 Patients operated with an IPAA for ulcerative coli
1 halt
Study of JDQ443 in advanced cancer with a specific mutation (G12C) of the KRAS gene
2023-508073-87-00 Ended Latest: 2024-10-14 Advance solid tumors harboring the KRAS G12C mutat
7 halts
A phase 3 clinical trial of a new combination treatment, domvanalimab and zimberelimab, plus chemotherapy, for people with an upper gastroin…
2023-507522-16-00 Ended Latest: 2025-12-22 Metastatic Esophageal or Gastric Cancer
1 unexpected event
A Phase III study to investigate the efficacy and safety of anifrolumab in adults with chronic and/or subacute cutaneous lupus erythematosus
2023-503692-24-00 Ended Latest: 2025-12-23 Cutaneous Lupus Erythematosus
1 breach
Phase Ib/II non-randomized non-comparative two-cohort study of Niraparib and Dostarlimab plus (Chemo)RadIotherapy in Locally-Advanced head a…
2024-516779-33-00 Ended Latest: 2026-01-29 Carcinoma
1 breach
Assessing the safety, tolerability, and effectiveness of crofelemer in people with the intestinal disease Microvillus Inclusion Disease (MVI…
2024-512845-18-00 Ended Latest: 2025-07-28 Microvillous Inclusion Disease (MVID)
1 corrective measure
A phase II trial investigating Gemcitabine/Oxaliplatin/Rituximab with Tafasitamab (MOR208) for patients aggressive Lymphoma.
2024-514775-17-00 Ended Latest: 2024-08-26 Malignant B-cell lymphoma
1 halt
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Ocrelizumab in Adult Patients with Primary Progressive Multiple Sc…
2022-502611-10-00 Ended Latest: 2026-02-13 Primary Progressive Multiple Sclerosis (PPMS)
1 urgent safety
Perioperative/Adjuvant atezolizumab in patients with MSI-high or MMRdeficient stage II high risk or stage III colorectal cancer ineligible f…
2024-515224-37-00 Ended Latest: 2024-09-05 Patients with MSI-high or MMR-deficient stage III
1 halt
REDEFINE 3: A research study to see the effects of CagriSema in people living with diseases in the heart and blood vessels
2023-506924-94-00 Ended Latest: 2026-04-17 Cardiovascular disease
1 breach
Modified autologous leukocyte cells for the treatment of acute kidney injury after cardiac surgery
2023-504610-30-01 Ended Latest: 2026-04-14 Acute kidney injury after cardiac surgery
1 halt
MLS-101-901: An Open-Label Extension Study to Assess the Long-Term Safety, Efficacy, and Tolerability of Lorundrostat in Subjects with Hyper…
2023-508670-28-00 Ended Latest: 2025-07-11 Hypertension
1 urgent safety
ELVN-002 combined with trastuzumab +/- chemotherapy in HER2 + Solid Tumors
2023-509716-29-00 Ended Latest: 2025-12-10 Solid Tumors, Colorectal Cancer and Breast Cancer
1 unexpected event
Study of safety and efficacy of DKY709 alone or in combination with PDR001 in patients with advanced solid tumors.
2024-513281-19-00 Ended Latest: 2024-08-19 Nasopharyngeal Carcinoma
2 halts
A research study to find out if the study treatment alpelisib (BYL719) is safe and can help others who have confirmed diagnosis of PIK3CA-re…
2023-508530-34-00 Ended Latest: 2025-09-17 PIK3CA-Related Overgrowth Spectrum (PROS)
4 unexpected events
A trial to learn how well capivasertib with docetaxel works and how safe it is in people with metastatic castration-resistant prostate cance…
2023-504996-26-00 Ended Latest: 2025-05-14 Metastatic Castration Resistant Prostate Cancer (m
1 unexpected event
A Phase 1/2 Study with Ascending Dose in order to Evaluate the Safety and Effects on Progranulin Levels of investigational product under cod…
2022-502942-29-01 Ended Latest: 2025-12-11 Fronto-Temporal Dementia with Progranulin Mutation
2 halts
MULTICENTER, RANDOMIZED, BLIND AND CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY IN THE CORRECTION OF DEFICIT IN SUBJECTS WI…
2024-514528-17-00 Ended Latest: 2025-03-05 Severe vitamin D deficiency
1 halt
HOVON 156 AML: Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin …
2022-502478-18-00 Ended Latest: 2026-03-17 Acute Myeloid Leukemia (AML)
2 breaches
A clinical study that compares a treatment with Iberdomide, Daratumumab and Dexamethasone against a treatment with Daratumumab, Bortezomib, …
2024-510800-35-00 Ended Latest: 2025-01-30 Relapsed or Refractory Multiple Myeloma (RRMM)
1 unexpected event
A study evaluating the efficacy of axicabtagene ciloleucel versus standard of care therapy in patients with relapsed/refractory Follicular L…
2024-511594-30-00 Ended Latest: 2025-09-02 Relapsed/Refractory Follicular Lymphoma
1 corrective measure
A study to test different doses of BI 1831169 alone and in combination with an anti-PD-1 antibody in people with different types of advanced…
2024-512504-19-00 Ended Latest: 2026-05-13 solid tumors
10 halts
Clinical trial with ivermectin to treat strongyloidiasis with the aim of demonstrating that both the independent and weight-dependent dose o…
2024-515968-32-00 Ended Latest: 2025-08-13 Strongyloidiasis is caused by a parasite that is g
1 breach 1 halt
RCT of Medical Cannabis Aerosol for DPNP Treatment
2023-508932-68-00 Ended Latest: 2025-12-18 Diabetic Peripheral Neuropathic Pain
1 unexpected event
PALLAS - PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy vers…
2024-514841-12-00 Ended Latest: 2025-07-02 To determine whether the addition of palbociclib t
1 breach
Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent Glioblastoma (GBM)
2024-511452-40-00 Ended Latest: 2024-09-16 Oncology - Glioblastoma (GBM)
2 halts
A Study to Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants with Previously Untreated High-…
2023-510178-15-00 Ended Latest: 2025-03-04 High-risk Large B-cell Lymphoma
1 halt 1 urgent safety 1 unexpected event
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
2023-507418-28-00 Ended Latest: 2024-10-18 Solid tumors
1 urgent safety
A study to investigate the efficacy and safety of trastuzumab deruxtecan as the first treatment option for locally advanced/metastatic Non-S…
2023-503674-20-00 Ended Latest: 2024-09-12 Unresectable, locally advanced, or metastatic Non-
1 breach
A PHASE 3, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED STUDY OF PF-06939926 IN DMD
2023-508510-42-00 Ended Latest: 2024-09-04 DUCHENNE MUSCULAR DYSTROPHY (DMD)
5 halts
A study to test Taldefgropeb Alfa in patients with Spinal Muscular Atrophy.
2024-511852-42-00 Ended Latest: 2024-07-18 Spinal Muscular Atrophy
1 breach
Daratumumab in ME/CFS
2024-512500-19-00 Ended Latest: 2024-10-30 Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
1 breach
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients with Multiple Sclerosis
2023-505974-14-00 Ended Latest: 2025-07-15 Multiple Sclerosis (MS)
1 unexpected event
A Phase 1, Multicenter, Open-Label Study of REM-422, an MYB mRNA Degrader, in Patients With Relapsed/Refractory AML or Higher-Risk MDS
2023-510479-72-00 Ended Latest: 2025-04-10 Relapsed/Refractory AML or Higher-Risk MDS
1 halt
CC-92480-MM-002 A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Prel…
2023-505219-19-00 Ended Latest: 2024-12-24 Relapsed or refractory multiple myeloma (RRMM) and
1 unexpected event
Study of EGF816 in combination with selected targeted agents in EGFR-mutant NSCLC.
2024-511757-21-00 Ended Latest: 2024-08-27 Patients with EGFR-mutant Non Small Cell Lung Canc
2 halts
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combin…
2023-503467-41-00 Ended Latest: 2024-12-17 Relapsed or Refractory Multiple Myeloma
1 urgent safety
A randomized active-controlled trial for vulvovaGinal atRophy in breAst Cancer patients on Endocrine therapy (GRACE-trial)
2024-510845-33-00 Ended Latest: 2024-11-25 Breast cancer patients on endocrine therapy (AI or
1 halt
AFAMOSI: Prospective, randomized, multicenter Phase IV study to evaluate the efficacy and safety of afatinib followed by osimertinib compare…
2024-511625-55-00 Ended Latest: 2024-07-11 EGFRmutated/T790M Mutation negative non-squamous N
1 halt
A multi-center, open-label extension study of subcutaneous secukinumab to evaluate the long-term safety and tolerability in polymyalgia rheu…
2023-508077-85-00 Ended Latest: 2025-06-26 Polymyalgia Rheumatica
1 corrective measure
A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of Lutathera in combination with best supportive …
2023-507443-10-00 Ended Latest: 2024-08-23 Patients with somatostatin receptor positive, well
1 unexpected event
Study of efficacy and safety of LXH254 combinations in patients with previously treated unresectable or metastatic melanoma
2024-511934-11-00 Ended Latest: 2024-08-13 Previously treated unresectable or metastatic BRAF
4 halts
A clinical study to assess the effectiveness and safety of LOXO-305 compared to standard of care treatment chosen by the Investigator in pat…
2023-507695-52-00 Ended Latest: 2024-08-05 Mantle cell lymphoma
1 breach
Study to evaluate the efficacy and safety of MAS825 in patients with autoinflammatory diseases.
2023-504419-34-00 Ended Latest: 2025-10-27 Autoinflammatory diseases including NLRC4-Gain of
1 corrective measure
ADP-A2M4 in Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
2024-512847-21-00 Ended Latest: 2026-02-04 Advanced Synovial Sarcoma
1 corrective measure
A translational RANDOMIZED phase III study exploring the effect of the addition of capecitabine to Carboplatinum based chemotherapy in early…
2022-501102-35-00 Ended Latest: 2025-02-11 Early triple negative breast cancer
1 breach
A Phase 2 Open-Label Safety and Efficacy Study of PF-06835375
2023-509338-21-00 Ended Latest: 2025-03-11 Primary immune thrombocytopenia
6 halts
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated …
2023-504027-78-00 Ended Latest: 2024-10-15 Previously Untreated Locally Advanced or Metastati
1 unexpected event
The goal of this clinical study is to learn more about the safety and dosing of the study drugs, KITE-363 and KITE-753, in participants with…
2024-511616-24-00 Ended Latest: 2024-12-19 Relapsed and/or Refractory B-cell Lymphoma
2 halts
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination with Standard of Care and in Recurrent Glioblasto…
2023-506719-17-00 Ended Latest: 2025-04-01 Glioblastoma
1 halt
A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants with Prodromal and Early Manife…
2023-503928-10-00 Ended Latest: 2025-05-07 Prodromal and Early Manifest Huntington’s Disease
2 breaches 1 urgent safety
A Multicenter, Open-Label, Single-Arm, Phase II Trial Exploring the Maintenance of Trastuzumab and Pertuzumab Following Trastuzumab Deruxtec…
2023-507306-13-00 Ended Latest: 2025-08-01 HER2-positive unresectable locally recurrent or me
1 breach
A study to evaluate the efficacy and safety of AMY109 in women with endometriosis
2023-507289-14-00 Ended Latest: 2025-02-24 Endometriosis
1 urgent safety
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants with…
2023-508697-28-00 Ended Latest: 2024-06-14 Frontotemporal Dementia (FTD)
6 halts
Safety and Efficacy Study of Epcoritamab in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
2023-504828-25-00 Ended Latest: 2024-07-31 Chronic Lymphocytic Leukemia
1 breach
A Study Evaluating the Safety, Pharmacokinetics (what the body does to a drug), and Efficacy of Mosunetuzumab given subcutaneously (SC) or i…
2023-507236-20-00 Ended Latest: 2024-07-03 Follicular Lymphoma (FL)
1 unexpected event
Efficacy and Safety of Oral Midazolam for Providing Care to Patients Who Refuse Treatment and Have Moderately Severe to Severe Neurocognitiv…
2023-510277-33-00 Ended Latest: 2026-01-29 Neurocognitive Disorders and Agitation in Older Ad
1 halt
A study of ONCOFID-P-B administered intravesically to patients with Carcinoma in Situ of the bladder who have not responded to the standard …
2024-512568-72-00 Ended Latest: 2026-05-05 BCG-unresponsive Carcinoma in Situ of the bladder
1 urgent safety
A global study of midostaurin in combination with chemotherapy to evaluate safety, efficacy, and pharmacokinetics in newly diagnosed pediatr…
2023-509834-20-00 Ended Latest: 2025-07-11 untreated FLT3-mutated Acute Myeloid Leukemia
1 corrective measure
A Clinical Study to Evaluate the Safety and Efficacy of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small …
2023-508256-19-00 Ended Latest: 2024-05-10 Unresectable Metastatic Non-small Cell Lung Cancer
5 halts
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease …
2023-506926-35-00 Ended Latest: 2025-12-08 Atherosclerotic cardiovascular disease, chronic ki
1 breach
"Open-Label Safety and Efficacy Study of Cenobamate (YKP3089) in Children with Partial-onset (Focal) Seizures "
2023-506841-52-00 Ended Latest: 2025-07-04 partial-onset (focal) seizures
1 unexpected event
A Phase I/II, open-label, multi-center trial of [177Lu]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing pep…
2023-506717-21-00 Ended Latest: 2026-05-27 Breast Cancer
2 unexpected events
A study to test the safety, dosage and effectiveness of maribavir for the treatment of cytomegalovirus (CMV) infection in children and adole…
2023-508988-73-00 Ended Latest: 2024-11-11 Cytomegalovirus (CMV) infection in children and ad
4 halts
A Randomized Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults …
2023-503640-14-00 Ended Latest: 2025-09-01 Newly diagnosed Philadelphia-negative B-cell precu
1 breach
Metformin treatment of patients with hand osteoarthritis: A randomised, placebo-controlled trial
2023-509181-38-00 Ended Latest: 2025-06-20 Osteoarthritis
1 breach
A study of patients with colorectal cancer that have a genetic abnormality in the BRAF gene taking encorafenib plus cetuximab with or withou…
2023-509405-77-00 Ended Latest: 2024-12-12 Colorectal cancer (BRAF V600E-mutant mCRC)
1 breach
A Phase 3 Study of Rusfertide (PTG-300) in Patients with Polycythemia Vera
2023-509750-58-00 Ended Latest: 2024-12-13 Polycythemia Vera
1 unexpected event
A Phase 2 Study of Dexlansoprazole Delayed-Release Capsules to Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Pediatric Sub…
2022-501349-64-00 Ended Latest: 2025-11-11 Symptomatic nonerosive GERD in paediatric subjects
1 halt
Minimal Residual Disease-based Strategy with T-Cell Redirector After Treatment with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone…
2023-508310-41-00 Ended Latest: 2024-12-18 Multiple myeloma
1 urgent safety
Phase 3 Study of ALXN1850 versus Placebo in Adolescent and Adult Participants with HPP who have not previously been treated with Asfotase Al…
2023-505673-32-00 Ended Latest: 2025-07-09 Hypophosphatasia
1 breach 1 corrective measure
EMBER-3 A Study of Imlunestrant, Investigator’s Choice of Endocrine Therapy, and Imlunestrant plus Abemaciclib in Participants with ER+, HER…
2023-506786-63-00 Ended Latest: 2025-08-07 Breast Cancer
1 unexpected event
Phase I/II Safety and Tolerability Study of striatal administration of AB-1001 in adult subjects with Early Manifest Huntington's Disease (H…
2024-510895-18-00 Ended Latest: 2024-03-28 Huntington's disease
1 halt
A Randomized Study Comparing JNJ-68284528 versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexametha…
2023-506588-32-00 Ended Latest: 2026-01-13 Relapsed and Lenalidomide-Refractory Multiple Myel
2 unexpected events
A research study to find out if the study treatment alpelisib (BYL719) is safe for a long period of time for who has confirmed diagnosis of …
2023-508522-95-00 Ended Latest: 2025-09-16 PIK3CA-Related Overgrowth Spectrum (PROS)
1 unexpected event
An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult P…
2024-510995-18-00 Ended Latest: 2024-07-16 Advanced Solid Tumors
1 corrective measure
Randomized, Double-Blind, Placebo-Controlled, Multiple-Attack Study with an Open-Label Extension to Evaluate the Efficacy, Safety, Tolerabil…
2023-506029-12-00 Ended Latest: 2024-06-27 Migraine
1 corrective measure
Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)
2023-507889-89-00 Ended Latest: 2026-04-21 Respiratory tract infection
1 breach 1 unexpected event
Phase 2 Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma
2023-505177-32-00 Ended Latest: 2025-07-28 Intermediate-high -risk RCC, high-risk RCC who hav
1 corrective measure
A Phase III Study to assess efficacy, safety, and tolerability of Zibotentan combined with Dapagliflozin, compared to Dapagliflozin, in pati…
2023-504124-26-00 Ended Latest: 2025-12-09 Chronic Kidney Disease and High Proteinuria
1 breach
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab Injections Before and After Surgery for the Treatment of Adult Patients wit…
2023-505928-59-00 Ended Latest: 2024-08-14 Triple Negative or Hormone Receptor low/HER2-negat
7 halts
A phase 2 study to investigate the efficacy and safety of CYP‑001 in combination with corticosteroids in adults with high-risk acute graft v…
2022-502673-41-01 Ended Latest: 2025-07-28 High-Risk Acute Graft Versus Host Disease
1 corrective measure
Vaccination to prevent Mpox Infection (MPOX-VAX Study)
2023-507881-19-00 Ended Latest: 2025-01-09 Mpox infection
1 breach
Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO712620…
2023-509678-52-00 Ended Latest: 2024-04-30 Alzheimer's disease
2 halts
Efficacy, Safety, and Pharmacokinetics of Guselkumab in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis
2022-502238-22-00 Ended Latest: 2025-07-11 Ulcerative Colitis
1 corrective measure
Long-term follow-up study to evaluate durability of treatment response in previous bepirovirsen study participants (B-Sure).
2023-506867-33-01 Ended Latest: 2025-05-23 Chronic Hepatitis B
1 corrective measure
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa (RO7227166, a CD19 targeted 4-1BB l…
2022-502616-37-00 Ended Latest: 2025-12-02 Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma
1 unexpected event
DALY 2-EU
2023-506270-13-00 Ended Latest: 2026-05-28 Relapsed/refractory diffuse large B cell lymphoma
1 breach 10 unexpected events
A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participan…
2023-503666-23-00 Ended Latest: 2025-09-10 Neovascular age-related macular degeneration
1 corrective measure
A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-…
2022-502446-27-00 Ended Latest: 2024-12-17 Relapsed or Refractory Myeloma
1 urgent safety
A multicentre, Phase II, single-arm, interventional study of neoadjuvant durvalumab and platinum-based chemotherapy (CT), followed by either…
2023-503357-35-00 Ended Latest: 2025-06-20 Non-small Cell Lung Cancer (NSCLC)
1 urgent safety
A study to test an oral medicine, belumosudil, in combination with corticosteroids in participants at least 12 years of age with newly diagn…
2023-505394-32-00 Ended Latest: 2025-06-03 chronic graft versus host disease
13 halts
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults with Relapsing Multiple Sclerosis
2023-506467-34-00 Ended Latest: 2025-07-15 Relapsing Multiple Sclerosis (MS)
1 unexpected event
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sc…
2023-506515-18-00 Ended Latest: 2025-07-15 Primary Progressive Multiple Sclerosis (PPMS)
1 unexpected event
Bosutinib in pediatric CML patients
2023-504311-32-00 Ended Latest: 2024-08-20 Chronic Myeloid Leukemia
1 breach
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and Adolescents with Relapsing-Remitting Mu…
2023-506516-40-00 Ended Latest: 2025-07-15 Relapsing-Remitting Multiple Sclerosis
1 unexpected event
MK-2870 versus Chemotherapy in Previously Treated or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) with EGFR Mutations or Other …
2023-503539-16-00 Ended Latest: 2025-07-18 Non-small Cell Lung Cancer (NSCLC)
7 halts
PSMAfore: A phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of androgen receptor-directed therap…
2023-507772-50-00 Ended Latest: 2024-08-23 PSMA-positive metastatic castration-resistant pros
1 unexpected event
An Open-label study comparing 177Lu-PSMA-617 plus Standard of Care vs. Standard of Care in the Treatment of mHSPC
2023-507970-42-00 Ended Latest: 2026-04-17 PSMA-positive metastatic hormone-sensitive prostat
2 unexpected events
Effects of BBP-418 (ribitol) in Patients with LGMD2I
2023-503379-33-01 Ended Latest: 2025-04-29 Limb Girdle Muscular Dystrophy 2I/R9
1 breach
EFFICACY AND SAFETY TRIAL OF EPCORITAMAB WITH OR WITHOUT LENALIDOMIDE AS FIRST LINE THERAPY FOR SUBJECTS WITH DIFFUSE LARGE B-CELL LYMPHOMA.
2023-504832-16-00 Ended Latest: 2025-08-28 DIFFUSE LARGE B CELL LYMPHOMA
2 breaches
A Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms of Radi…
2023-506301-20-00 Ended Latest: 2026-01-15 Tuberous Sclerosis Complex (TSC)
1 urgent safety 1 corrective measure
Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma
2022-500571-32-00 Ended Latest: 2025-10-28 Early-Stage Unfavorable Classical Hodgkin Lymphoma
2 breaches
A Phase I study of STA551 and STA551 in combination with atezolizumab in patients with solid tumours
2023-508764-30-00 Ended Latest: 2024-03-12 Locally advanced or metastatic solid tumors
1 halt
A study of sigvotatug vedotin versus docetaxel in previously treated non-small cell lung cancer (Be6A Lung-01)
2023-503827-25-01 Ended Latest: 2025-02-24 Non-Small Cell Lung Cancer (NSCLC)
1 breach 1 corrective measure
A study to test the effect of BI 456906 on cardiovascular safety in people with overweight or obesity
2022-502442-27-00 Ended Latest: 2025-12-24 Obesity
1 breach
DAREONTM-9: A study to test how well different doses of BI 764532 are tolerated by people with small cell lung cancer when taken together w…
2023-506007-26-00 Ended Latest: 2024-03-13 relapsed/refractory extensive stage - small cell l
1 corrective measure
A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRA…
2023-506241-30-00 Ended Latest: 2024-04-05 Advanced Colorectal Cancer with KRAS G12C Mutation
9 corrective measures
A randomized, controlled, open-label, phase III-trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combi…
2023-509242-35-00 Ended Latest: 2026-05-05 HR+/HER2- early breast cancer
2 breaches 1 urgent safety
Efficacy and safety of subcutaneous dupilumab in participants with asthma/asthmatic wheeze aged 2 to <6 years
2023-504331-41-00 Ended Latest: 2025-08-13 Respiratory tract diseases - Wheezing, Asthma
1 corrective measure
DAREON™-8: A study to test how well different doses of BI 764532 in addition to standard of care are tolerated by people with advanced small…
2023-506008-20-00 Ended Latest: 2024-08-01 Extensive-stage small cell lung carcinoma (ES-SCLC
1 halt
An international prospective open-label, multi-center, randomized, non-comparative phase II study of lutetium [177Lu] vipivotide tetraxetan …
2022-503040-41-00 Ended Latest: 2026-05-08 PSMA PET scan positive Castration-Resistant Prosta
4 unexpected events
Is there a survival benefit of administering thoracic radiotherapy concurrently with immunnotherapy and chemotherapy for patients with exten…
2023-505514-15-00 Ended Latest: 2025-12-11 Small-cell lung cancer, extensive stage
1 unexpected event
Tuvusertib (M1774) in Combination with Cemiplimab in Participants with Non-Squamous NSCLC (DDRiver NSCLC 322)
2022-502010-85-00 Ended Latest: 2024-03-06 Non-Squamous Non-Small Cell Lung Cancer
1 corrective measure
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination with Polatuzumab Ved…
2023-506986-74-00 Ended Latest: 2025-08-21 B-cell non-Hodgkin lymphoma (NHL)
1 unexpected event
Phase Ib Dose Finding Study of [177Lu]Lu-NeoB in Combination with RT and TMZ in Newly Diagnosed Glioblastoma and as a Single Agent in Recurr…
2022-502134-10-00 Ended Latest: 2025-04-01 Glioblastoma
1 halt
IMMUNE RESET TO ALLOW ACCESS TO HLA-COMPATIBLE KIDNEY TRANSPLANTATION IN HYPERIMMUNIZED PATIENTS
2023-506478-11-01 Ended Latest: 2025-04-30 chronic kidney disease
2 halts
Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women with Recurrent Vulvovaginal Candidiasis: A Randomize…
2023-507527-28-00 Ended Latest: 2024-03-20 Recurrent vulvovaginal candidiasis
1 halt
An Open-label Dosimetry, Tolerability and Safety Study of lutetium (177Lu) vipivotide tetraxetan in Patients with Progressive PSMA-Positive …
2023-503925-20-00 Ended Latest: 2024-08-22 Progressive PSMA-Positive Metastatic Castration-Re
1 unexpected event
A clinical study to assess how safe and effective it is for subjects with hepatocellular carcinoma (HCC) to receive radiation therapy with T…
2023-508945-41-00 Ended Latest: 2026-03-25 Hepatocellular Carcinoma
1 breach 1 halt
Phase 3 study of belzutifan plus pembrolizumab as adjuvant treatment in renal cell carcinoma (RCC)
2023-505023-31-00 Ended Latest: 2024-03-14 Renal cell carcinoma
14 halts
ANRS0407s -LKV.Cov40. A phase 1/2 multicenter, randomized study of the safety and immunogenicity of a sub-unit protein CD40.RBDv bivalent CO…
2023-504594-20-00 Ended Latest: 2025-01-03 Healthy volunteers
1 halt
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants with Moderate-to-Severe Thy…
2023-503309-13-00 Ended Latest: 2024-12-19 Moderate-to-Severe Thyroid Eye Disease
1 breach
A Phase III study to investigate two initial administrations of COMP360 in treatment-resistant depression
2023-505268-12-00 Ended Latest: 2025-01-17 Treatment-resistant depression
3 corrective measures
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants with Moderate-to-Severe Thy…
2023-503669-50-00 Ended Latest: 2025-04-28 Moderate-to-Severe Thyroid Eye Disease
1 breach
Determine effectiveness of Anifrolumab In Systemic sclerosis
2023-505976-31-00 Ended Latest: 2026-05-21 Systemic Sclerosis (SSc) presenting with Limited o
1 breach
Phase 3 Study of V940 and Pembrolizumab in Resected Melanoma
2023-503652-27-00 Ended Latest: 2025-07-29 Melanoma
1 corrective measure
A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
2023-503714-77-00 Ended Latest: 2024-05-30 Advanced Non-Small Cell Lung Cancer
6 halts 1 corrective measure
A study to determine the safe dose of iberdomide (CC-220) in combination with R-CHOP21 and CC-98282 in combination with R-CHOP21 in subjects…
2023-506094-35-00 Ended Latest: 2026-02-18 Newly diagnosed aggressive B-cell lymphoma (a-BCL)
2 halts
A STUDY TO INVESTIGATE THE SAFETY AND EFFECTIVENESS OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY FOR PATIENTS WITH NON-SMALL CEL…
2022-502977-41-00 Ended Latest: 2024-08-02 Non-Small Cell Lung Cancer
1 corrective measure
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events and Disease Activity in Adult Participants With Migraine…
2022-501172-25-00 Ended Latest: 2024-06-27 Chronic and Episodic Migraine
9 halts 1 corrective measure
Apremilast study in children with active oral ulcers associated with Behçet's Disease
2023-503436-40-00 Ended Latest: 2024-10-16 Behcet's disease
4 halts
A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab…
2022-500439-35-00 Ended Latest: 2024-01-25 treatment-naive chronic lymphocytic leukemia
1 breach
A Phase 3/3b, Randomized, Observer-blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Fluad and Fluad …
2022-503004-24-00 Ended Latest: 2026-02-06 Influenza virus
1 breach
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance T…
2022-501346-30-00 Ended Latest: 2025-09-10 Newly Diagnosed Multiple Myeloma with Suboptimal R
1 corrective measure
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)
2022-502839-19-00 Ended Latest: 2024-05-01 Obesity
1 breach
Long-term safety and efficacy evaluation of subcutaneous amlitelimab in adult participants with moderate to severe asthma who completed trea…
2023-503385-24-00 Ended Latest: 2026-04-28 Asthma
1 unexpected event
A phase Ib dose finding study assessing safety and activity of [177Lu]Lu-NeoB in combination with ribociclib and fulvestrant in participants…
2022-502465-18-00 Ended Latest: 2026-03-05 Advanced or metastatic breast cancer
2 halts
Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With HR+/HER2− Metastatic Breast Cancer Who Have Received …
2022-502593-17-00 Ended Latest: 2025-06-06 Locally advanced or metastatic hormone receptor (H
1 breach
Phase III Clinical Trial for CPX-351 in Myeloid Leukemia in Children with Down Syndrome 2018
2022-501457-37-00 Ended Latest: 2024-07-08 Myeloid Leukemia in Children with Down Syndrome
5 halts
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation
2022-501419-15-00 Ended Latest: 2025-06-24 Atrial Fibrillation
1 breach
SIERRA: Durvalumab and Tremelimumab as First Line Treatment in Participants with Advanced Hepatocellular Carcinoma
2022-502012-37-00 Ended Latest: 2023-09-04 Advanced Hepatocellular Carcinoma
1 corrective measure
A Phase 1/2a Study of UCART22 in B-cell Acute Lymphoblastic Leukemia (BALLI-01)
2022-502305-15-00 Ended Latest: 2024-11-08 Relapsed or refractory B-cell Acute Lymphoblastic
1 halt
Early versus postponed supplementary parenteral nutrition after major emergency abdominal surgery
2023-505378-14-00 Ended Latest: 2025-01-31 Major emergency abdominal surgery
1 breach
Safe, effective and cost-effective oxygen saturation targets for children and adolescents with respiratory distress: a randomized controlled…
2023-504817-56-00 Ended Latest: 2024-11-08 Bronchiolitis
1 breach
A Phase 2, Double-Blind, Randomized Clinical Trial to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of PRAX-562 in Pediat…
2022-502298-41-00 Ended Latest: 2026-02-23 SCN2A and SCN8A developmental and epileptic enceph
2 corrective measures
A phase II trial of 177Lutetium-DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma LuDO-N
2023-503684-42-00 Ended Latest: 2025-10-14 Neuroblastoma
6 halts
OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial
2022-501608-85-00 Ended Latest: 2024-12-19 Cardiovascular disease (atherosclerotic cardiovasc
1 breach
HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation.
2022-501939-16-00 Ended Latest: 2025-05-22 Heart failure (HF) with mildly reduced ejection fr
4 breaches
Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-2)
2022-500700-22-00 Ended Latest: 2025-01-31 Active Systemic Lupus Erythematosus (SLE)
2 halts
HOVON 164 HL: Tislelizumab plus Gemcitabine and Cisplatin for Relapsed or Refractory Hodgkin Lymphoma followed by Tislelizumab Consolidation…
2022-502225-17-00 Ended Latest: 2024-07-22 Hodgkin lymphoma
2 breaches
A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with N…
2022-500802-16-00 Ended Latest: 2026-03-17 Advanced or Metastatic PD-L1 TPS <50% Non-squamous
1 breach
Noisy Rebels; Non-inferiority study of rituximab compared to ocrelizumab in relapsing MS
2022-502664-21-00 Ended Latest: 2025-04-24 multiple sclerosis
1 breach
Phase II multicenter clinical trial: Mosunetuzumab for early relapse of follicular lymphoma in the Nordic countries (MERLIN/NLG-FL6/ML43841)
2022-500100-21-01 Ended Latest: 2024-11-04 Follicular lymphoma
1 breach
PhII Trial of Pembrolizumab in Advanced Solid Tumors
2022-501253-37-00 Ended Latest: 2024-01-24 (A) Anal Squamous Cell Carcinoma, (B) Biliary Aden
1 halt
A phase I/II open label, multicenter study evaluating the feasibility, safety and efficacy of point-of-care manufactured antiBCMA CAR T cell…
2022-500782-27-00 Ended Latest: 2026-01-08 relapsed/refractory Multiple Myeloma
1 unexpected event
A study evaluating the safety and efficacy of GLPG5101 (19CP02) in subjects with non-Hodgkin lymphoma
2022-502661-23-00 Ended Latest: 2026-01-12 Relapsed/refractory B-cell non-Hodgkin lymphoma
1 breach 2 halts 2 unexpected events
Phase 3 Study to Evaluate Mezigdomide (CC-92480/BMS-986348) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Mult…
2022-500861-29-00 Ended Latest: 2024-12-24 Relapsed or Refractory Multiple Myeloma (RRMM)
1 unexpected event 1 corrective measure
PRODIGE 81-FFCD 2101-TRIPLET: Study evaluating the benefit of adding Ipilimumab to the combination of Atezolizumab and Bevacizumab in patien…
2022-501217-31-00 Ended Latest: 2024-07-05 Hepatocellular carcinoma
1 urgent safety 1 unexpected event
Bicarbonate for the treatment of cardiac arrest
2022-501304-10-00 Ended Latest: 2025-10-10 In-hospital cardiac arrest
2 corrective measures
Phase 2a study to assess the efficacy and safety of GIA632 in adult participants with moderate to severe atopic dermatitis
2025-521503-43-00 Halted Latest: 2026-04-27 Atopic dermatitis
5 halts
A prospective, randomised, multi-centre, double-blind, placebo-controlled Phase III trial to investigate the efficacy and safety of lozenges…
2025-521764-35-01 Halted Latest: 2026-05-27 acute pharyngitis
1 halt
A Double-blind, Placebo-controlled, Multiple-Dose, 2-Period Crossover Study to Evaluate the Effect of Steady-state AZD6793 on the Steady-sta…
2025-522551-25-00 Halted Latest: 2026-04-13 Type 2 Diabetes Mellitus
1 halt
Perineural incobotulinumtoxin-A for Complex Regional Pain Syndrome - An open-label feasibility study (PINCom)
2024-519832-17-00 Halted Latest: 2026-04-10 Complex Regional Pain Syndrome
1 halt 1 urgent safety 1 unexpected event
Study of CC-97540 (BMS-986353), CD19-CAR T Cells, in Participants with Active SLE Despite Immunosuppressants (Breakfree-SLE)
2024-519278-37-00 Halted Latest: 2026-06-03 Lupus Nephritis
9 halts
Phase 1b Study of Tarlatamab in Combination with YL201 with or without Anti-PD-L1 in Subjects with Extensive Stage Small Cell Lung Cancer (D…
2024-515903-21-00 Halted Latest: 2026-04-01 Extensive Stage Small Cell Lung Cancer (ES-SCLC)
6 halts
Phase 2 Study of ALXN2420 versus Placebo in Combination with Somatostatin Analogs in Participants with Acromegaly
2025-521243-20-00 Halted Latest: 2026-04-07 Acromegaly
7 halts
Methotrexate PK (in combination with Novobiocin) in RA patients
2025-522531-34-00 Halted Latest: 2026-05-28 Rheumatoid arthritis
1 halt
A study of AZD2962, an IRAK4 inhibitor, in Participants with Haematologic Neoplasms
2025-520786-44-00 Halted Latest: 2026-04-17 Myelodysplastic syndromes
1 halt 1 urgent safety
Opioid-Free General Anesthesia Compared to Opioid-Based General Anesthesia for the Reduction of Postoperative Nausea and Vomiting in Patient…
2025-521047-20-00 Halted Latest: 2026-04-16 Obesity
1 halt
Corticotrophin Releasing Factor 2 Agonist For the Treatment of Worsening Heart Failure (WHF) – The CRAFT-WHF Study
2024-518951-52-00 Halted Latest: 2026-05-21 Worsening Heart Failure
5 halts
A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
2024-516916-93-00 Halted Latest: 2026-01-08 This study will be a Phase 1b, global, multicenter
3 halts 1 urgent safety
A study to test different doses of BI 765049 in people with advanced cancer of the colon, rectum, stomach, or pancreas
2024-519301-36-00 Halted Latest: 2025-12-12 colorectal carcinoma (CRC)
2 halts
Research into the effects of the drug DMT in healthy volunteers
2025-521605-40-00 Halted Latest: 2025-11-21 major depressive disorder (MDD)
1 halt
IMMUNORARE5 : A national platform of 5 academic phase II trials coordinated by Lyon university hospital to assess the safety and the efficac…
2024-517254-99-00 Halted Latest: 2026-01-23 The patients enrolled in IMMUNORARE will be adult
1 halt 1 urgent safety 1 unexpected event
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of T7-010 in Healthy Participants.
2024-518440-20-00 Halted Latest: 2025-10-14 Autoimmune Diseases (Healthy Volunteers)
1 halt
CEB-01 in paediatrics with locally resectable abdominal tumours.
2024-520054-38-00 Halted Latest: 2026-05-15 Desmoplastic small round cell tumour
1 halt
Public title :A Phase 1b/2a trial to evaluate Invobenitug also known as Procizumab (PCZ; AK1967) in critical cardiovascular care.
2024-518450-16-00 Halted Latest: 2026-05-12 Cardiogenic shock due to Acute Coronary Syndrome,
5 halts
VAsopressin and STeroids in addition to Adrenaline in cardiac arrest - a randomized clinical trial. VAST-A
2025-521283-35-00 Halted Latest: 2025-04-09 Cardiac arrest
1 halt
Neoadjuvant pembrolizumab with a watch-and-wait strategy for patients with mismatch repair-deficient or microsatellite instability-high (dMM…
2023-509322-22-00 Halted Latest: 2026-04-28 localized colon cancer
1 halt
NeoART – A phase Ib/II platform trial evaluating the safety and activity of neoadjuvant trastuzumab-deruxtecan containing combination therap…
2024-518841-12-00 Halted Latest: 2026-04-09 HER2 positive resectable esophagogastric adenocarc
2 halts
A 24-week with possible extension, prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel group with a randomiza…
2024-514538-19-00 Halted Latest: 2026-04-02 Mastocytosis
3 halts
A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 study to compare the efficacy and safety …
2024-516671-33-00 Halted Latest: 2026-04-02 Amyotrophic Lateral Sclerosis
5 halts
A 96-Week, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib…
2024-516672-16-00 Halted Latest: 2026-04-02 Multiple Sclerosis
5 halts
Application of antiCD19 CAR T lymphocytes for the treatment of adult patients with B-cell acute lymphoblastic leukemia with resistance, rela…
2024-519808-27-00 Halted Latest: 2025-03-28 B-cell acute lymphoblastic leukemia. with resistan
1 halt
Prevention of agitation and pain after anaesthesia in children less than or equal to 1 year
2024-520075-28-01 Halted Latest: 2026-05-07 Emergence agitation after anaesthesia
1 halt
Neoadjuvant electrochemotherapy for colorectal cancer - a phase 2 trial
2025-520755-91-00 Halted Latest: 2025-10-01 Colorectal cancer
1 halt
Evaluate the Efficacy, Safety and Tolerability of (+)-α-dihydrotetrabenazine for Treatment of Tardive Dyskinesia
2024-519105-35-00 Halted Latest: 2025-02-13 tardive dyskinesia
1 halt
Mechanisms of Action of Paradoxical Responses to Zolpidem: A Multimodal Study
2023-507404-31-03 Halted Latest: 2026-03-23 Patients with acquired partial/total vision impair
1 halt
Premixed glucagon/insulin solution for faster insulin absorption in Type 1 diabetes.
2023-510408-32-02 Halted Latest: 2025-05-22 Type 1 diabetes
1 halt
A Phase 2b, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety and Efficacy of AD04 in Patients with Early…
2024-518523-30-00 Halted Latest: 2026-01-19 early Alzheimer’s disease
2 halts
A study to investigate pharmacokinetics, safety, and tolerability of Cefepime-Enmetazobactam administered by intra-venous infusion over 2 ho…
2024-518003-22-00 Halted Latest: 2025-04-11 Complicated urinary tract infections including acu
6 halts
Is botulinum toxin injection better than corticosteroid injection in the management of persistent post-surgical pain
2024-518954-18-01 Halted Latest: 2026-06-02 Post-surgical scar pain
1 halt
A Phase 1/2 Study to Assess the Safety, Pharmacokinetics, and Efficacy of Daily Intravenous of AB8939 in patients with Relapsed/Refractory A…
2024-516641-39-00 Halted Latest: 2026-04-02 Acute Myeloid Leukemia
4 halts 2 corrective measures
Prospective pilot study, assessing imaging performance of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT in Patients with HepatoCell…
2023-508567-75-00 Halted Latest: 2026-06-02 Gastro-Entero-Pancreatic Neuroendocrine Neoplasms
1 halt
A phase I/II post-cord blood HCT dendritic cell vaccination trial directed against WT1 for pediatric and young adult acute myeloid leukemia:…
2024-517922-24-00 Halted Latest: 2025-09-26 AML: Acute Myeloid Leukemia/ cancer of blood and b
1 halt
Use of circulating tumor dna test to intensify post-operative treatment of patients with resected colon cancer.
2024-515152-20-00 Halted Latest: 2025-10-13 Stage III and high-risk stage II resected colon ca
1 halt
Changes in lymph nodes in patients with CLL treated with venetoclax-containing regimens
2024-515938-32-00 Halted Latest: 2025-04-18 Chronic Lymphocytic Leukemia
1 halt
Salvage Therapy for Patients with Inadequate Response to Standard of Care Therapy in Granulomatosis with Polyangiitis
2024-516687-28-00 Halted Latest: 2026-03-20 Patients with GPA and inadequate response to stand
1 halt
A phase II/III multi-centre, open-label, parallel group study to prove the non-inferiority of safety and efficacy of Metronidazole/Neomycin …
2024-518862-28-00 Halted Latest: 2024-12-16 female patients with bacterial vaginosis (BV), res
1 halt
Enhancing recovery in early schizophrenia: A study comparing cannabidiol and placebo as add-on to standard antipsychotic treatment.
2024-517198-26-00 Halted Latest: 2025-12-18 Remitted early phase schizophrenia
1 halt
Study of Taxane-Platinum followed by a maintenance with avelumab and cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma…
2023-510559-41-00 Halted Latest: 2025-05-28 Recurrent or Metastatic Squamous Cell Carcinoma of
1 halt 1 urgent safety 1 unexpected event
PHASE IB/II STUDY TO EVALUATE SAFETY AND EFFICACY OF DEBIO 0123 AND SACITUZUMAB GOVITECAN IN TNBC OR HR+/HER2- ADVANCED/ METASTATIC BREAST C…
2024-516322-60-00 Halted Latest: 2025-11-20 TRIPLE-NEGATIVE OR HR+/HER2– ADVANCED/METASTATIC B
1 halt
TryptoBPH - Proof-of-concept study to evaluate the safety and efficacy of tryptophan in patients with BPH
2024-519076-75-00 Halted Latest: 2026-04-02 Benign prostatic hyperplasia
1 halt
To Investigate whether the combination of molidustat and an IDH1 inhibitor (ivosidenib) effectively inhibits leukaemia cells in patients wit…
2024-514051-15-00 Halted Latest: 2026-02-02 Adult patients with relapsed or refractory IDH1-mu
1 halt 1 urgent safety 1 unexpected event
Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients with Stable Angina (ORESA Study)
2024-512313-41-00 Halted Latest: 2025-09-19 Stable Angina Pectoris
4 halts
Use of electronic cigarettes for smoking cessation
2024-518135-10-00 Halted Latest: 2026-03-27 Smokers smoking at least 10 cigarettes/day in the
1 halt
A Phase 1, Double-blind, Randomized, Three-arm, Parallel Group Study to Compare the Pharmacokinetics and Safety of a Single Subcutaneous Dos…
2024-519145-30-00 Halted Latest: 2024-11-04 Healthy volunteers
1 halt
A Phase 1b Study of Neoadjuvant Xaluritamig in Subjects With Newly Diagnosed Localized Intermediate or High-Risk Prostate Cancer
2024-511965-13-00 Halted Latest: 2026-04-28 Newly diagnosed localized Intermediate or High‐Ris
1 halt 1 corrective measure
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors with KRAS G12D Mutation
2023-507091-47-00 Halted Latest: 2026-03-02 Advanced or metastatic solid tumors
4 halts
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-6404…
2023-505096-68-00 Halted Latest: 2026-01-27 Preclinical Alzheimer’s Disease
5 halts
Ketamine to treat patients with post-comatose disorders of consciousness
2024-518433-29-00 Halted Latest: 2026-04-01 Disorder of Consciousness, severe brain injury
1 halt
Spartalizumab and low-dose PAzopanib in Refractory or Relapsed solid TumOrs of pediatric and adults SPARTO
2024-513535-24-00 Halted Latest: 2025-08-01 Refractory or Recurrent Solid Tumor
1 halt
A clinical research study comparing two cisplatin dosing schedules combined with radiation for patients with advanced head and neck cancer.
2024-515237-15-00 Halted Latest: 2025-09-23 Advanced head and neck cancer
1 halt
A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered Intravenously in Patient…
2024-510987-22-00 Halted Latest: 2026-02-19 Advanced High-Grade Osteosarcoma
1 halt
A 24-week, multicenter, randomized, double blind, placebo-controlled, dose-range finding phase II study to compare efficacy and safety of or…
2024-515193-27-00 Halted Latest: 2026-04-17 Mast cell activation syndrome
1 halt
Open-Label, Single Arm Phase II Trial Investigating the Efficacy, Safety and Quality of Life of Neoadjuvant Chemotherapy with Liposomal Irin…
2024-512951-18-00 Halted Latest: 2025-10-09 Hepatic Oligometastatic Adenocarcinoma of the Panc
1 halt
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulator…
2024-512626-28-00 Halted Latest: 2025-04-02 Duchenne Muscular Dystrophy
6 halts 2 corrective measures
Study of efficacy and safety of JDQ443 in comparison with docetaxel in participants with locally advanced or metastatic KRAS G12C mutant non…
2023-510082-10-00 Halted Latest: 2026-02-17 Advanced non-small cell lung cancer harboring the
8 halts
A phase 1, randomized, double-blind, single-center, placebo-controlled first-in-human trial to assess the safety, tolerability, pharmacokine…
2023-510371-55-00 Halted Latest: 2024-12-11 Complement-mediated diseases
1 halt
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinet…
2024-514744-91-00 Halted Latest: 2025-11-25 Obesity/overweight (healthy subjects)
1 halt
Study of efficacy and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C- muta…
2024-511708-18-00 Halted Latest: 2026-02-16 Locally advanced or metastatic KRAS G12C-mutated n
9 halts
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients with Cystic Fibrosis
2024-511184-28-00 Halted Latest: 2026-01-20 Cystic fibrosis
5 halts
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
2024-512927-36-00 Halted Latest: 2026-01-07 Advanced or Metastatic Urothelial Carcinoma or Oth
4 halts
Phase II Open-Label, Single Arm, Multicenter Study of Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma
2023-510560-12-00 Halted Latest: 2024-11-27 High-risk smoldering multiple myeloma
1 halt
A prospective randomized, single-blind, multicenter phase II study comparing two methods of cardioplegia in cardiac surgery due to congenita…
2024-511517-38-00 Halted Latest: 2025-09-30 congenital heart malformation inchildren
1 halt
Preoperative immunotherapy with atezolizumab (Tecentriq®) and tiragolumab or atezolizumab (Tecentriq®) and bevacizumab (Avastin®) in patient…
2022-503044-40-00 Halted Latest: 2025-11-14 Colorectal liver metastases (CRLM)
1 halt
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy in women with advanced ovarian cancer
2024-515996-37-00 Halted Latest: 2025-08-04 peritoneal carcinosis of ovarian origin cancer
1 halt
Study to assess the safety and expression of RO7494222 (SRP-9001) in participants under the age of 4 with Duchenne muscular dystrophy
2023-509901-57-00 Halted Latest: 2025-03-31 Duchenne Muscular Dystrophy
5 halts
A research study looking at a new treatment for patients with advanced cancer, to investigate different doses of the experimental study drug…
2024-514588-24-00 Halted Latest: 2025-05-01 Acute Myeloid Leukaemia (AML)
1 halt
A Phase I/II study of DYP688 treatment alone in patients with eye cancer and other types of cancers of the skin and mucosal membranes in the…
2023-509451-14-00 Halted Latest: 2025-07-15 Metastatic uveal melanoma
4 halts
Non-inferiority study of a new therapeutic strategy for gout: immediate prescription of a hypouricemia treatment, febuxostat, compared to it…
2024-515547-34-00 Halted Latest: 2026-03-12 The gout
2 halts
Safety and potential effect of innovative treatment by adjuvant injection of stromal vascular Fraction from autologous adipose tissue of URe…
2024-513306-65-00 Halted Latest: 2026-03-23 URethral stenosis
1 halt 1 corrective measure
A study to investigate whether treatment with a siplizumab-based regimen can induce allogeneic tolerance in liver transplant recipients.
2023-508397-29-00 Halted Latest: 2024-11-20 Prophylaxis against liver allograft rejection foll
1 halt
Extended Criteria Treatment for Liver Metastases With Heavy Tumour Burden
2024-512397-95-00 Halted Latest: 2026-05-21 Colorectal Liver Metastases
2 halts 1 urgent safety
PUMP-IT RCT: Hepatic arterial infusion PUMP chemotherapy combined with systemic therapy versus systemic therapy alone as Induction Therapy f…
2023-506194-35-00 Halted Latest: 2026-01-23 Colorectal liver metastases
1 halt
Study of Avelumab in combination with Lenvatinib for children with primary CNS tumors
2024-512940-51-00 Halted Latest: 2024-09-04 Central Nervous System Tumors
2 halts
A study to evaluate novel immunotherapy combinations in participants with advanced non-small cell lung cancer (NSCLC)
2023-508730-34-00 Halted Latest: 2026-05-13 Non-small cell lung cancer (NSCLC): - Locally adva
7 halts
A Phase 3 Study of NTLA 2001 in participants with amyloidosis with cardiac muscle disease.
2023-507220-23-00 Halted Latest: 2025-10-30 Transthyretin Amyloidosis with Cardiomyopathy
14 halts 1 corrective measure
A study of PF-08046050 (SGN-CEACAM5C) in adults with advanced solid tumors
2023-505858-18-00 Halted Latest: 2026-03-31 Pancreatic carcinoma
4 halts
Induction chemotherapy followed by standard concurrent chemoradiotherapy in cervical cancer with para-aortic lymph node involvement: A phase…
2024-513576-18-00 Halted Latest: 2025-03-07 Cervical Cancer
1 halt
PNOC022: A Combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) inc…
2023-507598-16-00 Halted Latest: 2025-08-18 Diffuse Midline Gliomas (DMGs) including Diffuse I
1 halt
A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with RMS, PMS, or MG(Breakfree-2)
2023-507820-22-00 Halted Latest: 2026-06-02 Myasthenia gravis (MG)
4 halts
A trial to understand if AZD0486 is safe and helps in people with Relapsed or Refractory B-cell acute lymphoblastic leukemia (B-ALL)
2023-505840-20-00 Halted Latest: 2026-04-13 B-Cell Acute Lymphoblastic Leukaemia
4 halts
A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with Severe, Refractory Autoimmune Diseases (Breakfree-1)
2023-503823-24-01 Halted Latest: 2026-06-02 Systemic Sclerosis
5 halts
A Study of Glucothera Plus for Peritoneal Dialysis in Children (ASTRA)
2024-512078-88-00 Halted Latest: 2026-05-20 End-stage Kidney Disease
1 halt
A prospective, multicentre, randomised, double-dummy, double-blind, placebo-controlled 3-way Phase III study to investigate the efficacy and…
2022-502903-31-00 Halted Latest: 2026-05-11 Patients with ADHD (according to ICD-10 / DSM-5)
2 halts
A phase 2 trial assessing Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis – MODIF-MS
2023-507874-42-00 Halted Latest: 2026-01-05 Multiple sclerosis
1 halt
A Proof of Concept, Multicentre, Phase 2, Double- Blind, Randomized, Placebo-Controlled Study on the Efficacy, Safety and Tolerability of d-…
2024-510968-22-00 Halted Latest: 2025-06-06 restless leg syndrome
1 halt
A phase 1/2 study of subcutaneous blinatumomab administration in adults and adolescents with R/R and MRD+ B-ALL
2023-506136-32-00 Halted Latest: 2026-05-21 Relapsed or Refractory B cell Precursor Acute Lymp
7 halts
A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small…
2023-503298-39-00 Halted Latest: 2025-11-28 Metastatic Non-Small Cell Lung Cancer (mNSCLC)
11 halts 1 urgent safety 2 corrective measures
VEN-R DASA-IPC 2022-067 Evaluation of DASATINIB monotherapy efficacy in acute myeloid leukemia patients refractory to VENETOCLAX-AZACITIDINE
2023-505846-24-00 Halted Latest: 2026-06-01 acute myeloid leukemia
1 halt
A Phase I/II Combination Study of NMS-03305293 and Temozolomide in Adult Patients with Recurrent Glioblastoma
2023-508318-41-00 Halted Latest: 2025-04-04 Recurrent Glioblastoma
2 halts
Comparative clinical trial of efficacy and satisfaction of 2% gel lidocaine versus tetracaine/oxybuprocaine anesthetic eye drops in patients…
2023-505131-13-01 Halted Latest: 2025-04-16 Glaucoma
1 halt
CAPSI - Cancer related major depression treated with a single dose of psilocybin - a multicenter randomized placebo controlled double blind …
2023-505532-35-00 Halted Latest: 2026-04-16 Malignant tumours ICD 10 C00 to C97
1 halt
A randomized, open-label, multicentric, two-arm pivotal trial of SonoCloud-9 combined with carboplatin (CBDCA) vs standard of care lomustine…
2023-505829-14-00 Halted Latest: 2025-10-17 First recurrence glioblastoma
9 halts
A phase 3, randomised, double-blind, placebo-controlled, parallel-arm efficacy trial of Imatinib in acute ischaemic stroke
2023-506178-11-00 Halted Latest: 2025-11-11 Acute ischemic stroke
3 halts
Dosimetry of a novel amino acid PET tracer, [18F]FELP
2022-501696-91-00 Halted Latest: 2026-01-22 Glioblastoma
1 halt
A dose finding study of LY3884961 in patients with Gaucher disease
2022-500281-10-02 Halted Latest: 2026-04-24 Type 1 Gaucher Disease (Peripheral/Non-neuronopath
4 halts
Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection
2023-506143-42-00 Halted Latest: 2025-03-28 Chronic Hepatitis B
1 halt
A Trial to Study if REGN5837 in Combination with Odronextamab is Safe for Adult Participants with Aggressive B-cell Non-Hodgkin Lymphomas
2022-502137-26-00 Halted Latest: 2026-04-09 B-cell Non-Hodgkins Lymphoma (B-NHL)
3 halts
Phase 2 Study of CAL02 plus Standard of Care in Severe Community-Acquired Bacterial Pneumonia (SCABP)
2022-502049-91-00 Halted Latest: 2025-05-19 SEVERE COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (SCA
9 halts
Evaluation of tolerance and pharmacokinetics profile of high dose favipiravir in healthy volunteers - FAVIDOSE
2022-502871-49-00 Halted Latest: 2026-04-08 healthy volunteers
1 halt
The NeoTRACK Trial – Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy – Dissection of IO efficacy in NSCLC by longitudinal tracKing: a…
2022-501322-38-00 Halted Latest: 2025-03-19 Non-small cell lung cancer (NSCLC)
1 halt
Phase I trial of CArbonic Anhydrase Inhibition in combination with radiochemotherapy or radioimmunotherapy in small cell lung carcinoma (ICA…
2022-503093-36-00 Halted Latest: 2024-12-31 lung carcinoma
1 halt
A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 Trial to compare the efficacy and safety …
2024-511244-12-01 Suspended Latest: 2026-04-22 Amyotrophic Lateral Sclerosis
5 corrective measures
Sentinel lymph node (SLN) detection in early oral cancer using Gallium-68-Tilmanocept PET/CT.
2025-521682-27-00 Suspended Latest: 2025-04-28 Oral cancer
1 corrective measure
A Phase 2/3 Study in Adult and Pediatric Participants with SCD
2023-508766-14-00 Suspended Latest: 2025-11-28 Sickle Cell Disease
1 corrective measure
LB−100 and azenosertib in metastatic colorectal cancer patients
2024-511227-33-00 Suspended Latest: 2024-11-08 Metastatic colorectal cancer
1 corrective measure
Open-label single dose trial to evaluate pharmacokinetics, safety, and acceptability/palatability of oveporexton in children from 6 years to…
2025-522034-31-00 Ended Latest: 2026-05-22 Narcolepsy with Cataplexy (Narcolepsy Type 1)
1 breach
A phase 1, randomized, double-blind, placebo-controlled study investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics…
2024-512106-26-02 Ended Latest: 2025-09-17 Cognitive impairment
1 corrective measure
A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients with Overt Hepatic Encep…
2025-521029-34-00 Ended Latest: 2025-09-25 Patients with overt hepatic encephalopathy (OHE) a
1 urgent safety
Phase 2b Randomized, Double-Blind Study with Phage for CF Subjects with Pseudomonas Lung Infection
2024-519856-94-00 Ended Latest: 2025-12-03 Cystic fibrosis
8 halts
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Adaptive Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Phar…
2025-521914-25-00 Ended Latest: 2025-07-31 Schizophrenia
1 corrective measure
Bioequivalence of Lenvatinib 10 mg Capsules in Healthy Participants Under Fasting Conditions
2025-522259-24-00 Ended Latest: 2025-09-11 No medical condition
1 halt
Immunosuppressive drug bioequivalence in kidney transplant recipients – Prograf and CellCept
2025-521800-22-00 Ended Latest: 2025-09-10 Organ transplantation
1 breach
Study to Learn How Safe EV25 is and the Amount of EV25 in the Body Over a Period of Time, When Taken [CCI] as a Dry Powder via the Nose by A…
2025-521783-35-00 Ended Latest: 2025-08-04 Influenza virus
1 halt
Cardiovascular safety assessment of Tanimilast in healthy volunteers
2024-516861-35-00 Ended Latest: 2025-09-15 This is Phase I study to assess the effect on the
1 halt
A Study to Investigate the Safety and Effectiveness of RO7759065 in Combination with Atezolizumab in Participants with Locally Advanced or M…
2024-513391-17-00 Ended Latest: 2025-09-03 Locally Advanced or Metastatic Solid Tumors
1 halt
Safety, Tolerability, and Efficacy of NVG-2089 in Participants with CIDP
2024-515386-34-00 Ended Latest: 2026-03-10 Chronic Inflammatory Demyelinating Polyneuropathy
1 breach 6 halts 1 corrective measure
The CALiPSO-1 Study: A Study of CNTY-101, a CD19-targeted CAR iNK Cell Product, in Participants with Refractory B cell-mediated Autoimmune D…
2024-518797-13-00 Ended Latest: 2025-07-31 systemic lupus erythematosus [SLE]/lupus nephritis
1 corrective measure
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents with Sickle Cell Disease during Vaso-Occlusive Crisis
2024-513440-29-00 Ended Latest: 2025-09-15 Sickle cell disease vaso-occlusive crisis
3 halts
A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity
2024-513679-42-00 Ended Latest: 2025-07-29 Obesity
1 unexpected event
A Study to Learn More About an Investigational Medicine called HDP-102 in Patients with Relapsed/Refractory B-cell Blood Cancers.
2023-508759-38-00 Ended Latest: 2025-09-04 Relapsed/Refractory B-cell Malignancies
2 halts
Phase II-III study to assess the efficacy and safety of subcutaneous cluster-immunotherapy in patients suffering from house dust mite allerg…
2024-517014-15-00 Ended Latest: 2025-05-21 Moderate-to-severe allergic rhinitis / rhino-conju
1 urgent safety
An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients with Focal Onset or Primary Generalized Tonic…
2024-517061-16-01 Ended Latest: 2025-09-29 Focal onset seizures or primary generalized tonic-
1 unexpected event
Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated
2024-512505-66-00 Ended Latest: 2025-06-12 HIV-1 Infection
5 halts 1 urgent safety 1 unexpected event
Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures
2024-514045-11-00 Ended Latest: 2025-07-04 Partial Onset Seizures
1 unexpected event
A Phase 2, Dose-Ranging Study of LY4100511 (DC-853) in Adult Participants with Moderate-to-Severe Plaque Psoriasis
2024-512207-39-00 Ended Latest: 2025-04-29 Plaque Psoriasis
1 unexpected event
The CanISleepinMS Study
2024-518280-35-00 Ended Latest: 2026-02-19 Insomnia
1 unexpected event
A study to evaluate S227928 as a Single Agent and in Combination with Venetoclax in Patients with R/R AML, MDS/AML, or CMML
2024-514356-33-00 Ended Latest: 2025-09-12 "Patients with Relapsed/Refractory (R/R) Acute Mye
1 urgent safety 1 unexpected event
A first-in-human trial of safety and efficacy of GEN1078 in participants with solid tumors.
2024-515752-21-00 Ended Latest: 2025-03-14 Malignant solid tumors
2 halts
N/A
2024-513121-22-00 Ended Latest: 2026-02-03 Recurrent or Metastatic Head and Neck Squamous Cel
3 halts 1 unexpected event
Phase I/II, First in Human, Dose Escalation Trial of TL-895 Monotherapy in Subjects with Relapsed/Refractory B-Cell Malignancies and Expansi…
2024-516691-14-00 Ended Latest: 2025-05-23 B Cell Malignancies and Chronic Lymphocytic Leukem
1 unexpected event
GENPAD
2024-518122-33-00 Ended Latest: 2025-06-13 Peripheral Arterial Disease
1 breach
Safety and efficacy of PC945 (opelconazole) in combination with other antifungal therapy for the treatment of refractory invasive pulmonary …
2024-511281-36-00 Ended Latest: 2026-01-16 Refractory Invasive Pulmonary Aspergillosis
1 breach 1 urgent safety 1 unexpected event
A Phase I Randomised Double-Blind Placebo Controlled Safety Study of Intramyocardial Injection of CLXR-001 in Patients Undergoing Coronary A…
2024-518524-69-00 Ended Latest: 2024-12-11 Ischaemic cardiomyopathy
1 halt
Study of Personalized Neoantigen Specific TCR T cells in the Treatment of Advanced Solid Cancers
2024-518201-18-00 Ended Latest: 2024-12-05 Advanced Solid Cancers
1 halt
Evaluation of safety i efficacy de-escalation antiplatelet strategies in acute coronary syndrome.
2024-518090-34-00 Ended Latest: 2026-02-12 Acute Coronary Syndrom (ACS)
1 unexpected event
A Study to Learn About How Different Formulations of the Medicine Called Mevrometostat are Taken up Into the Blood in Healthy Adult Particip…
2024-516907-18-00 Ended Latest: 2024-12-18 Small cell lung cancer, Castration-resistant prost
1 halt
Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of Melatonin Administration in Patients With…
2023-508457-10-00 Ended Latest: 2026-02-11 Primary Progressive Multiple Sclerosis
1 halt
A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Friedreich’s Ataxia
2024-517436-22-00 Ended Latest: 2025-06-16 Friedreich's ataxia
1 unexpected event
DAVINCY trial: optimal Duration of (fos)Aprepitant prophylaxis for nausea and Vomiting INduced by ChemotherapY in children: a double-blind p…
2024-517846-32-00 Ended Latest: 2025-03-24 Delayed chemotherapy induced nausea and vomiting (
1 breach
TGD001 SAD study in healthy volunteers
2024-514931-63-00 Ended Latest: 2025-03-07 A Phase I randomized, double-blind, placebo-contro
1 halt
Phase 2 Open Label Prospective Dose-Ranging Clinical Trial with Escalation and Expansion Cohorts to Evaluate Safety, Tolerability, Pharmacok…
2024-510582-42-02 Ended Latest: 2026-01-22 Acute graft versus host disease (aGvHD)
1 halt 2 unexpected events
Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With Ultrasound for Sonodynamic Therapy (SDT) in Patients With Ne…
2023-509238-20-00 Ended Latest: 2025-09-03 High grade glioma
1 halt
A study of osilodrostat in children and adolescents with Cushing's disease
2024-516825-30-00 Ended Latest: 2024-12-03 Cushing's disease
1 halt
M9466 in Combination with Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)
2024-514155-15-00 Ended Latest: 2025-02-18 Advanced solid tumors and colorectal cancer
1 halt
A clinical study of the V540A vaccine in healthy adults (V540A-001)
2024-515785-14-00 Ended Latest: 2025-02-12 Human Papilloma virus
1 corrective measure
A randomized, single-blind, placebo-controlled, study to examine the safety, tolerability, and pharmacokinetics of M6229 administered as a 1…
2024-512022-28-01 Ended Latest: 2025-02-07 Sepsis and Septic Shock
1 halt 1 corrective measure
Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Canc…
2024-513167-68-00 Ended Latest: 2024-11-21 endometrial cancer
1 urgent safety
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE I STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE ANDMULTIPLE…
2024-517955-10-00 Ended Latest: 2024-11-27 Healthy volunteers
1 halt
Safety of TEG001 in patients with r/r AML/high-risk MDS or r/r MM
2024-517381-42-00 Ended Latest: 2025-11-14 Acute Myeloid Leukemia (AML)
1 halt
Treatment of refractory Crohn's disease lesions by local injection of mesenchymal stem cells
2024-514033-37-00 Ended Latest: 2025-06-18 Crohn's Disease
1 halt
A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome
2023-507680-19-00 Ended Latest: 2026-02-04 Sjögren’s Syndrome
1 urgent safety
Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization
2024-512651-20-00 Ended Latest: 2025-04-08 Fetal and Neonatal Alloimmune Thrombocytopenia due
4 halts
CONGRATS : COMBINATION OF NIVOLUMAB PLUS RELATLIMAB IN PATIENTS WITH ADVANCED OR METASTATIC SOFT-TISSUE SARCOMA: A PROOF-OF-CONCEPT RANDOMIZ…
2023-509495-42-00 Ended Latest: 2025-04-30 Adult participants with advanced unresectable or m
1 urgent safety
A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy a…
2024-513104-34-00 Ended Latest: 2024-11-11 Major Depressive Disorder
7 halts
A safety and efficacy study of ARGX-119 in adult patients with Amyotrophic Lateral Sclerosis (ALS) (reALiSe)
2024-511318-19-00 Ended Latest: 2025-05-13 Amyotrophic Lateral Sclerosis (ALS)
1 breach
A Phase 2 Clinical Study in Children With HeFH Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)
2024-515864-30-00 Ended Latest: 2024-10-04 Heterozygous familial hypercholesterolemia
4 halts
VTX002 versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis
2023-509233-39-00 Ended Latest: 2024-11-06 Moderately to Severely Active Ulcerative Colitis
1 corrective measure
Pragmatic, randomized, multicentric, double-blind, controlled clinicial trial on the treatment of acute gout attacks with prednisolone versu…
2024-514738-18-00 Ended Latest: 2026-02-04 gout, acute gout attack
1 halt
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vosoritide in Children Wit…
2024-513129-22-00 Ended Latest: 2025-07-11 Hypochondroplasia
1 corrective measure
A Single-arm Study of Intrathecal SHP611 in Subjects with Metachromatic Leukodystrophy
2024-514402-31-00 Ended Latest: 2026-01-16 Late Metachromatic Leukodystrophy (MLD)
1 urgent safety
Study on the investigational drug SAN711, placebo-controlled, administered to healthy adults and elderly subjects at multiple ascending oral…
2024-514514-12-00 Ended Latest: 2024-12-19 Absence Seizure
1 halt
A research study comparing different ways of increasing the dose of NNC0519-0130 in participants with overweight or obesity
2023-508940-23-01 Ended Latest: 2025-02-14 Type 2 diabetes mellitus
1 halt
Phase I, first-in-man, randomised, placebo-controlled, single dose escalation study to investigate the effects of LPH-5 on safety, tolerabil…
2024-512330-15-00 Ended Latest: 2025-06-23 Depression
1 halt
A study in healthy men to test how BI 1839100 is taken up and handled by the body
2024-510870-26-00 Ended Latest: 2025-07-29 Healthy volunteer trial
1 halt
DTG/3TC vs BIC/FTC/TAF maintenance therapy in people living with HIV: an open-label randomized clinical trial
2024-515167-56-00 Ended Latest: 2025-11-20 HIV
4 breaches
Study of Nemvaleukin Alfa in Combination with Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients with Platinum-Resistant Ep…
2024-513230-38-00 Ended Latest: 2025-05-06 Platinum-Resistant Epithelial Ovarian, Fallopian T
1 unexpected event
A study to compare efficacy, pharmacokinetics, safety and immunogenicity of MB04 [proposed etanercept biosimilar] to Enbrel® [EU-sourced] in…
2024-510826-16-00 Ended Latest: 2024-11-28 Rheumatoid Arthritis
3 halts
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion …
2024-512624-11-00 Ended Latest: 2025-03-31 Duchenne muscular dystrophy (DMD)
1 halt
Phase 2b Study to Assess Efficacy and Safety of Batoclimab in Adult Participants with Active CIDP.
2024-512646-42-00 Ended Latest: 2024-10-24 Chronic Inflammatory Demyelinating Polyneuropathy
14 halts
Efficacy and Safety of secukinumab in patients with new onset of giant cell arteritis who are in clinical remission
2024-512856-40-00 Ended Latest: 2025-12-01 Giant Cell Arteritis
1 halt
A study to test whether BI 1839100 improves cough in people with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis
2023-510249-79-00 Ended Latest: 2025-05-26 Progressive pulmonary fibrosis (PPF)
14 halts
The SORT OUT XII DAPT Duration Trial
2024-515236-69-00 Ended Latest: 2025-06-25 Acute coronary syndromes
1 halt
Study of four-factor prothrombin complex concentrate, OCTAPLEX, in patients with acute major bleeding on direct oral anticoagulant (DOAC) th…
2024-515485-14-00 Ended Latest: 2026-01-02 Acute major bleeding in patients receiving DOAC th
4 halts
A study to compare the effect of AVT16 and Entyvio® in subjects with moderate to severe active ulcerative colitis.
2023-507705-34-00 Ended Latest: 2025-08-29 Moderate to Severe Active Ulcerative Colitis
18 halts
Vonafexor fixed dose-escalation safety and proof-of-concept study in patients with at risk of progression Alport syndrome
2023-509638-20-00 Ended Latest: 2025-05-21 Alport Syndrome
1 urgent safety
Iron chelation in the prevention of secondary degeneration after stroke
2024-514230-20-00 Ended Latest: 2025-01-31 Stroke
1 unexpected event
A Phase 3, randomized, double-blind, placebo-controlled, multicenter study of IV FDY-5301 in patients with a myocardial infarction (STEMI)
2024-514372-40-00 Ended Latest: 2025-12-12 Anterior ST-Elevation Myocardial Infarction
1 breach
Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy versus systemic chemotherapy alone as 1s…
2024-515343-39-00 Ended Latest: 2024-10-04 Malignant Peritoneal Mesothelioma
1 halt
A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF CYC140, AN ORAL PLK1 INHIBITOR, IN SU…
2024-516290-67-00 Ended Latest: 2024-08-28 ADVANCED SOLID TUMORS AND LYMPHOMA
1 halt
HEMolyse and Organ damage imPROvement in sickle cell disease by VoxElotor
2024-513096-41-00 Ended Latest: 2024-08-13 sickle cell disease
1 halt
Study on prevention of respiratory consequances related to bronchiolotis caused by respiratory sincizial virus (RSV) in preterm babies
2024-515418-41-00 Ended Latest: 2025-08-04 Respiratory sincizial (RSV) bronchiolitis
1 breach
A study to learn about how well a new drug called BAY3283142 works and how safe it is in reducing albumin in the urine of people with chroni…
2023-505755-40-00 Ended Latest: 2025-05-28 Chronic kidney disease
1 breach
Neoadjuvant Lu-PSMA radioligand therapy and Ipilimumab in men with very high-risk prostate cancer (NEPI)
2024-514386-19-00 Ended Latest: 2025-09-29 Patients with very high-risk prostate cancer (as d
1 halt
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 years of age) with Schizophrenia
2024-513194-44-00 Ended Latest: 2026-03-23 Adolescent Patients (13 to 17 years of age) with S
2 halts
SCLERITA - Safety and efficacy of itacitinib in adults with systemic sclerosis: a phase II, randomized, controlled trial
2024-513648-27-00 Ended Latest: 2024-10-25 Patients with newly or active diffuse Systemic scl
1 halt 1 urgent safety
A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin …
2024-513992-42-00 Ended Latest: 2025-11-28 venous thromboembolism (VTE) in patients with gast
1 breach
A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on…
2023-509569-19-00 Ended Latest: 2025-12-17 venous thromboembolism (VTE)
1 breach 12 halts
TOXSIALO-TRIAL : Evaluation of the long-term efficacy of the injection of botulinum toxin A into the salivary glands versus scopolamine patc…
2024-512160-58-00 Ended Latest: 2024-09-25 Cerebral palsy with pathological drooling
1 halt
Study to assess the efficacy and safety of alpelisib (BYL719) in combination with trastuzumab and pertuzumab as maintenance therapy in patie…
2024-512050-13-00 Ended Latest: 2025-09-16 HER2-positive advanced breast cancer
1 unexpected event
A dose-finding trial with LU AG90222 in adults with migraine who have not been helped by prior preventative treatments.
2023-508821-28-00 Ended Latest: 2025-04-02 Migraine
1 breach
Bioequivalence of Lenvatinib 10 mg Capsules versus Lenvima® 10 mg Capsules in Healthy Participants Under Fasting Conditions.
2024-512908-19-00 Ended Latest: 2024-10-03 No medical condition.
1 halt
EFRAIM II _ Empirical steroids and/or antifungals treatment of immunocompromised patients with acute respiratory failure of uknown origin: a…
2024-514344-82-00 Ended Latest: 2025-04-18 patients with acute respiratory failure from undet
1 urgent safety
EvAluation of the efficacy of MaaT013 as salvage theRapy in acute GVHD patiEntS with gastrointestinal involvement, refractory to ruxolitinib…
2024-513023-17-00 Ended Latest: 2025-05-12 Treatment of acute graft-versus host disease (aGvH
1 breach
Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo®…
2023-507865-24-00 Ended Latest: 2025-07-23 Advanced (unresectable/metastatic) melanoma
7 halts
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Gia…
2024-510744-31-00 Ended Latest: 2025-10-03 Giant cell arteritis (GCA)
17 halts
Phase 3 Study to Assess Batoclimab in Participants with Active Thyroid Eye Disease.
2024-512648-45-00 Ended Latest: 2024-10-11 Thyroid Eye Disease (TED)
1 urgent safety
Long-Term Extension Study (AtDvance) to Evaluate the Safety and Efficacy of GSK1070806 in Participants with Moderate to Severe Atopic Dermat…
2023-508474-29-00 Ended Latest: 2024-09-13 Dermatitis, Atopic
1 corrective measure
A Phase 2 study of durcabtagene autoleucel, B-cell maturation Antigen (BCMA)-directed CAR-T Cells in adult participants with relapsed and re…
2023-507140-37-00 Ended Latest: 2025-04-04 Adult patients with relapsed and refractory multip
5 halts
Debio 0123 in combination with carboplatin and etoposide in adult participants with small cell lung cancer that recurred or progressed after…
2024-510980-40-00 Ended Latest: 2025-07-31 Small cell lung cancer
1 halt
A clinical study to investigate if the investigational drug Diamyd is safe and can preserve insulin production and secretion in adolescents …
2024-513304-33-00 Ended Latest: 2026-04-09 Type 1 diabetes mellitus
1 breach 8 halts 1 unexpected event
Phase 3 Study to Assess Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants with Generalized Myasth…
2024-512258-91-00 Ended Latest: 2024-10-11 Generalized Myasthenia Gravis (gMG)
1 urgent safety
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed S…
2024-513559-34-00 Ended Latest: 2025-06-03 Small Cell Lung Cancer (SCLC)
2 breaches
A Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 given by subcutaneous injection in adult participants with non-cirrhoti…
2023-509704-14-00 Ended Latest: 2025-09-19 Non-cirrhotic non-alcoholic steatohepatitis with f
1 urgent safety
Study of safety and preliminary efficacy of VAY736 given alone or in combination with other antineoplastic agents in patients with NHL
2024-511489-35-00 Ended Latest: 2024-09-09 Relapsed/refractory Non Hodgkin Lymphoma
1 halt
Safety and preliminary efficacy trial of BNT142 in patients with CLDN6-positive advanced ovarian, lung, or testicular cancer
2024-512639-58-00 Ended Latest: 2025-09-03 Solid Tumors
1 breach
A Phase 3 Study of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in AdultsUndergoin…
2024-514471-18-00 Ended Latest: 2025-01-30 Invasive Fungal Diseases in Adults undergoing Allo
1 corrective measure
An Early Phase Study to Investigate the Safety and Efficacy of HS135 in Adult Patients With Pulmonary Arterial Hypertension (PAH)
2023-510452-23-00 Ended Latest: 2025-02-26 Pulmonary arterial hypertension
2 halts
Study of Two Treatment Regimens for Candidemia and/or Invasive Candidiasis: Intravenous Echinocandin followed by Oral Ibrexafungerp versus I…
2024-511755-18-00 Ended Latest: 2024-07-22 Invasive Candidiasis/ Candidemia
7 halts
A study to test how well BI 3720931 is tolerated and whether it improves lung function in people with cystic fibrosis (LenticlairTM 1)
2023-503281-23-00 Ended Latest: 2026-03-19 Cystic fibrosis
4 halts 1 corrective measure
A study to learn if UCB3101 is safe and how it moves through the body of healthy participants
2023-504586-24-00 Ended Latest: 2025-08-12 Healthy Participants
1 halt
An Early Phase Study with the Drug LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL…
2023-509270-37-00 Ended Latest: 2024-08-07 Chronic Lymphocytic Leukemia/Small Lymphocytic Lym
1 corrective measure
A study of PRS-344/S095012 (PD-L1x4-1BB bispecific antibody) in patients with solid tumors
2023-510046-25-00 Ended Latest: 2024-06-14 Soild Tumors
2 halts
Study of DFF332 alone and in combination with Everolimus or Immuno-oncology therapies in patients with renal cell carcinoma and other select…
2024-513379-41-00 Ended Latest: 2024-06-25 Advanced, relapsed Clear Cell Renal Cell Carcinoma
3 halts
Tiotropium in preventing preschool asthma (TIPP)
2024-513916-84-00 Ended Latest: 2024-06-06 Severe asthma exacerbations in partial and uncontr
1 halt
Randomized adaptive assessment of post COVID syndrome treatments (RAPID) Reducing Inflammatory Activity in Patients with post COVID Syndrome…
2024-511628-16-00 Ended Latest: 2025-07-11 Post Covid Syndrome (PCS)
1 halt
Effects of NNC0194-0499, cagrilintide, and semaglutide alone or in combinations on liver damage and alcohol use in people with alcohol-relat…
2023-508170-28-00 Ended Latest: 2024-10-15 alcohol-related liver disease
1 breach
A clinical study to evaluate a new medicinal product VS-01 in patients with an acute episode on top of a chronic liver disease (called acute…
2024-513706-56-00 Ended Latest: 2025-09-25 Acute-on-chronic liver failure (ACLF) is character
1 urgent safety
A Phase 1/2, adaptive, open-label, single ascending dose to multiple ascending dose study to evaluate the safety, tolerability, pharmacokine…
2022-502963-39-00 Ended Latest: 2024-12-16 Glycogen storage disease type 1a (GSD1a)
1 urgent safety
An Open-Label Multicenter 3-Arm Randomized Phase 2 Study to Assess the Efficacy and Safety of TTX-030 and Chemotherapy With or Without Budig…
2023-508356-19-00 Ended Latest: 2026-02-12 Pancreatic adenocarcinoma metastatic
1 unexpected event
Study of safety, tolerability, pharmacokinetics and pharmacodynamics of MSD-001 in healthy participants
2024-512939-67-00 Ended Latest: 2025-05-13 Mental health disorders
1 halt
PASSPORT
2023-508584-72-00 Ended Latest: 2024-09-26 Immune Bowel Disease (including Crohn's disease an
1 halt
A study to compare effectiveness and safety of a combination of vudalimab or pembrolizumab with chemotherapy in participants with advanced l…
2023-509644-10-00 Ended Latest: 2024-12-13 Advanced Non-small Cell Lung Cancer
5 halts
Phase 2 Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
2023-504825-38-00 Ended Latest: 2024-09-12 Lupus Nephritis (LN) Immunoglobulin A Nephropathy
3 halts
A Multicenter, Open-label Phase 1/2 Study of TYRA 300 in Advanced Urothelial Carcinoma and Other Solid Tumors
2023-507589-22-00 Ended Latest: 2025-07-07 Advanced Urothelial Carcinoma and Other Solid Tumo
3 halts
A Multi-national Phase IIIb Trial to Determine the Safety and Efficacy of STALORAL® Birch 300 IR in Children and Adolescents 5 to 17 Years o…
2023-509833-38-00 Ended Latest: 2024-07-05 Birch Pollen-induced Allergic Rhinoconjunctivitis
1 halt
Study of efficacy, safety, and tolerability of LNA043 in patients with symptomatic knee osteoarthritis
2023-509937-37-00 Ended Latest: 2024-12-09 Osteoarthritis
5 halts
Phase 1 study assessing the pharmacokinetics of NEX-22A in subjects with T2D
2023-508054-25-01 Ended Latest: 2024-11-08 Type 2 diabetes
1 halt
Comparison of cocaine, lidocaine/xylometazoline and saline for intranasal analgesia - A blinded triple crossover study
2023-506644-17-01 Ended Latest: 2024-09-16 Nasotracheal intubation
1 breach
A clinical study comparing different doses of a potential new medicine with an inactive medicine for patients with moderate to severe psoria…
2023-508992-35-00 Ended Latest: 2024-07-05 Plaque Psoriasis
1 unexpected event
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Cardiomyopathy
2023-506352-24-00 Ended Latest: 2024-12-24 Non-obstructive Hypertrophic Cardiomyopathy
1 breach
A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08 , an IL-15 Antibody Fusion Protein Targeting CTLA-4, Mo…
2024-511750-53-00 Ended Latest: 2024-10-16 Unresectable Locally Advanced or Metastatic Cancer
2 halts
MK-1200 for Advanced Solid Tumors
2023-508684-68-00 Ended Latest: 2024-07-05 Advanced solid tumor
1 corrective measure
Clinical Trial of Lenvatinib, Pembrolizumab, and Standard Chemotherapy for Head and Neck Squamous Cell Carcinoma That has Returned or Spread
2022-500820-31-00 Ended Latest: 2024-09-06 Recurrent or metastatic squamous cell carcinoma of
1 unexpected event
A safety study of PF-08046045/SGN-35T in adults with advanced cancers
2022-502390-41-00 Ended Latest: 2024-10-10 Enteropathy-Associated T-Cell Lymphoma
2 halts
A proof-of-concept study to examine QUC398 in participants with knee osteoarthritis
2023-509274-28-00 Ended Latest: 2024-12-26 Knee osteoarthritis
3 halts
Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumours
2024-511071-16-00 Ended Latest: 2024-05-29 Solid Tumours
5 halts
A randomised, double-blind, multicentre study comparing the efficacy, safety and immunogenicity of proposed Abatacept biosimilar (DRL_AB) wi…
2023-506664-14-00 Ended Latest: 2024-10-31 Rheumatoid Arthritis
6 halts
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
2024-511286-11-00 Ended Latest: 2025-11-20 Advanced Solid Tumors
1 halt
A study to compare efficacy, safety, and immune response of GME751 and EU-authorized Keytruda in adult participants with untreated metastati…
2023-506882-70-00 Ended Latest: 2025-04-30 Non-small-cell lung cancer
2 halts
A First-in-human study to learn how safe the study drug BAY2965501 is, find the best dose (single drug & combination), how it affects the bo…
2023-507905-33-00 Ended Latest: 2025-06-04 Advanced solid tumors
2 halts
A Phase 2 Study of the Effects of Ponsegromab on Health-Related Quality of Life and Safety in Patients With Heart Failure (GARDEN-TIMI 74)
2023-509747-27-00 Ended Latest: 2024-12-12 Heart failure
1 urgent safety
A phase I dose finding study of oral TNO155 in adult patients with advanced solid tumors
2023-508925-29-00 Ended Latest: 2024-05-17 Advanced solid tumors
3 halts
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
2023-503673-38-00 Ended Latest: 2025-04-24 Adults at high risk of cardiovascular events witho
2 breaches
A Phase 2, Double-Blind Study to Assess Dexlansoprazole Delayed-Release Capsules for Healing of EE and Maintenance of Healed EE in Pediatric…
2022-501350-11-00 Ended Latest: 2025-11-11 Erosive Esophagitis
1 halt
A Study of SGN-B7H4V in Advanced Solid Tumors
2023-503389-22-00 Ended Latest: 2025-01-08 Fallopian tube cancer
4 halts
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung)
2023-505035-12-00 Ended Latest: 2024-10-18 RET fusion−positive, metastatic Non-Small Cell Lun
1 urgent safety
A Study of the Efficacy, Safety, and Tolerability of KAN-101 in Participants With Celiac Disease
2023-507240-37-00 Ended Latest: 2025-04-16 celiac disease
1 breach
Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunoch…
2023-507498-16-00 Ended Latest: 2024-07-03 Diffuse Large B-Cell Lymphoma (DLBCL)
1 unexpected event
A study to Assess the Efficacy and Safety of Namilumab in subjects with lung inflammatory disease
2024-511115-25-00 Ended Latest: 2024-12-23 chronic pulmonary sarcoidosis
4 halts
A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma
2023-507324-23-00 Ended Latest: 2024-06-28 recurrent or persistent uterine serous carcinoma
1 halt 3 urgent safety
A study to investigate the reactogenicity, safety, and immunogenicity of mRNA-1345 in pregnant women, and safety and immunogenicity in their…
2023-505359-37-00 Ended Latest: 2025-06-20 Respiratory syncytial virus
1 breach
A Variable Length Study to Evaluate the Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol inhaler in Adults and Adolescents with S…
2023-505786-88-00 Ended Latest: 2025-11-05 Severe and inadequately controlled asthma
1 breach
A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)
2023-503693-20-01 Ended Latest: 2025-09-30 Severe eosinophilic asthma
1 urgent safety 1 corrective measure
Study with healthy volunteers to investigate the safety, tolerability, blood concentration and some effects of various amounts of the pharma…
2023-507753-15-00 Ended Latest: 2024-12-12 Healthy Volunteers
1 halt
A proof of concept and dose-finding study of XXB750 in patients with heart failure
2023-504678-39-00 Ended Latest: 2024-11-08 Heart Failure
9 halts 1 urgent safety
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the tr…
2023-506185-31-00 Ended Latest: 2025-02-13 Idiopathic pulmonary fibrosis (IPF)
11 halts
A study of efficacy and safety of various treatments in participants with idiopathic pulmonary fibrosis (IPF)
2023-508729-28-00 Ended Latest: 2024-04-04 Idiopathic pulmonary fibrosis
4 halts
Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION)
2023-508528-36-00 Ended Latest: 2024-06-28 Resected squamous cell carcinoma of the head and n
1 urgent safety
Study Comparing Bemarituzumab plus Chemotherapy with Placebo and Chemotherapy in Previously Untreated Advanced Gastric or Gastroesophageal J…
2023-505457-40-00 Ended Latest: 2024-11-11 Previously Untreated Advanced Gastric or Gastroeso
2 breaches
Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102)
2023-505458-16-00 Ended Latest: 2024-11-18 Gastric and Gastroesophageal Junction Cancer With
2 breaches
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)
2023-506918-45-00 Ended Latest: 2025-02-21 Mild cognitive impairment (MCI) or mild dementia,
1 breach
Study Drug vs Placebo as an “add on” treatment for Severe Community-Acquired Pneumonia.
2023-505985-28-01 Ended Latest: 2025-02-05 Severe Community-Acquired Pneumonia
1 corrective measure
A trial to determine how nanatinostat is absorbed, modified, and removed from the body and the amount of nanatinostat that becomes available…
2023-508184-74-00 Ended Latest: 2024-10-04 Advanced cancer
1 halt
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
2023-506919-18-00 Ended Latest: 2025-02-21 Mild cognitive impairment (MCI) or mild dementia,
1 breach
7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors
2023-505284-36-00 Ended Latest: 2024-12-20 Advanced solid tumors
1 urgent safety
"Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (MIRANDA)"
2023-505543-39-00 Ended Latest: 2026-02-27 Chronic Obstructive Pulmonary Disease (COPD)
1 breach
Study of BMS-986466 with Adagrasib with or without Cetuximab in Participants with KRAS G12C-mutant Solid Tumors
2023-505070-15-00 Ended Latest: 2024-03-04 Oncology, NSCLC and CRC
1 corrective measure
A study to test whether BI 456906 helps people living with overweight or obesity who also have diabetes to lose weight
2022-502531-18-00 Ended Latest: 2025-12-24 Obesity
1 breach
A Study to Investigate Efficacy, Pharmacokinetics, and Safety of Mirikizumab in Participants 2 Years to Less Than 18 Years of Age with Moder…
2022-502183-20-00 Ended Latest: 2025-10-08 Moderately to Severely Active Ulcerative Colitis
1 corrective measure
A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myelo…
2023-505910-10-00 Ended Latest: 2025-03-17 Relapsed or Refractory High-Risk Myelodysplastic S
1 urgent safety
A Phase 1, randomized, double blind, single center, placebo controlled, single escalating weight-adjusted dose, safety study of HI-6 dimethy…
2023-509020-17-00 Ended Latest: 2024-09-05 Treatment of patients poisoned with organophosphor
3 halts
Phase 2 study of SAR444656 in adult participants with moderate to severe atopic dermatitis.
2023-504346-66-00 Ended Latest: 2025-07-03 Dermatitis atopic
1 unexpected event
Phase II study evaluating Holmium-166 TARE followed by maIntenance Therapy in liver limited unresectable colorectal cancer patients after fi…
2023-505356-22-00 Ended Latest: 2025-02-03 Liver limited unresectable colorectal cancer
1 halt
Phase 3 Open label clinical trial with oral Atogepant for the prevention of migraine
2023-507096-21-00 Ended Latest: 2024-06-26 Chronic or Episodic Migraine (Migraine without aur
1 corrective measure
A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients with Relapsed or Refractory AML or CMML
2023-508655-39-00 Ended Latest: 2024-05-16 Acute Myeloid Leukemia (AML) or Chronic Myelomonoc
3 halts
A study to assess the efficacy and safety of tigulixostat at different doses as compared to a control drug (allopurinol) in gout patients wi…
2022-501421-20-00 Ended Latest: 2024-05-30 Gout with hyperuricemia
1 urgent safety
Phase I study of MGY825 in patients with lung cancer
2023-504350-36-00 Ended Latest: 2025-10-09 Advanced non-small cell lung cancer with or withou
2 halts
PH2a, VH3739937 Proof-Of-Concept in TN HIV-1 Infected Adults
2023-505780-37-00 Ended Latest: 2024-09-09 HIV Infections
3 halts
Imatinib PD in healthy subjects
2023-504958-35-00 Ended Latest: 2024-04-29 Immuno-oncology assessments
1 halt
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3…
2023-505322-34-00 Ended Latest: 2025-05-14 Advanced or metastatic solid tumors
1 halt
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
2023-503919-15-00 Ended Latest: 2024-02-21 Prostatic Neoplasms
2 halts
A study to evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and preliminary Anti-Tumor activity of RO7616789…
2023-506354-20-00 Ended Latest: 2024-08-09 Small Cell Lung Cancer and Neuroendocrine Carcinom
3 halts
A Phase 2 study to evaluate the efficacy and safety of SAR444656 compared with placebo in adult participants with moderate to severe hidrade…
2023-504328-25-00 Ended Latest: 2025-07-03 hidradenitis suppurativa
1 unexpected event
RANDOMIZED, CONTROLLED, OPEN, MULTICENTRIC CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A COMBINATION OF ANTI-TUBERCULOUS DRUGS BAS…
2023-509075-17-00 Ended Latest: 2023-12-05 Bacilliferous pulmonary tuberculosis
1 halt
A study to test how well BI 1291583 is tolerated by people with cystic fibrosis bronchiectasis (ClairaflyTM)
2022-502835-21-00 Ended Latest: 2024-02-07 cystic fibrosis bronchiectasis
1 corrective measure
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety deucravacitinib in patients with chronic hand eczem…
2023-504298-19-00 Ended Latest: 2024-07-18 Chronic Hand Eczema
1 halt 1 corrective measure
A PHASE-1, FIRST-IN-HUMAN, RANDOMIZED, DOUBLE-BLIND, PLACEBO­-CONTROLLED, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO ASSESS THE SAFETY, TOL…
2023-507504-31-00 Ended Latest: 2024-10-31 Lupus erythematosus
1 halt
A Study to Learn How Different Amounts and Forms of the Study Intervention Called PF-07899895 are Tolerated and Act in the Body of Healthy A…
2023-507354-32-00 Ended Latest: 2024-02-21 Ulcerative Colitis
1 halt
REIMAGINE 2: A research study to see how well CagriSema compared to semaglutide, cagrilintide and placebo lowers blood sugar and body weight…
2022-502678-18-00 Ended Latest: 2025-11-13 Type 2 diabetes
2 breaches
A study to test whether BI 765845 helps people who have had a heart attack
2022-502788-39-00 Ended Latest: 2025-09-09 acute myocardial infarction
7 halts
A study to test whether BI 907828 helps people with cancer in the biliary tract, pancreas, lung, or bladder
2023-506369-79-00 Ended Latest: 2024-01-08 Pancreatic ductal adenocarcinoma
5 halts
A Phase 2 study to evaluate the efficacy and safety of RPT193 in adults with moderate-to-severe T2-high asthma who are partially controlled …
2022-502854-16-00 Ended Latest: 2024-03-06 Asthma
4 halts
A Phase 1/2a Study Evaluating the Effects of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients with Idiopathic Pulmonary Fibrosi…
2023-504964-41-00 Ended Latest: 2024-11-05 Idiopathic pulmonary fibrosis
2 halts
This is a clinical trial (study), to be conducted in several clinical sites worldwide, of an oral study drug which will be investigated in a…
2023-503957-36-00 Ended Latest: 2023-11-20 Moderate-to-Severe pruritus in adult subjects with
1 corrective measure
​Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination with Chemotherapy Versus Pembrolizumab Plus Chemotherapy as Fir…
2023-506074-12-00 Ended Latest: 2024-12-20 Metastatic Non-Small Cell Lung Cancer
1 urgent safety
First-in-human study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of VTX-PID in healthy male volunteers
2023-503892-83-00 Ended Latest: 2024-06-25 Healthy volunteers with circulating Neutralising a
1 halt
A Phase 1/2 Study of VX-522 in Subjects with Cystic Fibrosis
2023-504786-23-00 Ended Latest: 2025-05-02 Cystic Fibrosis
11 halts
A Study of Lorigerlimab with Docetaxel or Docetaxel Alone in Participants with Metastatic Castration-Resistant Prostate Cancer
2022-502982-49-00 Ended Latest: 2024-05-07 Metastatic Castration-Resistant Prostate Cancer
5 halts
A Study to Investigate MBS2320 Patients with IPF
2023-504418-30-00 Ended Latest: 2024-03-19 Idiopathic Pulmonary Fibrosis
5 halts
A study in healthy men to test how well different doses of BI 3802876 are tolerated
2023-504538-23-00 Ended Latest: 2025-02-27 Healthy volunteer trial
1 halt
A Phase 1 Study to Assess Mass Balance, Pharmacokinetics, and Metabolism of [14C]Subasumstat in Patients With Advanced or Metastatic Solid T…
2023-503449-79-00 Ended Latest: 2024-03-06 Advanced or Metastatic Solid Tumours
1 halt
A 12-month, randomized, single-blind, placebo-controlled exposure-response study of TCD601 (siplizumab) in new onset type 1 diabetes patient…
2023-506837-31-00 Ended Latest: 2024-10-11 New onset type I diabetes
1 halt 1 corrective measure
A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)
2022-502227-22-00 Ended Latest: 2024-10-09 Autoimmune disease
4 halts
A study to find a suitable dose of BI 1821736 and test whether it helps people with advanced cancer
2022-502125-17-00 Ended Latest: 2024-08-27 Advanced solid tumors
2 halts
Study of efficacy and safety of secukinumab in participants with moderate-severe rotator cuff tendinopathy
2022-502080-38-00 Ended Latest: 2024-05-08 Moderate to severe rotator cuff tendinopathy
5 halts
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DG…
2023-503996-38-00 Ended Latest: 2025-05-26 Advanced or metastatic solid tumors
2 halts
A Study of HFB301001 in Adult Patients With Advanced Solid Tumors
2023-506402-39-00 Ended Latest: 2024-09-04 Advanced cancer of different organs
1 halt
A Study of ZL-1218 with or without Pembrolizumab in Subjects with Advanced Solid Tumor Cancers to Find a Suitable Dose and to Test How Diffe…
2022-503102-20-00 Ended Latest: 2024-09-16 Advanced solid tumors
2 halts
A Study to Evaluate CC-486 in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Cancer Partic…
2023-503427-26-00 Ended Latest: 2025-07-10 Myeloid malignancies with moderate or severe hepat
2 halts
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
2022-502022-41-00 Ended Latest: 2025-12-11 Acute lower respiratory infection
2 halts 1 unexpected event
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants with Early Idiopathic Pa…
2023-504412-14-00 Ended Latest: 2024-06-14 Early Idiopathic Parkinson’s Disease (PD)
1 halt
Study of efficacy and safety of secukinumab in participants with moderate-severe rotator cuff tendinopathy
2022-502068-19-00 Ended Latest: 2024-05-08 Moderate to severe rotator cuff tendinopathy
6 halts
Long-term extension study of ligelizumab in food allergy
2022-502366-25-00 Ended Latest: 2024-08-07 Food allergy
5 halts
A study to test the efficacy and safety of SAR442970 in adults with hidradenitis suppurativa
2022-502370-17-00 Ended Latest: 2023-08-23 Hidradenitis suppurativa
1 corrective measure
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Participants with Moderate to Severe Ulcerative Colitis
2022-503005-38-00 Ended Latest: 2024-01-02 Ulcerative Colitis
2 halts
Study comparing radiotherapy combined with cetuximab + Xevinapant (study drug) with radiotherapy combined with cetuximab + placebo in patien…
2022-502584-38-00 Ended Latest: 2024-07-11 Locally advanced squamous cell carcinoma of the he
1 halt
A Randomised Double-Blinded, Placebo-Controlled, Single and Multiple Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, and…
2023-504838-21-00 Ended Latest: 2025-05-05 Healthy
2 halts
Randomized, non-comparative, open-label early phase Ib study with OBT076 or OBT076 followed by Balstilimab in patients with Adenoid Cystic C…
2023-503270-20-00 Ended Latest: 2024-05-17 recurrent or metastatic Adenoid Cystic Carcinoma o
1 halt
Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma (CLAUDIO-01)
2023-504441-31-00 Ended Latest: 2024-12-17 gastric adenocarcinoma or adenocarcinoma of the ga
4 halts 1 urgent safety
A large global trial to evaluate the efficacy and safety of milvexian in reducing recurrent cardiovascular events in patients after a heart …
2022-501418-69-00 Ended Latest: 2025-02-10 Acute Coronary Syndrome
1 breach
A phase I study of [177Lu]Lu-FF58 in patients with advanced solid tumors
2022-502367-37-00 Ended Latest: 2024-10-24 Recurrent glioblastoma multiforme (GBM)
2 halts
Co-administration of Acetaminophen with Ibuprofen to Improve Duct-Related Outcomes in Extremely Premature Infants – The ACEDUCT Trial
2023-503209-13-00 Ended Latest: 2024-07-11 Patent ductus arteriosus (PDA)
1 halt
GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer
2022-502453-33-00 Ended Latest: 2024-03-13 Advanced Endometrial Cancer
1 halt
Radiotherapy plus xevinapant or placebo in older patients with locally advanced head and neck cancer
2022-502339-20-00 Ended Latest: 2024-08-05 Squamous cell carcinoma of head and neck
8 halts
Clinical trial of MK-7648A in adults and children with skin cancer
2022-501417-31-01 Ended Latest: 2023-07-26 melanoma
1 corrective measure
A Phase 2 Safety, Tolerability, and Proof-of-Concept Study of VGL101 in Patients With Adult-Onset Leukoencephalopathy With Axonal Spheroids …
2022-502505-15-00 Ended Latest: 2025-05-30 Leukoencephalopathy
3 halts
VItamin C in Thermal injuRY: The VICToRY Trial A phase III multi-center randomized trial
2023-504772-21-00 Ended Latest: 2024-04-19 Severely burned patients
1 corrective measure
Detection of tumor DNA in the blood of patients receiving standard therapy for hormone receptorpositive (HR+) non-HER2 expressing (HER2-) me…
2022-502372-22-01 Ended Latest: 2025-04-02 Metastatic Breast Cancer HR+, HER2-
1 halt
A Study Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso‑O…
2022-502546-26-00 Ended Latest: 2024-04-16 Sickle Cell Disease
6 halts
Evaluation of Upadacitinib in Adolescent and Adult Patients with Moderate to Severe Atopic Dermatitis (Eczema)– Measure Up 1
2022-502938-30-00 Ended Latest: 2023-07-28 Moderate and Severe Atopic Dermatitis
1 breach
A study to evaluate Intravitreal JNJ-81201887(AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary…
2022-500746-16-00 Ended Latest: 2025-09-10 Geographic Atrophy
1 corrective measure
An early-stage clinical study of a potential new medicine for patients with Netherton Syndrome
2022-502853-32-00 Ended Latest: 2024-12-20 Netherton's Syndrome
1 halt
Pembrolizumab (MK-3475) and pembrolizumab in combination with other investigational agents in high risk NMIBC patients unresponsive to BCG
2022-502526-41-00 Ended Latest: 2024-12-23 Non-Muscle Invasive Bladder Cancer (NMIBC)
1 urgent safety
A Phase 3 Study to Evaluate the Efficacy and Safety of Darvadstrocel in the Treatment of Complex Perianal Fistula in Pediatric Subjects with…
2023-503973-39-00 Ended Latest: 2024-10-24 Complex Perianal Fistulas in Crohn's Disease
3 halts
Efficacy evaluation of 188Re-SSS lipiodol Selective Internal Radiation Therapy of non operable hepatocellular carcinoma patients, a phase II…
2023-503341-60-00 Ended Latest: 2025-10-24 non-operable hepatocellular carcinoma
1 halt 1 corrective measure
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
2022-501476-25-00 Ended Latest: 2025-10-01 Atopic Dermatitis Eczema
1 corrective measure
A study of HFB200603 as a single agent and in combination with Tislelizumab in patients with advanced solid tumors
2022-502891-22-00 Ended Latest: 2025-11-20 Advanced Solid Tumors
2 halts
A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults with Tuberous Sclerosis Complex (TSC)-related Ep…
2022-503067-15-00 Ended Latest: 2024-11-12 Tuberous Sclerosis Complex (TSC) related epilepsy
1 urgent safety
The study evaluates the efficacy of the therapy of Mistletoe Extract in patients with superficial bladder cancer. There fore the Mistletoe E…
2023-503718-66-00 Ended Latest: 2025-01-23 Male and female patients aged ≥ 18 to ≤ 85 years w
1 halt 1 corrective measure
Phase 2a, double-blind, randomized, placebo-controlled trial of methylprednisolone versus placebo in patients with cognitive deficits in pos…
2023-504826-21-00 Ended Latest: 2024-04-24 Post COVID-19 Syndrome
1 halt
Phase 1 Study of BMS-986416 with and without Nivolumab in Solid Tumors
2022-501317-31-00 Ended Latest: 2024-01-25 Solid tumor
2 halts
Efficacy and Tolerability of AP707 in Patients with chronic Pain due to Diabetic Polyneuropathy
2022-500897-32-00 Ended Latest: 2025-02-10 Chronic pain due to diabetic polyneuropathy
2 halts 1 corrective measure
A randomized trial investigating the superiority of TDM-optimized teicoplanin dosing versus standard of care
2023-503411-15-00 Ended Latest: 2026-02-12 Sepsis
1 halt
A study to test how well different doses of BI 1815368 are tolerated by healthy men
2023-503815-13-00 Ended Latest: 2023-08-25 Healthy
1 halt
Bioequivalence of Ulipristal 30 mg Tablets in Healthy Subjects Under Fed Conditions
2023-504259-29-00 Ended Latest: 2023-12-28 No medical condition
1 halt
A Phase 1/2 Study of BMS-986408 with and without Nivolumab or Nivolumab and Ipilimumab in Participants with Solid Tumors
2022-500823-61-00 Ended Latest: 2024-01-18 Advanced Solid Tumours
2 halts
A study to test whether spesolimab helps people with a skin disease called hidradenitis suppurativa
2022-501074-19-00 Ended Latest: 2023-11-03 Hidradenitis suppurativa
12 halts
A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects Wi…
2022-501618-70-00 Ended Latest: 2025-08-07 BRAF-V600 Mutant Solid Tumors including Melanoma,
1 unexpected event
A Randomised, Placebo-Controlled, Double-blind, Single and Multiple Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, and …
2023-503917-31-00 Ended Latest: 2024-06-11 Inflammatory disease
2 halts
Safety and efficacy of GSK Neisseria gonorrhoeae GMMA (NgG) investigational vaccine when administered to healthy adults 18 to 50 years of ag…
2022-500883-37-00 Ended Latest: 2025-04-23 This FTiH-PoC study aims to provide an early evalu
1 corrective measure
A study to investigate efficacy and safety of OG-6219 twice a day in 3 dose levels compared with Placebo in participants aged 18 to 49 with …
2022-501310-57-00 Ended Latest: 2023-11-23 Endometriosis related pain
9 halts
A Phase 1, Multicentre, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single IV Dose of Rezafungin Acetat…
2022-501985-23-00 Ended Latest: 2024-05-07 Fungal infections
2 halts
A Study to Investigate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of RO7200220 Administered Intravitreally in Patients wit…
2022-501793-19-00 Ended Latest: 2024-07-05 Uveitic Macular Edema
1 breach
Efficacy and Tolerability of AP707 in Patients with chronic Pain due to traumatic or post-operative peripheral Neuropathy
2022-500898-13-00 Ended Latest: 2025-02-10 Chronic Pain due to traumatic or post-operative pe
2 halts 1 corrective measure
Efficacy and Tolerability of AP707 in Patients with chronic pain due to central Neuropathy of any Genesis
2022-500899-66-00 Ended Latest: 2025-02-10 Chronic pain due to central Neuropathy of any Gene
2 halts 1 corrective measure
Efficacy and Tolerability of AP707 in Patients with Chronic Back Pain
2022-502151-54-00 Ended Latest: 2025-02-10 Chronic back pain
2 halts 1 corrective measure
Phase I/II study to determine the safety and efficacy of Ribociclib in combination with hormone therapy and hypofractionated radiotherapy in…
2022-501527-24-00 Ended Latest: 2024-03-25 breast cancer
1 halt
A study to test if izokibep improves psoriatic arthritis symptoms and to see how safe izokibep is
2022-501362-22-00 Ended Latest: 2023-11-26 Psoriatic Arthritis
1 breach
Glucagon enhanced insulin absorption in Diabetes Mellitus type 1
2022-502455-57-01 Ended Latest: 2024-02-29 Diabetes mellitus type 1
1 halt
Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease with a History of Exacerbations.
2022-501063-41-00 Ended Latest: 2024-11-22 Chronic Obstructive Pulmonary Disease (COPD)
1 breach
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab Monotherapy in Moderate-to-severe AD (ROCKET-Ignite)
2022-501540-15-00 Ended Latest: 2024-10-18 Atopic Dermatitis
1 breach
A Phase 3 open-label, controlled, randomised, multi-centre trial comparing imlifidase and standard-of-care with standard-of-care alone in th…
2022-500121-33-01 Ended Latest: 2024-01-17 Anti-GBM antibody disease (Goodpasture disease)
1 breach
Xerostomia in patients with a life-limiting condition or frailty: a double-blind placebo-controlled randomized clinical trial
2022-501084-41-00 Ended Latest: 2023-12-21 Adult patients with a life-limiting condition or f
1 halt 1 corrective measure
NIHR127468 - The GHD Reversal Trial
2022-502008-62-00 Ended Latest: 2024-06-20 Growth Hormone Deficiency (GHD)
1 halt
Treatments of COVID-19 in primary care in the Netherlands
2022-501559-99-00 Ended Latest: 2023-07-25 Patients with symptomatic COVID-19 in the communit
1 halt
An open-label, single-arm, pilot study of Venetoclax in combination with 5 days Azacitidine in treatment-naïve subjects with acute myelogen…
2022-501537-23-00 Ended Latest: 2024-12-11 Acute myeloid leukemia
1 corrective measure
A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination with Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients wi…
2022-501601-12-00 Ended Latest: 2023-07-26 Diffuse large B-cell Lymphoma
2 halts
Olaparib Plus Pembrolizumab Compared to Chemotherapy Plus Pembrolizumab After Initial Treatment With Chemotherapy Plus Pembrolizumab in Trip…
2022-500418-24-00 Ended Latest: 2023-04-29 Locally Recurrent Inoperable or Metastatic Triple
1 unexpected event
Pembrolizumab as adjuvant therapy for resectable high-risk LA cSCC
2022-500395-57-00 Ended Latest: 2024-09-05 Resectable high-risk Locally Advanced Cutaneous Sq
1 unexpected event
European randomised clinical trial on mPOX Infection (EPOXI)
2022-501979-10-00 Ended Latest: 2022-12-28 Monkeypox
1 corrective measure
STRIDES - A Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia
2022-501004-10-00 Ended Latest: 2023-12-26 Spinocerebellar Ataxia type-3 (SCA3)
1 halt
A study to investigate the safety and tolerability of intravenous QEQ278 in patients with advanced solid tumors
2022-500540-38-00 Ended Latest: 2024-11-20 Non-small cell lung cancer Oesophageal squamous ce
3 halts
A study to investigate the safety, tolerability and preliminary efficacy of NGI226 microparticles in patients with Achilles tendinopathy
2022-500863-10-00 Ended Latest: 2025-09-08 Achilles Tendinopathy
2 halts
Ezurpimtrostat autophagy inhibitor in association with Atezolizumab-Bevacizumab in first line treatment of unresectable hepatocellular carci…
2022-502078-17-00 Ended Latest: 2023-03-29 unresectable hepatocellular carcinoma
1 corrective measure
An extension of the orchestra (PD0053) study to learn how safe minzasolmin is and if it works long-term in participants with Parkinson’s dis…
2022-500424-30-00 Ended Latest: 2024-12-19 Parkinson’s disease
1 unexpected event
Outcome measures in SMA patients treated with Risdiplam.
2022-501760-17-00 Ended Latest: 2023-02-21 Spinal Muscular Atrophy (SMA)
1 corrective measure
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study with a Long-Term Extension Treatment Period to Assess the …
2022-501188-42-00 Ended Latest: 2025-12-05 Early Alzheimer's Disease
2 urgent safety 1 unexpected event
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy of Methotrexate as Remission Maintenance Thera…
2022-501058-12-00 Ended Latest: 2023-10-10 Giant cell arteritis
1 breach
A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus …
2022-500177-13-00 Ended Latest: 2024-02-16 Metastatic Colorectal Cancer (mCRC)
5 halts
A 4-week double-blind, randomized, placebo-controlled, phase II study evaluating the effects of oral pamapimod 150 mg with pioglitazone 10 m…
2022-500244-37-00 Ended Latest: 2025-03-07 COVID-19
1 halt
A Phase 1 Study of SGN-ALPV in Advanced Solid Tumors
2022-500094-14-00 Ended Latest: 2023-09-29 gastroesophageal junction [GEJ] carcinoma
2 halts
Efficacy and Safety of AXL-Inhibitor bemcentinib for the Treatment of Moderate COVID-19 (AXL-SolidAct)
2022-500363-12-00 Ended Latest: 2023-05-02 SARS CoV-2 (COVID-19)
9 halts
Safety, tolerability and pharmacokinetics of intra‐articular (IA) single ascending dose of 4P‐004 in patient with Kellgren and Lawrence grad…
2022-500271-31-00 Ended Latest: 2023-05-09 Knee osteoarthritis
1 halt
Data is sourced from the CTIS public registry. Serious breaches, temporary halts, urgent safety measures, unexpected events, and corrective measures are each visible on the individual trial detail page.